data_6hka_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6hka _Structure_validation_residue.Date_analyzed 2019-03-22 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.508 ' C ' ' H ' ' A' ' 74' ' ' GLY . 26.7 m . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -51.18 -10.14 0.45 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.508 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -72.62 -49.91 16.92 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.9 mp0 -79.27 -39.23 33.51 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.18 -1.188 . . . . 0.0 109.139 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 13.9 t -62.48 -54.5 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 108.585 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -54.5 -49.18 70.77 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.58 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 40.8 tp -48.02 -50.61 27.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.092 -1.005 . . . . 0.0 108.862 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.9 tp -55.88 -31.98 63.29 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 110.973 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -74.32 -38.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.583 -1.323 . . . . 0.0 109.851 -178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -64.87 -53.44 46.59 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.176 -0.953 . . . . 0.0 110.362 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.776 HE21 ' H ' ' A' ' 82' ' ' GLN . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.425 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.482 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.8 m . . . . . 0 N--CA 1.481 1.109 0 CA-C-O 121.229 0.538 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.404 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -48.47 -15.33 0.44 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -73.18 -51.94 9.47 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.568 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 2.6 mp0 -82.94 -42.28 17.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.169 -1.195 . . . . 0.0 109.528 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 32.9 t -56.61 -52.05 58.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.469 ' OD1' ' NE2' ' A' ' 81' ' ' GLN . 8.1 t-20 -61.77 -53.35 57.21 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 42.3 tp -50.39 -31.83 15.91 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.117 -0.989 . . . . 0.0 109.143 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.7 tp -75.61 -30.13 59.44 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.273 -0.892 . . . . 0.0 110.539 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.434 HG21 HD11 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -82.56 -19.95 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 120.831 -1.168 . . . . 0.0 109.526 -179.094 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.469 ' NE2' ' OD1' ' A' ' 77' ' ' ASN . 6.7 mt-30 -90.46 -35.52 15.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.592 -1.317 . . . . 0.0 110.34 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.9 tp60 . . . . . 0 N--CA 1.488 1.465 0 O-C-N 120.948 -1.095 . . . . 0.0 108.782 -179.521 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.436 ' O ' ' N ' ' A' ' 74' ' ' GLY . 23.7 m . . . . . 0 N--CA 1.481 1.099 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -43.96 -23.73 0.43 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.96 -44.84 54.42 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.592 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 2.3 mp0 -62.31 -29.21 70.28 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.7 t -70.33 -44.91 77.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.524 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 9.1 t-20 -60.58 -57.76 11.36 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 33.2 tp -47.94 -28.94 2.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 108.969 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.1 tp -70.7 -40.04 73.1 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.353 -0.842 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.434 HD11 HG21 ' A' ' 80' ' ' ILE . 0.2 OUTLIER -67.9 -38.75 80.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.944 -1.098 . . . . 0.0 109.45 -179.276 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 2.5 mp0 -68.6 -31.99 71.55 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.895 -1.128 . . . . 0.0 108.529 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.399 0 O-C-N 121.453 -0.779 . . . . 0.0 109.684 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.5 m . . . . . 0 N--CA 1.477 0.922 0 CA-C-O 121.375 0.607 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -48.69 -9.82 0.1 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -79.93 -62.68 2.08 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.053 -1.263 . . . . 0.0 110.109 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.566 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 0.6 OUTLIER -74.03 -30.32 62.37 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.073 -1.251 . . . . 0.0 108.841 -179.638 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 41.2 t -67.81 -51.57 48.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 14.7 t-20 -55.11 -36.34 65.61 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.133 -0.979 . . . . 0.0 108.803 178.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.5 tp -73.95 -46.93 40.97 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 120.715 -1.241 . . . . 0.0 108.88 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 7.9 mp -65.87 -15.71 63.17 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.567 -0.708 . . . . 0.0 109.298 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 81' ' ' GLN . 0.4 OUTLIER -80.33 -54.51 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.819 -1.176 . . . . 0.0 108.306 -179.885 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 4.6 mt-30 -54.97 -53.82 50.79 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.066 -1.021 . . . . 0.0 110.095 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 75' ' ' GLN . 18.9 m . . . . . 0 N--CA 1.476 0.836 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -24.71 3.08 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.647 -1.781 . . . . 0.0 108.647 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.551 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -72.57 -42.05 49.05 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.413 ' N ' ' O ' ' A' ' 72' ' ' VAL . 10.9 mp0 -58.64 -21.8 54.91 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 178.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.4 ' C ' ' N ' ' A' ' 78' ' ' LEU . 5.1 t -83.87 -53.64 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.573 HD21 ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -57.05 -14.66 3.98 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.632 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.573 ' N ' HD21 ' A' ' 77' ' ' ASN . 65.9 tp -88.0 -66.05 0.95 Allowed 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.97 -13.88 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 110.027 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.494 ' CG2' ' N ' ' A' ' 81' ' ' GLN . 0.2 OUTLIER -95.71 -55.0 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.931 -1.105 . . . . 0.0 110.221 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.622 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 2.3 pp0? -55.35 -12.67 1.11 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.072 -1.642 . . . . 0.0 108.256 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.622 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 178.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.2 m . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 121.361 0.6 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -9.37 0.06 OUTLIER Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -74.85 -63.78 2.49 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.848 -1.384 . . . . 0.0 110.387 -179.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -75.25 -28.31 59.8 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.02 -1.282 . . . . 0.0 109.744 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 25.7 t -68.7 -57.71 8.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 108.747 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.768 HD21 HE22 ' A' ' 81' ' ' GLN . 8.7 t30 -51.98 -44.26 63.97 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.208 -0.932 . . . . 0.0 108.574 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.3 mp -57.2 -30.39 64.5 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.037 -1.039 . . . . 0.0 108.516 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.65 -29.26 62.23 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.317 -0.864 . . . . 0.0 110.779 -178.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -80.11 -27.15 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.626 -1.296 . . . . 0.0 110.399 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.768 HE22 HD21 ' A' ' 77' ' ' ASN . 3.1 pt20 -95.02 -10.87 29.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 108.854 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 15.9 mt-30 . . . . . 0 N--CA 1.498 1.935 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 -179.785 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.484 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.9 m . . . . . 0 N--CA 1.481 1.122 0 CA-C-O 120.921 0.391 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -49.15 -13.41 0.36 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -80.9 -62.07 2.06 Favored Glycine 0 N--CA 1.492 2.392 0 O-C-N 121.213 -1.169 . . . . 0.0 110.666 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.489 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 3.4 mp0 -73.78 -32.12 63.62 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.882 -1.364 . . . . 0.0 108.8 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 39.9 t -66.57 -59.72 3.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -50.46 -30.82 13.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.105 -0.997 . . . . 0.0 109.305 179.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 61.1 tp -78.61 -29.81 46.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.077 -1.014 . . . . 0.0 109.654 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.6 mp -72.7 -35.34 67.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.061 -1.024 . . . . 0.0 109.685 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.24 -42.43 23.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.719 -1.238 . . . . 0.0 109.464 -179.476 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -66.07 -29.59 69.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.952 -1.093 . . . . 0.0 110.394 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 pp0? . . . . . 0 N--CA 1.498 1.926 0 O-C-N 120.632 -1.293 . . . . 0.0 109.013 179.407 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.6 m . . . . . 0 N--CA 1.483 1.205 0 CA-C-O 121.385 0.612 . . . . 0.0 109.772 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -46.56 -14.57 0.11 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.86 -53.09 12.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -74.25 -32.45 62.96 Favored 'General case' 0 N--CA 1.485 1.289 0 O-C-N 120.985 -1.303 . . . . 0.0 109.228 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -70.8 -60.0 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.185 -0.947 . . . . 0.0 108.773 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 29.7 t-20 -55.48 -24.82 33.34 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.095 -1.003 . . . . 0.0 108.973 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.9 tp -81.65 -41.8 20.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.843 -1.161 . . . . 0.0 109.047 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.3 tp -58.9 -35.89 73.79 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.357 -0.84 . . . . 0.0 110.432 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.513 ' CG2' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -79.21 -49.12 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.853 -1.154 . . . . 0.0 108.891 -179.523 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 0.1 OUTLIER -58.57 -12.06 3.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.756 -1.215 . . . . 0.0 108.841 178.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 . . . . . 0 N--CA 1.487 1.418 0 O-C-N 121.173 -0.954 . . . . 0.0 109.686 -178.98 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' GLY . 30.5 m . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 121.311 0.577 . . . . 0.0 109.638 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -44.92 -17.97 0.11 Allowed Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.94 -54.87 25.35 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.641 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 2.1 mp0 -74.69 -36.01 62.76 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.185 -1.185 . . . . 0.0 109.624 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 7.4 t -65.84 -58.91 4.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.027 -1.046 . . . . 0.0 109.053 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.486 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -54.24 -31.02 52.36 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 108.74 179.726 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.3 tp -73.23 -37.79 66.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.183 -0.948 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.6 mp -61.64 -40.81 96.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.197 -0.939 . . . . 0.0 109.425 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.92 -46.71 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.777 -1.202 . . . . 0.0 109.957 -179.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.674 HE21 ' N ' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -53.45 -39.88 64.78 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.641 -1.287 . . . . 0.0 109.981 -179.372 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.493 ' NE2' ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.702 0 O-C-N 120.859 -1.15 . . . . 0.0 110.143 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 74' ' ' GLY . 20.4 m . . . . . 0 N--CA 1.485 1.29 0 CA-C-O 121.356 0.598 . . . . 0.0 109.631 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.63 -22.57 0.73 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -61.04 -46.93 93.57 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -81.69 -46.55 14.14 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.142 -1.211 . . . . 0.0 109.488 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.8 t -57.04 -51.33 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.206 -0.934 . . . . 0.0 108.683 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.565 ' C ' HE21 ' A' ' 81' ' ' GLN . 6.6 t-20 -58.46 -50.17 74.68 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.2 tp -47.9 -36.37 12.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.985 -1.072 . . . . 0.0 109.305 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 7.2 mp -70.88 -33.94 71.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.184 -0.947 . . . . 0.0 109.926 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.434 HD11 HG23 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -75.8 -31.95 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 120.572 -1.33 . . . . 0.0 109.06 -179.541 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.565 HE21 ' C ' ' A' ' 77' ' ' ASN . 6.0 mt-30 -74.93 -22.15 58.76 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.177 -0.952 . . . . 0.0 109.317 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.572 179.905 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.522 ' C ' ' H ' ' A' ' 74' ' ' GLY . 34.7 m . . . . . 0 N--CA 1.487 1.392 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.456 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -49.35 -10.06 0.17 Allowed Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -75.59 -55.7 4.91 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 68.6 mm-40 -74.99 -26.33 59.48 Favored 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.202 -1.175 . . . . 0.0 109.702 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.0 t -73.03 -62.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -0.906 . . . . 0.0 108.946 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.497 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -51.59 -36.76 46.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.028 -1.045 . . . . 0.0 108.476 179.405 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.443 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 11.1 tp -66.7 -43.0 85.51 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -56.74 -53.91 52.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.305 -0.872 . . . . 0.0 110.057 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.11 -38.52 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.887 -1.133 . . . . 0.0 110.134 -178.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.618 HE21 ' N ' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -66.14 -41.22 90.73 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.497 -1.377 . . . . 0.0 109.883 -179.766 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.508 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.638 0 O-C-N 120.717 -1.239 . . . . 0.0 110.102 -179.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.559 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.7 m . . . . . 0 N--CA 1.481 1.124 0 CA-C-O 120.895 0.379 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -42.85 -17.63 0.04 OUTLIER Glycine 0 N--CA 1.498 2.83 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -77.72 -52.54 5.4 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -72.78 -36.56 67.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.135 -1.215 . . . . 0.0 108.839 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.3 t -65.52 -53.45 39.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.615 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.3 t-20 -51.93 -31.24 27.81 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.0 mp -72.24 -47.69 48.39 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.117 . . . . 0.0 108.294 179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.65 -48.24 49.41 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.576 -0.703 . . . . 0.0 110.286 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -72.57 -43.83 61.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 120.763 -1.21 . . . . 0.0 109.802 -178.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.615 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 0.0 OUTLIER -47.43 -25.26 1.0 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.824 -1.173 . . . . 0.0 108.587 179.303 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 . . . . . 0 N--CA 1.496 1.838 0 O-C-N 121.73 -0.606 . . . . 0.0 109.454 179.438 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.6 m . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 121.166 0.508 . . . . 0.0 109.872 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.434 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -48.22 -11.67 0.14 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.939 -1.264 . . . . 0.0 109.939 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -84.45 -64.51 1.57 Allowed Glycine 0 N--CA 1.493 2.447 0 O-C-N 121.197 -1.178 . . . . 0.0 110.208 -179.561 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -70.61 -9.77 57.72 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.004 -1.292 . . . . 0.0 109.242 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.5 t -93.24 -64.15 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.049 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.661 HD21 ' N ' ' A' ' 78' ' ' LEU . 0.1 OUTLIER -52.19 -20.4 2.57 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.966 -1.084 . . . . 0.0 108.084 178.945 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.661 ' N ' HD21 ' A' ' 77' ' ' ASN . 24.5 tp -84.97 -68.44 0.72 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.6 tp -47.0 -11.9 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.098 -1.001 . . . . 0.0 110.74 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -95.11 -55.34 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.795 -1.191 . . . . 0.0 109.53 -179.821 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.492 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 3.2 pp0? -56.69 -21.96 31.48 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.411 -1.431 . . . . 0.0 110.069 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.524 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.07 0 O-C-N 120.814 -1.179 . . . . 0.0 109.208 178.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.462 ' CG2' ' H ' ' A' ' 73' ' ' GLY . 33.1 m . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 120.947 0.403 . . . . 0.0 110.477 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.462 ' H ' ' CG2' ' A' ' 72' ' ' VAL . . . -53.6 -15.52 4.48 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -72.74 -59.25 4.48 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -80.64 -41.82 23.2 Favored 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.098 -1.236 . . . . 0.0 109.085 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.85 -47.53 63.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 108.659 179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.631 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.8 t30 -62.9 -57.84 9.41 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.237 -0.915 . . . . 0.0 108.709 179.027 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.5 tp -51.51 -30.78 21.51 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.056 -1.027 . . . . 0.0 109.958 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -76.37 -30.23 57.47 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.995 -1.065 . . . . 0.0 110.289 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -77.85 -28.31 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.357 -1.464 . . . . 0.0 110.069 -178.946 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.631 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -85.97 -36.9 19.54 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.153 -1.592 . . . . 0.0 110.381 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.497 ' NE2' ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.501 2.093 0 O-C-N 120.68 -1.262 . . . . 0.0 111.738 -178.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.9 m . . . . . 0 N--CA 1.478 0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -43.91 -21.13 0.19 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -65.31 -47.12 83.18 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.484 ' OE1' ' N ' ' A' ' 75' ' ' GLN . 1.4 mp0 -79.9 -38.0 33.48 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.324 -1.103 . . . . 0.0 109.654 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.76 -57.64 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 108.994 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.732 HD21 HE22 ' A' ' 81' ' ' GLN . 0.2 OUTLIER -56.54 -51.79 67.24 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.014 -1.054 . . . . 0.0 108.435 179.712 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.618 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 28.0 tp -47.31 -35.89 8.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.062 179.457 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 3.6 mp -71.46 -26.65 62.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.461 -0.774 . . . . 0.0 109.31 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.436 ' N ' ' O ' ' A' ' 77' ' ' ASN . 0.3 OUTLIER -69.77 -34.17 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.896 -1.127 . . . . 0.0 109.651 -179.389 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.732 HE22 HD21 ' A' ' 77' ' ' ASN . 0.0 OUTLIER -87.67 -19.93 27.0 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.878 -1.139 . . . . 0.0 110.09 -179.8 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 . . . . . 0 N--CA 1.493 1.689 0 O-C-N 121.082 -1.011 . . . . 0.0 108.738 -179.768 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 74' ' ' GLY . 21.2 m . . . . . 0 N--CA 1.479 1.024 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.93 -14.86 0.09 OUTLIER Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.55 -55.48 8.57 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -74.06 -34.47 64.06 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.015 -1.285 . . . . 0.0 109.549 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.46 -61.22 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.738 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -50.67 -31.2 15.62 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.439 -0.788 . . . . 0.0 108.912 179.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.57 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 41.0 tp -74.23 -39.61 62.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.346 -0.846 . . . . 0.0 109.172 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 21.6 tp -62.75 -28.12 69.75 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 111.056 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.62 -40.04 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.683 -1.26 . . . . 0.0 110.832 -178.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.64 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -66.67 -23.48 66.15 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.957 -1.089 . . . . 0.0 109.289 -178.885 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.64 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 4.0 tp60 . . . . . 0 N--CA 1.494 1.742 0 O-C-N 120.965 -1.084 . . . . 0.0 108.56 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.497 ' O ' ' N ' ' A' ' 74' ' ' GLY . 24.2 m . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 121.262 0.553 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.18 -18.71 0.16 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.65 -46.67 89.29 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.443 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 1.9 mp0 -80.71 -41.76 23.09 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.239 -1.154 . . . . 0.0 109.397 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 3.6 t -59.17 -53.01 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 108.732 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.554 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 23.1 t-20 -57.76 -55.19 38.08 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.0 tp -50.16 -31.71 14.28 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.432 -0.792 . . . . 0.0 109.1 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.2 tp -64.76 -59.7 3.93 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.367 -0.833 . . . . 0.0 110.358 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -73.01 -21.74 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 110.602 -178.386 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.554 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 1.4 mp0 -70.98 -46.5 62.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.507 -1.371 . . . . 0.0 109.341 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 2.4 pp0? . . . . . 0 N--CA 1.499 1.983 0 O-C-N 121.087 -1.008 . . . . 0.0 110.031 -179.051 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.416 ' C ' ' N ' ' A' ' 74' ' ' GLY . 28.6 m . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.81 -20.5 1.22 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.416 ' N ' ' C ' ' A' ' 72' ' ' VAL . . . -76.77 -39.0 30.04 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 179.557 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.54 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 0.5 OUTLIER -64.41 -33.48 75.96 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.954 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.06 -48.2 33.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.577 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 7.2 t-20 -56.45 -34.7 67.11 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.9 tp -67.11 -37.24 83.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.248 -0.908 . . . . 0.0 108.789 179.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 40.7 tp -60.53 -40.04 90.05 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.154 -0.966 . . . . 0.0 109.947 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.496 ' CG2' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -85.53 -50.03 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 120.549 -1.344 . . . . 0.0 109.224 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.577 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -45.48 -32.0 2.0 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.631 -1.293 . . . . 0.0 110.375 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.593 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 O-C-N 120.828 -1.17 . . . . 0.0 110.045 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLY . 28.8 m . . . . . 0 N--CA 1.48 1.068 0 CA-C-O 121.078 0.466 . . . . 0.0 109.785 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.403 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -49.73 -12.8 0.45 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -81.24 -41.9 9.83 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -82.48 -41.8 19.29 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.221 -1.164 . . . . 0.0 108.851 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.4 t -62.43 -55.82 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.623 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 0.5 OUTLIER -56.36 -53.78 53.32 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.542 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 27.4 tp -47.6 -35.65 9.56 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.174 -0.954 . . . . 0.0 108.597 179.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.616 ' C ' HE22 ' A' ' 82' ' ' GLN . 0.7 OUTLIER -63.59 -38.68 92.03 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.729 -0.607 . . . . 0.0 109.769 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.45 HD12 HG22 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -76.88 -22.96 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.715 -1.24 . . . . 0.0 109.558 -179.577 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.623 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 8.0 mt-30 -74.51 -48.45 27.06 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 111.527 -178.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.722 HE21 ' H ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 O-C-N 120.304 -1.497 . . . . 0.0 109.315 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.435 ' O ' ' N ' ' A' ' 75' ' ' GLN . 20.9 m . . . . . 0 N--CA 1.476 0.866 0 CA-C-O 120.893 0.378 . . . . 0.0 110.019 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -43.5 -27.06 0.75 Allowed Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.22 -36.66 26.8 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . 0.435 ' N ' ' O ' ' A' ' 72' ' ' VAL . 11.3 mt-30 -66.07 -23.49 66.53 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 178.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.4 t -73.67 -47.16 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -56.11 -49.44 73.88 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 31.8 tp -59.85 -36.33 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.511 -0.743 . . . . 0.0 110.085 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.5 mp -69.05 -24.74 64.21 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.118 -0.988 . . . . 0.0 111.495 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.63 -26.32 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 120.378 -1.451 . . . . 0.0 110.708 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -86.51 -22.02 26.62 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.372 -1.455 . . . . 0.0 109.94 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 . . . . . 0 N--CA 1.494 1.746 0 O-C-N 120.95 -1.093 . . . . 0.0 108.843 179.58 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.8 m . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.313 0.578 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' C ' ' H ' ' A' ' 71' ' ' SER . 2.4 p 175.08 112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 55.8 mt 48.16 11.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.128 -0.982 . . . . 0.0 109.659 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.535 ' H ' ' C ' ' A' ' 69' ' ' VAL . 29.8 t -82.6 118.25 23.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.997 0.903 . . . . 0.0 109.591 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.508 ' C ' ' H ' ' A' ' 74' ' ' GLY . 26.7 m -93.85 -18.33 6.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -51.18 -10.14 0.45 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.508 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -72.62 -49.91 16.92 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.9 mp0 -79.27 -39.23 33.51 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.18 -1.188 . . . . 0.0 109.139 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 13.9 t -62.48 -54.5 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 108.585 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -54.5 -49.18 70.77 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.58 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 40.8 tp -48.02 -50.61 27.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.092 -1.005 . . . . 0.0 108.862 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.9 tp -55.88 -31.98 63.29 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 110.973 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -74.32 -38.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.583 -1.323 . . . . 0.0 109.851 -178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -64.87 -53.44 46.59 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.176 -0.953 . . . . 0.0 110.362 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.776 ' H ' HE21 ' A' ' 82' ' ' GLN . 0.1 OUTLIER -56.31 -42.57 77.84 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.425 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -64.99 -19.6 66.08 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.757 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 84' ' ' ILE . 3.1 mm -89.1 -6.79 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.09 -1.006 . . . . 0.0 109.153 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -135.65 57.23 18.18 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.376 -0.827 . . . . 0.0 109.798 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -75.85 11.84 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.673 2.249 . . . . 0.0 111.497 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.0 mmmm -58.78 -31.67 68.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.458 -0.776 . . . . 0.0 109.573 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.757 HD21 ' H ' ' A' ' 89' ' ' LEU . 0.2 OUTLIER -74.57 -67.29 0.64 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.322 -179.788 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.757 ' H ' HD21 ' A' ' 88' ' ' ASN . 6.7 tp -51.75 -41.82 61.87 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.351 -0.843 . . . . 0.0 109.073 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.742 ' OG ' ' CH2' ' A' ' 99' ' ' TRP . 30.0 t -58.09 -46.22 85.86 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.285 -0.885 . . . . 0.0 109.195 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 6.0 tpp180 -53.7 -32.28 51.23 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.263 -0.898 . . . . 0.0 108.875 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 16.0 mt -82.28 10.24 7.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.808 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 95' ' ' GLY . 32.2 m-85 -141.45 153.98 66.34 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.253 -0.904 . . . . 0.0 109.082 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -39.58 -15.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.708 2.272 . . . . 0.0 113.057 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -44.92 -32.9 3.36 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 120.326 -0.94 . . . . 0.0 110.757 -179.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.526 ' O ' ' N ' ' A' ' 98' ' ' ALA . 67.0 p-90 -84.22 -34.9 23.8 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.696 -1.473 . . . . 0.0 110.944 -178.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -49.51 -9.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.163 . . . . 0.0 110.284 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.526 ' N ' ' O ' ' A' ' 96' ' ' TRP . . . -112.81 -19.88 11.83 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.124 -0.985 . . . . 0.0 108.541 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.742 ' CH2' ' OG ' ' A' ' 90' ' ' SER . 23.2 m0 -83.02 -4.66 58.56 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.724 -0.61 . . . . 0.0 109.859 -178.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' A' ' 99' ' ' TRP . 30.9 m . . . . . 0 C--N 1.306 -1.305 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.608 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 59.5 m . . . . . 0 N--CA 1.492 1.646 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' A' ' 71' ' ' SER . 0.6 OUTLIER -171.89 -41.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.186 -0.946 . . . . 0.0 109.221 -179.75 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 14.3 mt -45.79 -12.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.579 -0.701 . . . . 0.0 110.303 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.556 ' N ' ' O ' ' A' ' 69' ' ' VAL . 2.6 t -155.01 124.39 6.37 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.027 -1.046 . . . . 0.0 109.562 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.482 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.8 m -79.49 -45.95 23.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-O 121.229 0.538 . . . . 0.0 109.569 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.404 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -48.47 -15.33 0.44 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -73.18 -51.94 9.47 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.568 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 2.6 mp0 -82.94 -42.28 17.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.169 -1.195 . . . . 0.0 109.528 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 32.9 t -56.61 -52.05 58.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.469 ' OD1' ' NE2' ' A' ' 81' ' ' GLN . 8.1 t-20 -61.77 -53.35 57.21 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 42.3 tp -50.39 -31.83 15.91 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.117 -0.989 . . . . 0.0 109.143 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.7 tp -75.61 -30.13 59.44 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.273 -0.892 . . . . 0.0 110.539 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.434 HG21 HD11 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -82.56 -19.95 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 120.831 -1.168 . . . . 0.0 109.526 -179.094 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.469 ' NE2' ' OD1' ' A' ' 77' ' ' ASN . 6.7 mt-30 -90.46 -35.52 15.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.592 -1.317 . . . . 0.0 110.34 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.9 tp60 -86.61 -36.7 18.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.948 -1.095 . . . . 0.0 108.782 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.48 -11.45 0.86 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.167 -0.958 . . . . 0.0 109.782 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.513 ' CD1' ' N ' ' A' ' 85' ' ' ASP . 1.9 pp -142.29 -126.29 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 O-C-N 121.068 -1.02 . . . . 0.0 108.675 -179.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.513 ' N ' ' CD1' ' A' ' 84' ' ' ILE . 74.4 m-20 -89.16 115.9 64.89 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 120.917 -1.114 . . . . 0.0 109.05 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -80.25 5.81 5.78 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.818 1.679 . . . . 0.0 112.128 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.402 ' NZ ' HH22 ' A' ' 91' ' ' ARG . 4.2 mtpm? -50.61 -34.32 25.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.193 -0.942 . . . . 0.0 109.336 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.802 HD21 ' H ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -65.3 -57.25 8.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.369 179.933 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.802 ' H ' HD21 ' A' ' 88' ' ' ASN . 30.5 tp -48.1 -31.5 5.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.054 -1.029 . . . . 0.0 109.119 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.4 m -87.69 -19.69 27.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 109.923 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.548 ' HE ' ' CA ' ' A' ' 91' ' ' ARG . 0.0 OUTLIER -77.83 -21.35 51.62 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.009 -1.057 . . . . 0.0 109.655 -179.415 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 16.7 mt -47.29 -16.29 0.05 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.991 -1.068 . . . . 0.0 109.23 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.497 ' N ' ' O ' ' A' ' 91' ' ' ARG . 71.3 m-85 -112.85 90.06 14.67 Favored Pre-proline 0 N--CA 1.496 1.847 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -41.02 -21.55 0.11 Allowed 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 122.033 1.822 . . . . 0.0 112.473 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 99' ' ' TRP . . . -58.91 -9.25 6.84 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.411 ' CD1' ' CE3' ' A' ' 99' ' ' TRP . 7.3 m95 -80.65 -9.54 59.78 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -1.194 . . . . 0.0 109.543 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 13.7 ptpt -66.25 -17.51 64.79 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.084 -1.01 . . . . 0.0 110.328 -179.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.67 -21.52 10.19 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 21.4 m0 -72.86 -2.21 19.81 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 119.524 -0.87 . . . . 0.0 109.368 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m . . . . . 0 C--N 1.305 -1.329 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.68 -179.978 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.7 m . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.281 0.562 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.567 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.2 m -86.5 68.04 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.265 -0.897 . . . . 0.0 109.268 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.472 ' O ' ' CB ' ' A' ' 71' ' ' SER . 23.6 mt 65.0 -32.57 0.15 Allowed 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.794 -0.567 . . . . 0.0 110.383 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.567 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.5 OUTLIER 166.2 114.91 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.125 -0.985 . . . . 0.0 109.171 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.436 ' O ' ' N ' ' A' ' 74' ' ' GLY . 23.7 m -54.75 -39.61 48.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -43.96 -23.73 0.43 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.96 -44.84 54.42 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.592 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 2.3 mp0 -62.31 -29.21 70.28 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.7 t -70.33 -44.91 77.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.524 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 9.1 t-20 -60.58 -57.76 11.36 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 33.2 tp -47.94 -28.94 2.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 108.969 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.1 tp -70.7 -40.04 73.1 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.353 -0.842 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.434 HD11 HG21 ' A' ' 80' ' ' ILE . 0.2 OUTLIER -67.9 -38.75 80.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.944 -1.098 . . . . 0.0 109.45 -179.276 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 2.5 mp0 -68.6 -31.99 71.55 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.895 -1.128 . . . . 0.0 108.529 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -53.81 53.29 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.453 -0.779 . . . . 0.0 109.684 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -47.06 -51.34 17.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.47 -0.769 . . . . 0.0 110.375 -179.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.408 ' O ' ' OD2' ' A' ' 85' ' ' ASP . 7.5 mm -46.78 -44.49 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.405 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 88' ' ' ASN . 25.5 m-20 -151.51 102.27 2.92 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -81.58 -2.17 11.36 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.973 1.782 . . . . 0.0 112.323 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.49 -27.63 39.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.109 -0.994 . . . . 0.0 108.886 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.621 ' ND2' ' N ' ' A' ' 89' ' ' LEU . 2.0 p-10 -64.47 -50.62 66.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.214 -0.929 . . . . 0.0 109.028 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.621 ' N ' ' ND2' ' A' ' 88' ' ' ASN . 9.6 tp -57.99 -45.54 86.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.303 -0.873 . . . . 0.0 108.815 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.8 p -70.3 -26.74 63.93 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.345 -0.847 . . . . 0.0 109.417 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' A' ' 93' ' ' PHE . 2.8 tmm_? -69.97 -24.56 63.35 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.331 -0.856 . . . . 0.0 109.808 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 71.9 mt -47.0 -17.84 0.06 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.161 -0.962 . . . . 0.0 109.299 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.475 ' N ' ' O ' ' A' ' 91' ' ' ARG . 1.0 OUTLIER -106.97 100.52 32.49 Favored Pre-proline 0 N--CA 1.497 1.878 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.439 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -42.7 -27.49 0.86 Allowed 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.896 1.731 . . . . 0.0 112.25 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.82 -5.55 14.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 4.9 p-90 -66.86 -12.56 59.63 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.854 -1.38 . . . . 0.0 109.292 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.2 ptpt -60.36 -12.56 9.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -120.23 -21.93 6.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.615 -0.678 . . . . 0.0 109.453 -179.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 22.8 m0 -69.56 -30.61 68.44 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.367 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--N 1.304 -1.389 0 CA-C-O 117.961 -1.018 . . . . 0.0 109.511 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.402 ' CG2' ' H ' ' A' ' 69' ' ' VAL . 2.7 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.514 ' CG1' ' H ' ' A' ' 70' ' ' LEU . 4.8 p -172.65 -60.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.141 -0.974 . . . . 0.0 110.038 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.514 ' H ' ' CG1' ' A' ' 69' ' ' VAL . 45.1 mt -44.17 -38.62 3.83 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.438 -0.788 . . . . 0.0 109.555 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER 26.48 99.02 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.375 0 CA-C-O 121.981 0.896 . . . . 0.0 111.683 179.625 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.5 m -63.52 -42.89 97.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 CA-C-O 121.375 0.607 . . . . 0.0 109.488 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -48.69 -9.82 0.1 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -79.93 -62.68 2.08 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.053 -1.263 . . . . 0.0 110.109 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.566 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 0.6 OUTLIER -74.03 -30.32 62.37 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.073 -1.251 . . . . 0.0 108.841 -179.638 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 41.2 t -67.81 -51.57 48.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 14.7 t-20 -55.11 -36.34 65.61 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.133 -0.979 . . . . 0.0 108.803 178.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.5 tp -73.95 -46.93 40.97 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 120.715 -1.241 . . . . 0.0 108.88 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 7.9 mp -65.87 -15.71 63.17 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.567 -0.708 . . . . 0.0 109.298 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 81' ' ' GLN . 0.4 OUTLIER -80.33 -54.51 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.819 -1.176 . . . . 0.0 108.306 -179.885 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 4.6 mt-30 -54.97 -53.82 50.79 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.066 -1.021 . . . . 0.0 110.095 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -39.59 90.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.23 -37.99 86.86 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.133 -0.979 . . . . 0.0 110.159 -179.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.74 88.51 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.13 -0.981 . . . . 0.0 108.484 179.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.577 ' N ' ' CD ' ' A' ' 86' ' ' PRO . 0.6 OUTLIER -56.85 -41.69 92.58 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.421 179.689 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.577 ' CD ' ' N ' ' A' ' 85' ' ' ASP . 33.5 Cg_exo -61.4 18.32 0.04 OUTLIER 'Trans proline' 0 N--CA 1.5 1.866 0 C-N-CA 122.583 2.188 . . . . 0.0 112.456 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.561 ' H ' ' C ' ' A' ' 85' ' ' ASP . 47.9 pttt -46.85 -23.57 0.46 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.218 -0.926 . . . . 0.0 109.219 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.625 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 2.6 p-10 -74.47 -58.04 3.55 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.625 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 30.7 tp -47.41 -30.14 3.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.576 -0.702 . . . . 0.0 109.322 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 72.3 m -90.04 -26.37 20.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 110.183 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.478 ' O ' ' N ' ' A' ' 93' ' ' PHE . 29.7 ttm180 -85.55 -17.42 36.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.028 -1.045 . . . . 0.0 110.701 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 71.5 mt -47.42 -18.52 0.12 Allowed 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.849 -1.157 . . . . 0.0 108.679 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 95' ' ' GLY . 17.7 m-85 -122.93 86.02 50.56 Favored Pre-proline 0 N--CA 1.494 1.731 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -41.67 -17.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.213 1.942 . . . . 0.0 112.081 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -67.67 -5.21 36.63 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 1.5 p-90 -72.58 -10.09 59.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.897 -1.355 . . . . 0.0 109.361 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -59.83 -9.8 3.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.31 -0.869 . . . . 0.0 109.853 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -124.12 -21.68 4.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 108.906 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.576 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 7.2 m0 -77.95 -2.59 37.68 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.415 -0.803 . . . . 0.0 109.414 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 99' ' ' TRP . 1.8 m . . . . . 0 N--CA 1.488 1.459 0 CA-C-O 117.924 -1.036 . . . . 0.0 109.459 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.237 0.541 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.534 ' C ' ' H ' ' A' ' 71' ' ' SER . 10.9 m -145.06 104.85 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 14.1 mt 50.07 9.09 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.945 -1.097 . . . . 0.0 109.745 -179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.534 ' H ' ' C ' ' A' ' 69' ' ' VAL . 26.7 t -74.08 106.43 5.75 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 122.137 0.97 . . . . 0.0 109.116 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 75' ' ' GLN . 18.9 m -79.48 -27.77 12.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -24.71 3.08 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.647 -1.781 . . . . 0.0 108.647 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.551 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -72.57 -42.05 49.05 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.413 ' N ' ' O ' ' A' ' 72' ' ' VAL . 10.9 mp0 -58.64 -21.8 54.91 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 178.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.4 ' C ' ' N ' ' A' ' 78' ' ' LEU . 5.1 t -83.87 -53.64 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.573 HD21 ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -57.05 -14.66 3.98 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.632 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.573 ' N ' HD21 ' A' ' 77' ' ' ASN . 65.9 tp -88.0 -66.05 0.95 Allowed 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.97 -13.88 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 110.027 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.494 ' CG2' ' N ' ' A' ' 81' ' ' GLN . 0.2 OUTLIER -95.71 -55.0 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.931 -1.105 . . . . 0.0 110.221 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.622 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 2.3 pp0? -55.35 -12.67 1.11 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.072 -1.642 . . . . 0.0 108.256 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.622 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -94.37 -50.71 5.11 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 178.832 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.53 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -51.42 -8.4 0.05 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.793 -0.567 . . . . 0.0 110.307 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.493 ' H ' ' C ' ' A' ' 82' ' ' GLN . 5.4 mm -42.89 -19.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.375 -0.828 . . . . 0.0 109.931 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 87' ' ' LYS . 0.4 OUTLIER -48.87 172.1 0.09 OUTLIER Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.733 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -37.45 -22.89 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.159 1.906 . . . . 0.0 112.354 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.539 ' N ' ' O ' ' A' ' 85' ' ' ASP . 63.0 mmtt -50.38 -26.82 5.38 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.421 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.9 OUTLIER -71.92 -45.45 61.12 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.117 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.421 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 23.9 tp -50.46 -37.74 39.99 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' A' ' 87' ' ' LYS . 13.6 p -76.61 -26.91 55.47 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.468 -0.77 . . . . 0.0 109.069 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.439 ' O ' ' N ' ' A' ' 93' ' ' PHE . 7.5 tpt180 -62.7 -35.65 80.39 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.282 -0.886 . . . . 0.0 109.513 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 15.8 mt -46.36 -21.92 0.21 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.173 -0.955 . . . . 0.0 108.892 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.536 ' O ' ' N ' ' A' ' 95' ' ' GLY . 31.5 m-85 -115.05 88.96 18.42 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -42.53 -14.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 122.224 1.949 . . . . 0.0 112.296 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -63.99 -5.23 13.7 Favored Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 1.4 p-90 -64.52 -12.16 41.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.947 -1.325 . . . . 0.0 109.034 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 49.2 mtmt -58.78 -9.69 1.93 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.497 -0.752 . . . . 0.0 110.022 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -123.34 -21.03 5.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.035 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.495 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 23.4 m0 -71.77 -9.07 57.75 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.501 -0.749 . . . . 0.0 109.557 -179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 12.2 m . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.548 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 11.5 m . . . . . 0 N--CA 1.496 1.838 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.552 ' C ' ' H ' ' A' ' 71' ' ' SER . 16.0 m -113.3 45.23 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.54 -0.725 . . . . 0.0 109.113 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 24.5 mt 65.33 -32.49 0.15 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.777 -0.577 . . . . 0.0 110.49 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.552 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.5 p 172.92 107.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.169 -0.957 . . . . 0.0 109.192 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.2 m -57.16 -29.85 33.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 CA-C-O 121.361 0.6 . . . . 0.0 109.531 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -9.37 0.06 OUTLIER Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -74.85 -63.78 2.49 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.848 -1.384 . . . . 0.0 110.387 -179.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -75.25 -28.31 59.8 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.02 -1.282 . . . . 0.0 109.744 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 25.7 t -68.7 -57.71 8.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 108.747 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.768 HD21 HE22 ' A' ' 81' ' ' GLN . 8.7 t30 -51.98 -44.26 63.97 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.208 -0.932 . . . . 0.0 108.574 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.3 mp -57.2 -30.39 64.5 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.037 -1.039 . . . . 0.0 108.516 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.65 -29.26 62.23 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.317 -0.864 . . . . 0.0 110.779 -178.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.489 ' O ' ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -80.11 -27.15 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.626 -1.296 . . . . 0.0 110.399 -178.685 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.768 HE22 HD21 ' A' ' 77' ' ' ASN . 3.1 pt20 -95.02 -10.87 29.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 108.854 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.527 ' O ' ' N ' ' A' ' 84' ' ' ILE . 15.9 mt-30 -95.48 -65.72 0.96 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -44.35 -16.06 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.584 -0.697 . . . . 0.0 111.012 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.59 ' CD1' ' N ' ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.37 31.74 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.235 -0.916 . . . . 0.0 109.032 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.523 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 2.7 m-20 60.96 150.97 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.992 . . . . 0.0 109.22 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.29 -25.32 13.53 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.125 1.883 . . . . 0.0 112.354 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 8.4 ptmt -48.79 -24.49 1.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.354 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.665 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -70.28 -47.81 59.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.317 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.665 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 6.6 tp -64.53 -23.58 67.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.344 -0.847 . . . . 0.0 109.13 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.9 m -79.73 -47.4 15.36 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 93' ' ' PHE . 66.5 mtt85 -75.58 -52.15 11.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.755 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 41.7 mt -46.07 -19.45 0.07 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.179 -0.951 . . . . 0.0 109.032 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.554 ' O ' ' N ' ' A' ' 95' ' ' GLY . 29.9 m-85 -111.05 95.29 24.05 Favored Pre-proline 0 N--CA 1.494 1.769 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -42.43 -12.73 0.04 OUTLIER 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.413 2.075 . . . . 0.0 112.621 -179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -56.69 -18.83 25.76 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 121.236 -0.915 . . . . 0.0 111.105 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 8.0 p-90 -65.54 -20.28 66.27 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.493 -1.592 . . . . 0.0 110.075 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -63.75 -11.52 27.15 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.144 -0.972 . . . . 0.0 109.76 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.27 -21.21 9.43 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.516 ' CD1' ' O ' ' A' ' 95' ' ' GLY . 25.0 m0 -70.64 -15.54 62.74 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.44 -178.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.505 179.914 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.7 m . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.527 ' C ' ' H ' ' A' ' 71' ' ' SER . 7.4 p -172.45 121.46 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.411 -0.805 . . . . 0.0 109.246 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 81.8 mt 49.69 10.02 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.113 -0.992 . . . . 0.0 109.944 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.527 ' H ' ' C ' ' A' ' 69' ' ' VAL . 53.9 p -43.83 113.5 0.52 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.484 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.9 m -95.38 -50.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.9 -178.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -49.15 -13.41 0.36 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -80.9 -62.07 2.06 Favored Glycine 0 N--CA 1.492 2.392 0 O-C-N 121.213 -1.169 . . . . 0.0 110.666 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.489 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 3.4 mp0 -73.78 -32.12 63.62 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.882 -1.364 . . . . 0.0 108.8 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 39.9 t -66.57 -59.72 3.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -50.46 -30.82 13.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.105 -0.997 . . . . 0.0 109.305 179.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 61.1 tp -78.61 -29.81 46.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.077 -1.014 . . . . 0.0 109.654 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.6 mp -72.7 -35.34 67.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.061 -1.024 . . . . 0.0 109.685 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.24 -42.43 23.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.719 -1.238 . . . . 0.0 109.464 -179.476 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -66.07 -29.59 69.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.952 -1.093 . . . . 0.0 110.394 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 pp0? -89.89 -26.97 20.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.632 -1.293 . . . . 0.0 109.013 179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.436 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -77.05 -8.61 57.74 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.488 -0.757 . . . . 0.0 110.282 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.436 ' C ' ' O ' ' A' ' 83' ' ' ALA . 6.0 mm -38.28 -57.84 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.428 ' OD2' ' N ' ' A' ' 85' ' ' ASP . 9.0 p30 -171.68 129.07 0.66 Allowed Pre-proline 0 C--N 1.299 -1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.03 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -77.35 7.37 3.79 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.828 1.685 . . . . 0.0 112.17 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 39.4 pttt -50.26 -34.96 25.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.165 -0.959 . . . . 0.0 109.289 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.405 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 2.4 p30 -74.72 -45.84 41.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.26 -0.9 . . . . 0.0 108.993 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.405 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 32.0 tp -59.93 -42.0 93.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.571 -0.706 . . . . 0.0 109.668 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 6.0 m -75.53 -21.75 57.67 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.254 -0.904 . . . . 0.0 110.266 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.513 ' O ' ' N ' ' A' ' 93' ' ' PHE . 57.2 ttm-85 -76.27 -28.71 57.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.032 -1.042 . . . . 0.0 109.71 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 18.3 mt -46.87 -16.77 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.016 -1.052 . . . . 0.0 108.962 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.552 ' O ' ' N ' ' A' ' 95' ' ' GLY . 21.8 m-85 -124.37 84.75 56.19 Favored Pre-proline 0 N--CA 1.492 1.634 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -39.82 -17.08 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.645 2.23 . . . . 0.0 112.586 -178.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -62.62 -5.82 9.87 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.6 p-90 -68.1 -10.78 56.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.588 -1.536 . . . . 0.0 109.44 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -61.83 -12.68 18.61 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.461 -0.774 . . . . 0.0 110.174 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -121.85 -21.07 6.18 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.542 -0.723 . . . . 0.0 109.276 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.519 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.7 m0 -71.32 -14.46 62.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.364 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.434 ' OXT' ' O ' ' A' ' 99' ' ' TRP . 3.5 m . . . . . 0 C--N 1.305 -1.362 0 CA-C-O 118.078 -0.963 . . . . 0.0 109.602 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.9 m . . . . . 0 N--CA 1.497 1.911 0 CA-C-O 121.274 0.559 . . . . 0.0 110.49 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.628 ' C ' ' H ' ' A' ' 71' ' ' SER . 32.8 m -76.5 120.79 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 121.3 -0.875 . . . . 0.0 109.143 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.445 ' O ' ' O ' ' A' ' 71' ' ' SER . 21.3 mt 60.7 -13.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.385 -0.822 . . . . 0.0 110.141 -179.174 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.628 ' H ' ' C ' ' A' ' 69' ' ' VAL . 29.8 t 47.3 98.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.158 -0.964 . . . . 0.0 110.162 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.6 m -45.26 -25.68 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 CA-C-O 121.385 0.612 . . . . 0.0 109.772 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -46.56 -14.57 0.11 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.86 -53.09 12.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -74.25 -32.45 62.96 Favored 'General case' 0 N--CA 1.485 1.289 0 O-C-N 120.985 -1.303 . . . . 0.0 109.228 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -70.8 -60.0 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.185 -0.947 . . . . 0.0 108.773 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 29.7 t-20 -55.48 -24.82 33.34 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.095 -1.003 . . . . 0.0 108.973 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.9 tp -81.65 -41.8 20.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.843 -1.161 . . . . 0.0 109.047 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.3 tp -58.9 -35.89 73.79 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.357 -0.84 . . . . 0.0 110.432 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.513 ' CG2' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -79.21 -49.12 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.853 -1.154 . . . . 0.0 108.891 -179.523 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 0.1 OUTLIER -58.57 -12.06 3.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.756 -1.215 . . . . 0.0 108.841 178.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -88.85 -55.39 3.72 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.173 -0.954 . . . . 0.0 109.686 -178.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.467 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -48.78 -71.76 0.06 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.82 -1.175 . . . . 0.0 109.867 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.467 ' C ' ' O ' ' A' ' 83' ' ' ALA . 9.7 mm 28.03 69.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 CA-C-O 121.224 0.535 . . . . 0.0 112.095 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.425 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 0.2 OUTLIER 177.66 -53.08 0.0 OUTLIER Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.878 . . . . 0.0 109.46 179.504 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 88' ' ' ASN . 89.5 Cg_endo -82.81 -51.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.035 1.823 . . . . 0.0 111.966 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 10.7 pttm -48.59 -16.74 0.12 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.24 -0.913 . . . . 0.0 109.11 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.691 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -73.63 -61.2 1.92 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.691 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 3.3 tt -54.8 -22.97 16.02 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.109 -0.994 . . . . 0.0 108.742 179.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.447 ' O ' ' N ' ' A' ' 95' ' ' GLY . 8.5 t -87.26 -34.49 18.91 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.309 -0.869 . . . . 0.0 110.271 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -72.82 -20.42 61.14 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.057 -1.027 . . . . 0.0 110.002 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.494 ' O ' ' CD1' ' A' ' 93' ' ' PHE . 82.0 mt -76.61 -2.03 30.57 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.917 -1.114 . . . . 0.0 110.863 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' A' ' 92' ' ' LEU . 11.1 m-85 -159.95 -72.93 0.01 OUTLIER Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 120.542 -1.349 . . . . 0.0 111.485 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 96' ' ' TRP . 73.5 Cg_endo -69.6 -53.26 0.29 Allowed 'Trans proline' 0 N--CA 1.5 1.86 0 C-N-CA 121.53 1.487 . . . . 0.0 112.751 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 90' ' ' SER . . . -46.63 -11.69 0.05 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.119 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.612 ' NE1' ' CH2' ' A' ' 99' ' ' TRP . 26.3 m0 -50.02 -19.56 0.75 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.606 ' HZ2' ' N ' ' A' ' 97' ' ' LYS . 3.4 mmpm? -58.6 -8.4 1.25 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.91 -17.29 19.33 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 120.877 -1.139 . . . . 0.0 108.331 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.612 ' CH2' ' NE1' ' A' ' 96' ' ' TRP . 31.2 m0 -73.43 -25.64 60.6 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.117 -178.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 C--N 1.304 -1.393 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.645 -179.92 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.401 ' CG2' ' H ' ' A' ' 69' ' ' VAL . 1.7 m . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.445 ' C ' ' H ' ' A' ' 71' ' ' SER . 34.5 m -83.66 53.34 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.488 -0.757 . . . . 0.0 109.505 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.436 ' O ' ' OG ' ' A' ' 71' ' ' SER . 22.0 mt 60.17 6.07 0.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.521 -0.737 . . . . 0.0 109.076 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.445 ' H ' ' C ' ' A' ' 69' ' ' VAL . 16.0 m -173.49 115.83 0.25 Allowed 'General case' 0 N--CA 1.487 1.396 0 CA-C-O 121.964 0.888 . . . . 0.0 109.212 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' GLY . 30.5 m -71.16 -28.02 31.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 CA-C-O 121.311 0.577 . . . . 0.0 109.638 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -44.92 -17.97 0.11 Allowed Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.94 -54.87 25.35 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.641 ' H ' ' NE2' ' A' ' 75' ' ' GLN . 2.1 mp0 -74.69 -36.01 62.76 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.185 -1.185 . . . . 0.0 109.624 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 7.4 t -65.84 -58.91 4.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.027 -1.046 . . . . 0.0 109.053 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.486 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -54.24 -31.02 52.36 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 108.74 179.726 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.3 tp -73.23 -37.79 66.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.183 -0.948 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.6 mp -61.64 -40.81 96.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.197 -0.939 . . . . 0.0 109.425 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.92 -46.71 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.777 -1.202 . . . . 0.0 109.957 -179.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.674 ' N ' HE21 ' A' ' 81' ' ' GLN . 0.0 OUTLIER -53.45 -39.88 64.78 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.641 -1.287 . . . . 0.0 109.981 -179.372 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.493 ' C ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -80.87 -31.7 35.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.859 -1.15 . . . . 0.0 110.143 -179.128 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -65.62 -9.97 31.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.125 -0.984 . . . . 0.0 111.112 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 2.7 pp -112.43 17.9 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.365 0 O-C-N 121.035 -1.041 . . . . 0.0 110.767 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.447 ' C ' ' H ' ' A' ' 87' ' ' LYS . 10.7 p30 -158.67 150.08 16.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 120.905 -1.122 . . . . 0.0 109.501 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -72.35 24.33 0.27 Allowed 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 122.166 1.911 . . . . 0.0 111.636 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.447 ' H ' ' C ' ' A' ' 85' ' ' ASP . 21.4 mmtm -50.65 -36.78 37.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.21 -0.931 . . . . 0.0 109.11 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.721 HD21 ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -59.7 -26.3 65.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.403 -0.811 . . . . 0.0 109.137 179.555 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.721 ' H ' HD21 ' A' ' 88' ' ' ASN . 7.5 tt -81.53 -57.77 3.32 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.377 -0.827 . . . . 0.0 109.019 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 7.8 p -53.92 -23.02 11.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.249 -0.907 . . . . 0.0 109.091 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.528 ' O ' ' CD1' ' A' ' 96' ' ' TRP . 12.6 mtp180 -76.15 -63.37 1.33 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.437 -0.789 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 44.1 mt -51.27 -25.12 5.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -0.947 . . . . 0.0 109.499 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.547 ' O ' ' N ' ' A' ' 95' ' ' GLY . 2.1 m-85 -57.25 158.21 10.66 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.118 -0.989 . . . . 0.0 108.818 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_exo -40.44 -14.07 0.03 OUTLIER 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.804 2.336 . . . . 0.0 113.245 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -48.13 -44.62 26.54 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.611 ' NE1' ' CZ3' ' A' ' 99' ' ' TRP . 13.6 m0 -58.19 -22.52 52.06 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.121 -1.223 . . . . 0.0 110.071 -179.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.7 mmpt? -59.34 -9.38 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.153 -0.967 . . . . 0.0 110.412 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.22 -20.57 12.27 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.611 ' CZ3' ' NE1' ' A' ' 96' ' ' TRP . 23.7 m0 -76.88 -16.95 59.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.346 -179.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 1.1 t . . . . . 0 C--N 1.306 -1.299 0 CA-C-O 117.929 -1.034 . . . . 0.0 108.869 -179.857 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.604 ' C ' ' H ' ' A' ' 71' ' ' SER . 34.5 m -129.2 2.09 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.197 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.443 ' O ' ' O ' ' A' ' 71' ' ' SER . 17.1 mt 58.93 -6.9 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.43 -0.794 . . . . 0.0 110.468 179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.604 ' H ' ' C ' ' A' ' 69' ' ' VAL . 8.6 t 55.83 110.25 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 122.202 1.001 . . . . 0.0 109.98 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 74' ' ' GLY . 20.4 m -95.67 -26.18 4.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 CA-C-O 121.356 0.598 . . . . 0.0 109.631 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.63 -22.57 0.73 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -61.04 -46.93 93.57 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -81.69 -46.55 14.14 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.142 -1.211 . . . . 0.0 109.488 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.8 t -57.04 -51.33 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.206 -0.934 . . . . 0.0 108.683 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.565 ' C ' HE21 ' A' ' 81' ' ' GLN . 6.6 t-20 -58.46 -50.17 74.68 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.2 tp -47.9 -36.37 12.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.985 -1.072 . . . . 0.0 109.305 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 7.2 mp -70.88 -33.94 71.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.184 -0.947 . . . . 0.0 109.926 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.434 HG23 HD11 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -75.8 -31.95 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 120.572 -1.33 . . . . 0.0 109.06 -179.541 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.565 HE21 ' C ' ' A' ' 77' ' ' ASN . 6.0 mt-30 -74.93 -22.15 58.76 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.177 -0.952 . . . . 0.0 109.317 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -79.82 -56.77 4.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.572 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.619 ' C ' ' H ' ' A' ' 85' ' ' ASP . . . -78.28 -40.81 35.85 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.279 -0.888 . . . . 0.0 110.034 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 1.3 mp 57.45 -16.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.386 -0.821 . . . . 0.0 111.564 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.619 ' H ' ' C ' ' A' ' 83' ' ' ALA . 2.1 p30 -83.51 129.89 58.3 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 120.318 -1.489 . . . . 0.0 109.328 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -79.05 -2.35 12.33 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.941 1.76 . . . . 0.0 111.951 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.473 ' NZ ' ' CG ' ' A' ' 85' ' ' ASP . 23.4 pttm -69.32 -21.09 63.87 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.306 -0.871 . . . . 0.0 108.935 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.63 ' ND2' ' N ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -90.43 -62.84 1.37 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.833 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.63 ' N ' ' ND2' ' A' ' 88' ' ' ASN . 34.3 tp -48.48 -25.17 1.54 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.107 -0.995 . . . . 0.0 109.442 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.458 ' OG ' ' CB ' ' A' ' 96' ' ' TRP . 5.2 t -94.28 -46.24 7.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 110.278 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 93' ' ' PHE . 55.5 ttt180 -56.27 -38.76 71.62 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.147 -0.97 . . . . 0.0 109.912 -179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.8 mt -49.62 -11.44 0.05 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.957 -1.089 . . . . 0.0 109.444 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.558 ' O ' ' N ' ' A' ' 95' ' ' GLY . 64.2 m-85 -146.02 119.0 5.16 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.279 -0.888 . . . . 0.0 108.847 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.16 -11.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.103 1.869 . . . . 0.0 112.782 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -61.72 -3.25 4.21 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 120.272 -0.966 . . . . 0.0 110.885 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.458 ' CB ' ' OG ' ' A' ' 90' ' ' SER . 2.3 p-90 -69.2 -10.11 56.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.642 -1.505 . . . . 0.0 109.188 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 7.9 ptpt -61.39 -9.98 6.5 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.592 -0.693 . . . . 0.0 110.768 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.89 -19.96 13.58 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.774 0.797 . . . . 0.0 109.007 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.438 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 20.3 m95 -77.27 6.36 6.87 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.743 -0.598 . . . . 0.0 109.898 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.579 -179.995 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.57 ' O ' ' N ' ' A' ' 71' ' ' SER . 0.2 OUTLIER -167.16 -31.38 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.069 -1.02 . . . . 0.0 108.505 -179.587 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 69' ' ' VAL . 9.7 mt -30.93 -31.51 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.253 0 CA-C-O 121.057 0.456 . . . . 0.0 111.372 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.57 ' N ' ' O ' ' A' ' 69' ' ' VAL . 51.7 m -163.56 126.77 2.67 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.033 -1.042 . . . . 0.0 110.207 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.522 ' C ' ' H ' ' A' ' 74' ' ' GLY . 34.7 m -95.29 -51.21 11.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.705 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.456 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -49.35 -10.06 0.17 Allowed Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -75.59 -55.7 4.91 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 68.6 mm-40 -74.99 -26.33 59.48 Favored 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.202 -1.175 . . . . 0.0 109.702 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.0 t -73.03 -62.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -0.906 . . . . 0.0 108.946 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.497 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -51.59 -36.76 46.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.028 -1.045 . . . . 0.0 108.476 179.405 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.443 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 11.1 tp -66.7 -43.0 85.51 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -56.74 -53.91 52.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.305 -0.872 . . . . 0.0 110.057 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -68.11 -38.52 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.887 -1.133 . . . . 0.0 110.134 -178.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.618 ' N ' HE21 ' A' ' 81' ' ' GLN . 0.0 OUTLIER -66.14 -41.22 90.73 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.497 -1.377 . . . . 0.0 109.883 -179.766 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.508 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -83.37 -32.58 26.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.717 -1.239 . . . . 0.0 110.102 -179.116 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -74.32 -63.27 1.27 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.117 -0.989 . . . . 0.0 111.221 -178.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 3.9 mt 43.72 55.86 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 O-C-N 121.093 -1.004 . . . . 0.0 110.079 -178.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.657 ' H ' ' CD ' ' A' ' 86' ' ' PRO . 2.0 t70 -157.11 -39.08 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.263 -0.898 . . . . 0.0 110.826 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.657 ' CD ' ' H ' ' A' ' 85' ' ' ASP . 59.8 Cg_endo -93.83 36.1 0.19 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.422 2.081 . . . . 0.0 111.531 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.401 ' C ' ' HG ' ' A' ' 90' ' ' SER . 0.1 OUTLIER -54.3 -27.22 33.95 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.374 -0.829 . . . . 0.0 108.839 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.638 ' ND2' ' N ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -77.09 -68.95 0.56 Allowed 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.638 ' N ' ' ND2' ' A' ' 88' ' ' ASN . 3.9 tt -49.73 -26.21 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.355 -0.841 . . . . 0.0 109.405 -179.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.52 ' OG ' ' CZ2' ' A' ' 96' ' ' TRP . 60.5 p -77.26 -51.39 10.99 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.226 -0.921 . . . . 0.0 109.759 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 63.3 mtm180 -50.13 -29.73 9.71 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.958 -1.089 . . . . 0.0 109.289 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.1 mt -58.29 -32.76 68.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.079 -1.013 . . . . 0.0 109.118 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -67.36 153.3 95.06 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.172 -0.955 . . . . 0.0 108.478 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -75.16 -14.48 20.79 Favored 'Trans proline' 0 N--CA 1.493 1.477 0 C-N-CA 122.207 1.938 . . . . 0.0 112.868 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.07 -11.43 66.94 Favored Glycine 0 N--CA 1.497 2.73 0 C-N-CA 119.97 -1.11 . . . . 0.0 110.414 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.52 ' CZ2' ' OG ' ' A' ' 90' ' ' SER . 26.9 m95 -89.44 -7.14 55.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.177 -1.19 . . . . 0.0 110.088 -179.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.28 -23.24 2.17 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.164 -0.96 . . . . 0.0 111.244 -178.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.63 -20.06 10.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.939 . . . . 0.0 109.408 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.503 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 23.0 m0 -73.61 -12.41 60.74 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.836 -178.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.2 m . . . . . 0 C--N 1.304 -1.372 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.366 179.998 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 121.344 0.592 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 71' ' ' SER . 2.2 p -175.1 -49.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.88 . . . . 0.0 109.152 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.486 ' O ' ' CB ' ' A' ' 71' ' ' SER . 53.7 mt -48.19 -10.16 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.534 -0.728 . . . . 0.0 109.828 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 69' ' ' VAL . 1.4 p 76.89 126.75 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.22 -0.925 . . . . 0.0 109.161 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.559 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.7 m -60.22 -25.48 33.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.17 -179.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -42.85 -17.63 0.04 OUTLIER Glycine 0 N--CA 1.498 2.83 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -77.72 -52.54 5.4 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -72.78 -36.56 67.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.135 -1.215 . . . . 0.0 108.839 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.3 t -65.52 -53.45 39.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.615 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.3 t-20 -51.93 -31.24 27.81 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.0 mp -72.24 -47.69 48.39 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.117 . . . . 0.0 108.294 179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.65 -48.24 49.41 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.576 -0.703 . . . . 0.0 110.286 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.477 ' O ' ' N ' ' A' ' 84' ' ' ILE . 0.0 OUTLIER -72.57 -43.83 61.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 120.763 -1.21 . . . . 0.0 109.802 -178.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.615 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 0.0 OUTLIER -47.43 -25.26 1.0 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.824 -1.173 . . . . 0.0 108.587 179.303 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 -95.58 -33.34 12.42 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.73 -0.606 . . . . 0.0 109.454 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.568 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -91.3 -8.57 47.84 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.421 -0.8 . . . . 0.0 111.047 -178.181 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.542 ' C ' ' O ' ' A' ' 83' ' ' ALA . 0.4 OUTLIER 2.88 -69.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.428 0 C-N-CA 123.632 0.773 . . . . 0.0 111.994 -179.568 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.568 ' N ' ' O ' ' A' ' 83' ' ' ALA . 30.5 t70 37.55 62.04 3.79 Favored Pre-proline 0 N--CA 1.498 1.933 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.113 179.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -82.56 -8.37 11.47 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.775 2.316 . . . . 0.0 112.068 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.4 ptmt -58.75 -22.61 58.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 110.145 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 85' ' ' ASP . 3.0 p30 -75.59 -53.62 8.31 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.111 -0.993 . . . . 0.0 109.89 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.482 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 59.8 tp -71.87 -21.82 61.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.558 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 16.2 m -83.56 -47.21 11.55 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.234 -0.916 . . . . 0.0 110.621 -179.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.492 ' C ' ' H ' ' A' ' 93' ' ' PHE . 0.1 OUTLIER -66.58 -37.41 84.87 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.903 -1.123 . . . . 0.0 110.256 -179.029 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.0 mt -68.85 8.2 0.56 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.896 -1.127 . . . . 0.0 109.641 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.524 ' O ' ' N ' ' A' ' 95' ' ' GLY . 59.1 m-85 -150.23 151.39 31.5 Favored Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.149 -0.969 . . . . 0.0 109.858 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -37.76 -22.13 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.739 2.293 . . . . 0.0 112.76 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.526 ' O ' ' NE1' ' A' ' 99' ' ' TRP . . . -39.14 -42.21 1.6 Allowed Glycine 0 N--CA 1.491 2.342 0 O-C-N 121.807 -0.558 . . . . 0.0 112.26 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.644 ' HE1' ' CE ' ' A' ' 97' ' ' LYS . 0.6 OUTLIER -91.8 -29.12 16.93 Favored 'General case' 0 N--CA 1.504 2.25 0 O-C-N 120.667 -1.49 . . . . 0.0 111.896 -177.903 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.644 ' CE ' ' HE1' ' A' ' 96' ' ' TRP . 24.7 mmtp -50.63 -9.0 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.526 -1.359 . . . . 0.0 109.808 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.514 ' H ' ' C ' ' A' ' 96' ' ' TRP . . . -106.01 -19.8 13.62 Favored 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.119 -0.988 . . . . 0.0 108.838 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.526 ' NE1' ' O ' ' A' ' 95' ' ' GLY . 26.2 m0 -74.62 -26.05 59.64 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.814 -0.754 . . . . 0.0 109.55 -178.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 C--N 1.305 -1.344 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.564 179.87 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.1 m . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.765 0.793 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.667 ' C ' ' H ' ' A' ' 71' ' ' SER . 10.3 m -147.25 169.11 4.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 71' ' ' SER . 20.1 mt -57.42 10.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.287 -0.883 . . . . 0.0 110.645 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.667 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.7 OUTLIER 76.56 107.83 0.08 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 122.125 0.964 . . . . 0.0 109.691 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.6 m -95.45 -46.66 13.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.872 -179.548 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.434 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -48.22 -11.67 0.14 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.939 -1.264 . . . . 0.0 109.939 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -84.45 -64.51 1.57 Allowed Glycine 0 N--CA 1.493 2.447 0 O-C-N 121.197 -1.178 . . . . 0.0 110.208 -179.561 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -70.61 -9.77 57.72 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.004 -1.292 . . . . 0.0 109.242 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.5 t -93.24 -64.15 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.049 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.661 HD21 ' N ' ' A' ' 78' ' ' LEU . 0.1 OUTLIER -52.19 -20.4 2.57 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.966 -1.084 . . . . 0.0 108.084 178.945 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.661 ' N ' HD21 ' A' ' 77' ' ' ASN . 24.5 tp -84.97 -68.44 0.72 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.6 tp -47.0 -11.9 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.098 -1.001 . . . . 0.0 110.74 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -95.11 -55.34 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.795 -1.191 . . . . 0.0 109.53 -179.821 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.492 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 3.2 pp0? -56.69 -21.96 31.48 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.411 -1.431 . . . . 0.0 110.069 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.617 ' NE2' ' N ' ' A' ' 83' ' ' ALA . 0.0 OUTLIER -93.49 -49.8 5.74 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 120.814 -1.179 . . . . 0.0 109.208 178.927 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.617 ' N ' ' NE2' ' A' ' 82' ' ' GLN . . . -66.04 -66.12 0.59 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.221 -0.924 . . . . 0.0 110.134 -179.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.489 ' O ' ' CB ' ' A' ' 85' ' ' ASP . 3.4 mt 65.87 -44.24 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 O-C-N 121.79 -0.569 . . . . 0.0 109.993 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' A' ' 87' ' ' LYS . 0.0 OUTLIER 164.69 -60.14 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.554 -0.716 . . . . 0.0 109.349 178.713 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.404 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 92.2 Cg_exo -33.39 -26.12 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.521 2.147 . . . . 0.0 113.548 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.551 ' N ' ' O ' ' A' ' 85' ' ' ASP . 26.4 pttt -46.43 -23.09 0.32 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.016 -1.053 . . . . 0.0 109.771 -179.326 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.803 HD21 ' H ' ' A' ' 89' ' ' LEU . 0.2 OUTLIER -88.87 -70.73 0.63 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.315 -0.866 . . . . 0.0 109.847 -179.708 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.803 ' H ' HD21 ' A' ' 88' ' ' ASN . 7.3 tp -47.61 -15.9 0.06 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.927 -1.108 . . . . 0.0 109.57 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 95' ' ' GLY . 12.3 m -95.27 -67.85 0.83 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.438 -0.789 . . . . 0.0 110.672 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 43.2 ttt180 -56.89 -26.12 58.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.212 -0.93 . . . . 0.0 111.214 -178.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.55 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 66.6 mt -56.42 -36.43 68.96 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.824 -1.172 . . . . 0.0 110.348 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 4.5 m-85 -163.26 -66.96 0.01 OUTLIER Pre-proline 0 N--CA 1.497 1.923 0 C-N-CA 118.533 -1.267 . . . . 0.0 111.493 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.439 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 27.5 Cg_endo -60.21 -34.38 94.1 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 122.202 1.934 . . . . 0.0 112.743 -178.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . . . -47.08 -24.83 2.26 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 16.6 m95 -56.11 -9.63 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.203 -1.175 . . . . 0.0 109.657 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' A' ' 95' ' ' GLY . 0.2 OUTLIER -64.35 -10.39 24.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.345 -0.847 . . . . 0.0 110.626 -179.442 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.78 -19.2 16.1 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.438 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.3 m95 -76.99 7.69 4.61 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.2 0.524 . . . . 0.0 109.898 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 m . . . . . 0 C--N 1.304 -1.394 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.357 179.926 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 53.6 m . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.376 0.607 . . . . 0.0 109.892 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.442 ' C ' ' H ' ' A' ' 71' ' ' SER . 14.3 m -146.66 -47.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.421 ' N ' ' CG2' ' A' ' 69' ' ' VAL . 7.4 mt -71.08 5.1 2.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -0.981 . . . . 0.0 108.645 178.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.442 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.2 m 65.89 109.32 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.937 0.875 . . . . 0.0 108.819 -179.145 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.462 ' CG2' ' H ' ' A' ' 73' ' ' GLY . 33.1 m -60.87 -56.68 16.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.477 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.462 ' H ' ' CG2' ' A' ' 72' ' ' VAL . . . -53.6 -15.52 4.48 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -72.74 -59.25 4.48 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -80.64 -41.82 23.2 Favored 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.098 -1.236 . . . . 0.0 109.085 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.85 -47.53 63.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 108.659 179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.631 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.8 t30 -62.9 -57.84 9.41 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.237 -0.915 . . . . 0.0 108.709 179.027 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.5 tp -51.51 -30.78 21.51 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.056 -1.027 . . . . 0.0 109.958 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -76.37 -30.23 57.47 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.995 -1.065 . . . . 0.0 110.289 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.441 ' O ' ' CD1' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -77.85 -28.31 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.357 -1.464 . . . . 0.0 110.069 -178.946 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.631 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -85.97 -36.9 19.54 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.153 -1.592 . . . . 0.0 110.381 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.497 ' C ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -90.95 -40.44 11.69 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.68 -1.262 . . . . 0.0 111.738 -178.044 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.495 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -53.72 -71.37 0.07 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.279 -178.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.531 ' O ' ' O ' ' A' ' 85' ' ' ASP . 34.1 mm 25.94 65.94 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 122.14 -0.35 . . . . 0.0 111.633 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.531 ' O ' ' O ' ' A' ' 84' ' ' ILE . 3.9 p-10 39.3 103.68 0.02 OUTLIER Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.84 -0.537 . . . . 0.0 111.155 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_endo -77.14 27.78 0.44 Allowed 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.568 1.512 . . . . 0.0 111.902 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -51.83 -36.85 49.54 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.279 -0.888 . . . . 0.0 108.88 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 1.3 p30 -57.13 -48.61 78.24 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.386 -0.821 . . . . 0.0 108.852 179.481 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.456 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 62.5 tp -56.88 -47.14 81.16 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.52 -0.737 . . . . 0.0 109.109 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 35.5 t -73.53 -14.37 61.2 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.309 -0.87 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.571 ' NH2' ' NE1' ' A' ' 96' ' ' TRP . 18.0 tpt85 -71.03 -49.61 43.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.184 -0.947 . . . . 0.0 109.508 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 31.3 mt -50.77 -11.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.444 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.572 ' O ' ' N ' ' A' ' 95' ' ' GLY . 64.8 m-85 -119.09 111.82 36.72 Favored Pre-proline 0 N--CA 1.498 1.958 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_exo -42.77 -11.41 0.03 OUTLIER 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 122.123 1.882 . . . . 0.0 112.617 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -43.22 -33.99 2.11 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.571 ' NE1' ' NH2' ' A' ' 91' ' ' ARG . 69.2 p-90 -52.64 -9.14 0.11 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.884 -1.362 . . . . 0.0 110.499 -178.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.472 ' H ' ' C ' ' A' ' 95' ' ' GLY . 25.7 pttt -58.3 -15.93 12.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.056 -1.027 . . . . 0.0 110.581 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.18 -18.81 14.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 108.814 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.441 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 13.6 m95 -75.56 -3.95 37.13 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.222 0.534 . . . . 0.0 109.908 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.2 m . . . . . 0 C--N 1.305 -1.359 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.621 -179.996 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 63.1 m . . . . . 0 N--CA 1.494 1.751 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.552 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.3 m -146.52 -19.14 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.3 -0.875 . . . . 0.0 109.077 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' A' ' 71' ' ' SER . 22.7 mt -61.71 1.39 0.25 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.351 -0.843 . . . . 0.0 108.996 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.552 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.3 t 74.08 114.13 0.06 Allowed 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 122.025 0.916 . . . . 0.0 109.49 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.9 m -70.46 -25.29 26.65 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -43.91 -21.13 0.19 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -65.31 -47.12 83.18 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.484 ' OE1' ' N ' ' A' ' 75' ' ' GLN . 1.4 mp0 -79.9 -38.0 33.48 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.324 -1.103 . . . . 0.0 109.654 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.76 -57.64 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 108.994 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.732 HD21 HE22 ' A' ' 81' ' ' GLN . 0.2 OUTLIER -56.54 -51.79 67.24 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.014 -1.054 . . . . 0.0 108.435 179.712 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.618 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 28.0 tp -47.31 -35.89 8.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.062 179.457 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 3.6 mp -71.46 -26.65 62.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.461 -0.774 . . . . 0.0 109.31 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.436 ' N ' ' O ' ' A' ' 77' ' ' ASN . 0.3 OUTLIER -69.77 -34.17 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.896 -1.127 . . . . 0.0 109.651 -179.389 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.732 HE22 HD21 ' A' ' 77' ' ' ASN . 0.0 OUTLIER -87.67 -19.93 27.0 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.878 -1.139 . . . . 0.0 110.09 -179.8 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -93.4 -34.45 13.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.082 -1.011 . . . . 0.0 108.738 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -61.71 -21.29 64.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.25 -0.906 . . . . 0.0 110.051 -179.464 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.417 ' C ' ' CD1' ' A' ' 84' ' ' ILE . 2.3 pp -89.4 -1.39 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.154 -0.966 . . . . 0.0 109.951 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.509 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 7.6 t0 -98.98 126.76 37.18 Favored Pre-proline 0 N--CA 1.497 1.89 0 O-C-N 121.213 -0.93 . . . . 0.0 108.784 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -38.11 -39.73 1.0 Allowed 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 122.237 1.958 . . . . 0.0 113.261 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -50.92 -16.93 0.49 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.928 -1.108 . . . . 0.0 109.279 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.676 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -76.37 -50.05 15.23 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.278 -0.889 . . . . 0.0 109.04 179.546 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.676 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 3.3 tt -62.09 -21.42 64.95 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.323 -0.861 . . . . 0.0 108.821 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.701 ' HG ' ' HE1' ' A' ' 96' ' ' TRP . 11.0 p -95.53 -33.02 12.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.135 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 93' ' ' PHE . 0.0 OUTLIER -76.76 -43.14 38.23 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.141 -0.974 . . . . 0.0 110.633 -178.732 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 64.2 mt -44.31 -19.15 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.223 -0.923 . . . . 0.0 109.387 -179.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.537 ' O ' ' N ' ' A' ' 95' ' ' GLY . 92.5 m-85 -106.77 102.73 43.67 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.497 ' O ' ' N ' ' A' ' 96' ' ' TRP . 81.6 Cg_exo -45.21 -9.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 122.036 1.824 . . . . 0.0 112.095 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.0 -14.73 0.14 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.701 ' HE1' ' HG ' ' A' ' 90' ' ' SER . 3.7 m95 -47.9 -14.46 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.997 -1.296 . . . . 0.0 109.176 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.504 ' N ' ' O ' ' A' ' 95' ' ' GLY . 50.5 mtmt -69.09 -9.19 51.46 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.305 -0.872 . . . . 0.0 110.168 -179.63 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.26 -19.49 14.09 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.261 -0.899 . . . . 0.0 108.581 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.425 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 22.3 m95 -76.04 -8.86 57.95 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.243 0.544 . . . . 0.0 110.005 -178.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 C--N 1.305 -1.333 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.541 -179.898 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 90.2 m . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.548 ' C ' ' H ' ' A' ' 71' ' ' SER . 3.4 p -170.97 -118.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.525 ' H ' ' CG2' ' A' ' 69' ' ' VAL . 20.4 mt -64.61 3.61 0.49 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.269 -1.52 . . . . 0.0 108.883 179.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.548 ' H ' ' C ' ' A' ' 69' ' ' VAL . 38.8 m 55.4 110.81 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.195 0.998 . . . . 0.0 109.966 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 74' ' ' GLY . 21.2 m -83.47 -16.51 11.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.93 -14.86 0.09 OUTLIER Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.55 -55.48 8.57 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -74.06 -34.47 64.06 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.015 -1.285 . . . . 0.0 109.549 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.46 -61.22 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.738 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -50.67 -31.2 15.62 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.439 -0.788 . . . . 0.0 108.912 179.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.57 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 41.0 tp -74.23 -39.61 62.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.346 -0.846 . . . . 0.0 109.172 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 21.6 tp -62.75 -28.12 69.75 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 111.056 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.62 -40.04 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.683 -1.26 . . . . 0.0 110.832 -178.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.64 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -66.67 -23.48 66.15 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.957 -1.089 . . . . 0.0 109.289 -178.885 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.64 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 4.0 tp60 -95.12 -36.96 11.29 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.965 -1.084 . . . . 0.0 108.56 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.559 ' C ' ' H ' ' A' ' 85' ' ' ASP . . . -62.19 -11.7 15.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.209 -0.932 . . . . 0.0 110.733 -179.089 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 85' ' ' ASP . 27.0 mm -52.66 -4.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.725 -1.235 . . . . 0.0 110.216 -179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.569 ' C ' ' H ' ' A' ' 87' ' ' LYS . 0.4 OUTLIER -47.43 170.3 0.1 OUTLIER Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 120.924 -1.11 . . . . 0.0 109.104 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.95 8.92 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 1.99 0 C-N-CA 122.571 2.181 . . . . 0.0 113.653 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.569 ' H ' ' C ' ' A' ' 85' ' ' ASP . 22.8 pttp -48.27 -21.21 0.47 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.683 -1.26 . . . . 0.0 109.545 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.687 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 2.6 p-10 -71.19 -61.25 1.83 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.298 -0.876 . . . . 0.0 109.227 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.687 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 1.9 tt -51.86 -27.88 14.17 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 16.1 t -89.52 -24.27 21.82 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.431 -0.793 . . . . 0.0 109.734 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.404 ' O ' ' N ' ' A' ' 93' ' ' PHE . 15.9 tpp85 -70.46 -23.72 62.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.109 -0.994 . . . . 0.0 109.318 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.512 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 84.0 mt -47.84 -19.19 0.21 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.147 -0.971 . . . . 0.0 109.748 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.512 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 5.3 m-85 -160.0 -66.63 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.975 . . . . 0.0 110.02 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.44 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 77.2 Cg_exo -31.95 -52.7 0.33 Allowed 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 122.591 2.194 . . . . 0.0 113.238 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.526 ' O ' ' CE2' ' A' ' 99' ' ' TRP . . . -47.26 -41.92 16.76 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.429 ' CD1' ' N ' ' A' ' 96' ' ' TRP . 14.6 m95 -85.55 -9.89 56.72 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.1 -1.235 . . . . 0.0 110.425 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 7.2 mmpt? -72.75 -9.43 58.64 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.949 -1.095 . . . . 0.0 110.189 -179.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.13 -20.59 9.21 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.526 ' CE2' ' O ' ' A' ' 95' ' ' GLY . 23.9 m0 -74.77 -22.6 58.68 Favored 'General case' 0 C--N 1.3 -1.577 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.765 -178.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.6 m . . . . . 0 C--N 1.304 -1.378 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.453 -179.912 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.43 ' O ' ' O ' ' A' ' 69' ' ' VAL . 94.1 m . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.54 ' C ' ' H ' ' A' ' 71' ' ' SER . 35.9 m -62.21 -143.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.234 -0.916 . . . . 0.0 109.205 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 15.5 mt -55.81 -4.38 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.991 -1.068 . . . . 0.0 109.53 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.54 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.6 m 62.56 111.63 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.292 -0.88 . . . . 0.0 109.668 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.497 ' O ' ' N ' ' A' ' 74' ' ' GLY . 24.2 m -48.27 -40.36 9.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-O 121.262 0.553 . . . . 0.0 109.622 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.18 -18.71 0.16 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.65 -46.67 89.29 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.443 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 1.9 mp0 -80.71 -41.76 23.09 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.239 -1.154 . . . . 0.0 109.397 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 3.6 t -59.17 -53.01 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 108.732 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.554 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 23.1 t-20 -57.76 -55.19 38.08 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.0 tp -50.16 -31.71 14.28 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.432 -0.792 . . . . 0.0 109.1 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.41 ' O ' ' CB ' ' A' ' 83' ' ' ALA . 5.2 tp -64.76 -59.7 3.93 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.367 -0.833 . . . . 0.0 110.358 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -73.01 -21.74 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 110.602 -178.386 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.554 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 1.4 mp0 -70.98 -46.5 62.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.507 -1.371 . . . . 0.0 109.341 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 2.4 pp0? -92.13 -30.33 16.03 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.087 -1.008 . . . . 0.0 110.031 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.522 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -86.51 -32.98 20.46 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.063 -1.023 . . . . 0.0 109.813 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' A' ' 83' ' ' ALA . 1.2 mp 41.27 22.11 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 CA-C-O 121.58 0.705 . . . . 0.0 110.073 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 83' ' ' ALA . 67.5 m-20 46.38 87.57 0.12 Allowed Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.301 -0.874 . . . . 0.0 110.024 179.22 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.54 -8.99 9.99 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 122.428 2.085 . . . . 0.0 112.095 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -47.14 -22.09 0.33 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.335 -0.853 . . . . 0.0 109.532 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.679 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.3 OUTLIER -69.93 -54.42 13.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.325 -0.86 . . . . 0.0 109.811 -179.671 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.679 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 2.0 tt -59.66 -33.56 71.69 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.256 -0.903 . . . . 0.0 108.889 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 76.9 p -79.39 -33.33 42.88 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.307 -0.871 . . . . 0.0 109.475 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' C ' ' N ' ' A' ' 93' ' ' PHE . 35.0 ttm180 -56.16 -42.27 76.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.254 -0.904 . . . . 0.0 109.555 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 61.2 mt -48.23 -20.01 0.34 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.119 -0.988 . . . . 0.0 109.252 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.55 ' O ' ' N ' ' A' ' 95' ' ' GLY . 1.8 m-85 -116.69 121.97 32.28 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.352 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 96' ' ' TRP . 74.1 Cg_exo -40.63 -16.99 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.138 1.892 . . . . 0.0 112.472 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.84 -9.39 0.06 OUTLIER Glycine 0 N--CA 1.489 2.192 0 C-N-CA 120.392 -0.909 . . . . 0.0 110.93 -179.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.53 ' N ' ' O ' ' A' ' 94' ' ' PRO . 62.0 p-90 -73.05 -11.73 60.66 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.798 -1.413 . . . . 0.0 109.963 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.529 ' CB ' ' NZ ' ' A' ' 97' ' ' LYS . 0.1 OUTLIER -61.75 -9.02 5.47 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.172 -0.955 . . . . 0.0 110.313 -179.73 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.76 -19.83 13.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.184 -0.948 . . . . 0.0 109.199 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.439 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.4 m95 -76.22 6.93 4.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.765 -0.584 . . . . 0.0 110.149 -178.573 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.0 m . . . . . 0 N--CA 1.487 1.411 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.613 179.979 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.429 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.7 m -86.43 10.55 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.099 -1.001 . . . . 0.0 109.676 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 19.2 mt 56.79 7.05 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.93 . . . . 0.0 109.793 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.429 ' H ' ' C ' ' A' ' 69' ' ' VAL . 76.9 p -171.18 115.49 0.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.416 ' C ' ' N ' ' A' ' 74' ' ' GLY . 28.6 m -53.99 -28.34 17.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.81 -20.5 1.22 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.416 ' N ' ' C ' ' A' ' 72' ' ' VAL . . . -76.77 -39.0 30.04 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 179.557 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.54 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 0.5 OUTLIER -64.41 -33.48 75.96 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.954 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.06 -48.2 33.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.577 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 7.2 t-20 -56.45 -34.7 67.11 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.9 tp -67.11 -37.24 83.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.248 -0.908 . . . . 0.0 108.789 179.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 40.7 tp -60.53 -40.04 90.05 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.154 -0.966 . . . . 0.0 109.947 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.496 ' CG2' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -85.53 -50.03 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 120.549 -1.344 . . . . 0.0 109.224 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.577 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -45.48 -32.0 2.0 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.631 -1.293 . . . . 0.0 110.375 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.593 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -94.36 -30.53 14.45 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.828 -1.17 . . . . 0.0 110.045 -179.355 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.83 -9.84 2.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.124 -0.985 . . . . 0.0 111.183 -178.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.495 ' CD1' ' N ' ' A' ' 85' ' ' ASP . 1.6 pp -124.57 -120.74 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.989 -1.069 . . . . 0.0 108.908 -179.495 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.574 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -172.9 -58.72 0.0 OUTLIER Pre-proline 0 C--N 1.3 -1.549 0 O-C-N 120.799 -1.188 . . . . 0.0 109.898 179.625 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.449 ' O ' ' N ' ' A' ' 88' ' ' ASN . 86.6 Cg_endo -77.2 -49.46 0.1 Allowed 'Trans proline' 0 N--CA 1.5 1.873 0 C-N-CA 122.044 1.829 . . . . 0.0 112.351 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 7.8 mmmm -49.54 -14.85 0.12 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.308 -0.87 . . . . 0.0 109.188 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.714 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -70.06 -51.78 29.23 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.234 -0.986 . . . . 0.0 108.43 179.836 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.714 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 10.9 tp -67.66 -22.91 65.28 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.334 -0.853 . . . . 0.0 108.887 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 m -77.39 -47.07 20.78 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.41 -0.806 . . . . 0.0 110.376 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.504 ' O ' ' N ' ' A' ' 93' ' ' PHE . 78.0 mtt-85 -85.63 -45.26 11.88 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.019 -1.051 . . . . 0.0 110.57 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 63.5 mt -45.79 -19.28 0.05 Allowed 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.975 -1.078 . . . . 0.0 108.982 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.554 ' O ' ' N ' ' A' ' 95' ' ' GLY . 52.8 m-85 -114.71 87.57 14.82 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 178.584 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -41.62 -12.81 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.6 2.2 . . . . 0.0 112.718 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -59.98 -11.89 20.0 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 59.8 p-90 -59.11 -19.72 47.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.579 -1.542 . . . . 0.0 109.556 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -64.6 -8.86 15.79 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.29 -0.881 . . . . 0.0 109.641 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.81 -17.5 16.86 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.455 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 31.9 m0 -71.8 7.46 1.53 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.317 -178.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.002 179.936 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.437 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.517 ' C ' ' H ' ' A' ' 71' ' ' SER . 4.6 m -98.61 12.75 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.141 -0.974 . . . . 0.0 109.692 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.3 mt 53.09 8.19 0.1 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.0 -1.062 . . . . 0.0 109.257 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.517 ' H ' ' C ' ' A' ' 69' ' ' VAL . 15.4 m -69.33 113.73 6.93 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.999 0.904 . . . . 0.0 108.962 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLY . 28.8 m -88.15 -45.98 15.81 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.785 -179.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' N ' ' CG2' ' A' ' 72' ' ' VAL . . . -49.73 -12.8 0.45 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -81.24 -41.9 9.83 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -82.48 -41.8 19.29 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.221 -1.164 . . . . 0.0 108.851 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.4 t -62.43 -55.82 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.623 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 0.5 OUTLIER -56.36 -53.78 53.32 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.542 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 27.4 tp -47.6 -35.65 9.56 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.174 -0.954 . . . . 0.0 108.597 179.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.616 ' C ' HE22 ' A' ' 82' ' ' GLN . 0.7 OUTLIER -63.59 -38.68 92.03 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.729 -0.607 . . . . 0.0 109.769 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.45 HG22 HD12 ' A' ' 80' ' ' ILE . 0.3 OUTLIER -76.88 -22.96 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.715 -1.24 . . . . 0.0 109.558 -179.577 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.623 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 8.0 mt-30 -74.51 -48.45 27.06 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 111.527 -178.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.722 ' H ' HE21 ' A' ' 82' ' ' GLN . 0.0 OUTLIER -85.01 -19.14 32.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.304 -1.497 . . . . 0.0 109.315 -179.285 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.454 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -83.58 -66.28 0.91 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.161 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.454 ' C ' ' O ' ' A' ' 83' ' ' ALA . 0.5 OUTLIER 29.93 77.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 CA-C-O 121.662 0.744 . . . . 0.0 110.612 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 88' ' ' ASN . 42.3 t0 51.43 65.08 6.97 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.199 -0.938 . . . . 0.0 109.331 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.44 ' O ' ' OG ' ' A' ' 90' ' ' SER . 76.9 Cg_endo -76.23 -7.29 17.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.636 2.224 . . . . 0.0 112.183 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -26.42 67.78 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.164 -0.96 . . . . 0.0 108.554 179.555 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.697 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -86.69 -67.7 0.8 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.436 -0.79 . . . . 0.0 109.061 179.7 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.697 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 10.9 tp -45.96 -28.93 1.26 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.218 -0.926 . . . . 0.0 109.399 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 86' ' ' PRO . 95.6 p -83.07 -40.85 19.33 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.424 -0.797 . . . . 0.0 110.35 -179.481 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 2.8 ttp-105 -79.82 -20.27 46.51 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.623 -1.298 . . . . 0.0 110.678 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.522 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 39.5 mt -89.62 6.96 38.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.02 -1.05 . . . . 0.0 110.875 -178.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.522 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 14.4 m-85 -154.24 -74.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 120.583 -1.323 . . . . 0.0 111.275 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 95.1 Cg_endo -74.49 -45.5 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 121.567 1.512 . . . . 0.0 113.237 -179.426 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 99' ' ' TRP . . . -41.62 -39.89 2.7 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.347 -0.846 . . . . 0.0 111.317 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.439 ' CD1' ' CE3' ' A' ' 99' ' ' TRP . 23.7 m0 -82.97 -23.38 33.41 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.698 -1.472 . . . . 0.0 110.196 -178.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 3.3 mmpp? -64.05 -9.05 13.87 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.137 -0.977 . . . . 0.0 110.337 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.58 -20.01 10.9 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 108.599 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.552 ' CD1' ' O ' ' A' ' 95' ' ' GLY . 22.1 m0 -80.98 -4.6 55.63 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.634 -178.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.5 m . . . . . 0 C--N 1.305 -1.349 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.537 -179.957 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.1 m . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.109 -0.701 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.552 ' C ' ' H ' ' A' ' 71' ' ' SER . 6.7 p -160.75 117.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 O-C-N 121.121 -0.987 . . . . 0.0 110.159 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 50.4 mt 50.56 5.01 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -0.803 . . . . 0.0 110.537 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.552 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -84.94 105.49 15.75 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.846 -1.159 . . . . 0.0 108.636 179.528 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.435 ' O ' ' N ' ' A' ' 75' ' ' GLN . 20.9 m -79.41 -41.99 22.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.019 -179.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -43.5 -27.06 0.75 Allowed Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.22 -36.66 26.8 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . 0.435 ' N ' ' O ' ' A' ' 72' ' ' VAL . 11.3 mt-30 -66.07 -23.49 66.53 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 178.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.4 t -73.67 -47.16 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -56.11 -49.44 73.88 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 31.8 tp -59.85 -36.33 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.511 -0.743 . . . . 0.0 110.085 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.5 mp -69.05 -24.74 64.21 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.118 -0.988 . . . . 0.0 111.495 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.63 -26.32 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 120.378 -1.451 . . . . 0.0 110.708 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -86.51 -22.02 26.62 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.372 -1.455 . . . . 0.0 109.94 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -95.19 -42.12 8.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.95 -1.093 . . . . 0.0 108.843 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.436 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -98.01 -27.39 14.26 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.216 -0.927 . . . . 0.0 111.459 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.446 ' O ' ' O ' ' A' ' 85' ' ' ASP . 0.1 OUTLIER 36.9 32.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.296 0 O-C-N 121.635 -0.666 . . . . 0.0 110.274 -177.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 84' ' ' ILE . 5.4 p-10 39.11 95.13 0.04 OUTLIER Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 121.863 -0.523 . . . . 0.0 110.543 179.296 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -80.23 23.26 0.7 Allowed 'Trans proline' 0 N--CA 1.491 1.344 0 C-N-CA 121.896 1.731 . . . . 0.0 111.948 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 28.5 mtmm -58.5 -32.82 69.17 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.222 -0.924 . . . . 0.0 109.219 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.739 HD21 ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -63.7 -25.29 68.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.317 -0.864 . . . . 0.0 108.96 179.814 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.739 ' H ' HD21 ' A' ' 88' ' ' ASN . 2.5 tt -80.89 -45.16 17.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.962 . . . . 0.0 108.598 179.322 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 93' ' ' PHE . 16.6 t -69.73 -20.62 63.51 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.788 ' HE ' ' HE1' ' A' ' 96' ' ' TRP . 0.0 OUTLIER -78.09 -54.52 6.18 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.283 -0.886 . . . . 0.0 109.656 -179.782 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 32.4 mt -65.4 7.75 0.2 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.199 -0.938 . . . . 0.0 109.715 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' GLY . 31.1 m-85 -146.3 157.4 49.24 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.091 -1.006 . . . . 0.0 109.463 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.548 ' O ' ' N ' ' A' ' 96' ' ' TRP . 90.6 Cg_exo -43.4 -6.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 122.651 2.234 . . . . 0.0 112.975 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.27 -11.19 0.07 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . 0.788 ' HE1' ' HE ' ' A' ' 91' ' ' ARG . 5.3 m0 -44.94 -16.58 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.269 -1.136 . . . . 0.0 109.374 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' A' ' 95' ' ' GLY . 0.1 OUTLIER -62.35 -8.49 6.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.85 . . . . 0.0 110.218 179.829 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -94.49 -19.23 20.73 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.845 -1.159 . . . . 0.0 108.118 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.446 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 20.0 m95 -76.07 -13.0 60.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.261 0.553 . . . . 0.0 109.78 -178.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.6 m . . . . . 0 C--N 1.304 -1.373 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.489 179.917 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.482 ' C ' ' H ' ' A' ' 74' ' ' GLY . 26.7 m . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -51.18 -10.14 0.45 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -72.62 -49.91 16.92 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.9 mp0 -79.27 -39.23 33.51 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.18 -1.188 . . . . 0.0 109.139 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 13.9 t -62.48 -54.5 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 108.585 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -54.5 -49.18 70.77 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.425 ' O ' ' OE1' ' A' ' 82' ' ' GLN . 40.8 tp -48.02 -50.61 27.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.092 -1.005 . . . . 0.0 108.862 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.9 tp -55.88 -31.98 63.29 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 110.973 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -74.32 -38.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.583 -1.323 . . . . 0.0 109.851 -178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -64.87 -53.44 46.59 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.176 -0.953 . . . . 0.0 110.362 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.483 ' OE1' ' N ' ' A' ' 82' ' ' GLN . 6.9 mp0 . . . . . 0 N--CA 1.493 1.686 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.567 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.8 m . . . . . 0 N--CA 1.481 1.109 0 CA-C-O 121.229 0.538 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.567 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.47 -15.33 0.44 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -73.18 -51.94 9.47 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.44 ' N ' ' CD ' ' A' ' 75' ' ' GLN . 2.0 mp0 -82.94 -42.28 17.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.169 -1.195 . . . . 0.0 109.528 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 32.9 t -56.61 -52.05 58.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -61.77 -53.35 57.21 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.194 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 42.3 tp -50.39 -31.83 15.91 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.117 -0.989 . . . . 0.0 109.143 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.7 tp -75.61 -30.13 59.44 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.273 -0.892 . . . . 0.0 110.539 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.556 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -82.56 -19.95 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 120.831 -1.168 . . . . 0.0 109.526 -179.094 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 -90.46 -35.52 15.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.592 -1.317 . . . . 0.0 110.34 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.9 tp60 . . . . . 0 N--CA 1.488 1.465 0 O-C-N 120.948 -1.095 . . . . 0.0 108.782 -179.521 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.531 HG23 ' N ' ' A' ' 73' ' ' GLY . 23.7 m . . . . . 0 N--CA 1.481 1.099 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.531 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.96 -23.73 0.43 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.96 -44.84 54.42 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 19.0 mp0 -62.31 -29.21 70.28 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.7 t -70.33 -44.91 77.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.662 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -60.58 -57.76 11.36 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 33.2 tp -47.94 -28.94 2.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 108.969 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.1 tp -70.7 -40.04 73.1 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.353 -0.842 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -67.9 -38.75 80.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.944 -1.098 . . . . 0.0 109.45 -179.276 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -68.6 -31.99 71.55 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.895 -1.128 . . . . 0.0 108.529 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.304 -1.399 0 O-C-N 121.453 -0.779 . . . . 0.0 109.684 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.561 HG23 ' N ' ' A' ' 73' ' ' GLY . 15.5 m . . . . . 0 N--CA 1.477 0.922 0 CA-C-O 121.375 0.607 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.561 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.69 -9.82 0.1 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -79.93 -62.68 2.08 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.053 -1.263 . . . . 0.0 110.109 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.492 ' O ' HD13 ' A' ' 79' ' ' LEU . 1.4 mp0 -74.03 -30.32 62.37 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.073 -1.251 . . . . 0.0 108.841 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 72' ' ' VAL . 41.2 t -67.81 -51.57 48.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.493 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -55.11 -36.34 65.61 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.133 -0.979 . . . . 0.0 108.803 178.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.5 tp -73.95 -46.93 40.97 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 120.715 -1.241 . . . . 0.0 108.88 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.492 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.9 mp -65.87 -15.71 63.17 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.567 -0.708 . . . . 0.0 109.298 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 81' ' ' GLN . 0.4 OUTLIER -80.33 -54.51 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.819 -1.176 . . . . 0.0 108.306 -179.885 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.489 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 15.9 mt-30 -54.97 -53.82 50.79 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.066 -1.021 . . . . 0.0 110.095 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.6 pp0? . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.682 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 75' ' ' GLN . 18.9 m . . . . . 0 N--CA 1.476 0.836 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -24.71 3.08 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.647 -1.781 . . . . 0.0 108.647 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.401 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -72.57 -42.05 49.05 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.413 ' N ' ' O ' ' A' ' 72' ' ' VAL . 10.9 mp0 -58.64 -21.8 54.91 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 178.521 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.4 ' C ' ' N ' ' A' ' 78' ' ' LEU . 5.1 t -83.87 -53.64 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.401 ' OD1' ' O ' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -57.05 -14.66 3.98 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.632 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 80' ' ' ILE . 65.9 tp -88.0 -66.05 0.95 Allowed 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.453 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -48.97 -13.88 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 110.027 -179.806 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -95.71 -55.0 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.931 -1.105 . . . . 0.0 110.221 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.494 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -55.35 -12.67 1.11 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.072 -1.642 . . . . 0.0 108.256 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.48 ' N ' ' OE1' ' A' ' 81' ' ' GLN . 1.5 tt0 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 178.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.2 m . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 121.361 0.6 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -9.37 0.06 OUTLIER Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -74.85 -63.78 2.49 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.848 -1.384 . . . . 0.0 110.387 -179.263 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -75.25 -28.31 59.8 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.02 -1.282 . . . . 0.0 109.744 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 25.7 t -68.7 -57.71 8.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 108.747 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.461 ' OD1' ' NE2' ' A' ' 81' ' ' GLN . 14.5 t-20 -51.98 -44.26 63.97 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.208 -0.932 . . . . 0.0 108.574 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.405 HD13 ' O ' ' A' ' 74' ' ' GLY . 4.3 mp -57.2 -30.39 64.5 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.037 -1.039 . . . . 0.0 108.516 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.534 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -73.65 -29.26 62.23 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.317 -0.864 . . . . 0.0 110.779 -178.81 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.42 ' H ' HG23 ' A' ' 80' ' ' ILE . 0.9 OUTLIER -80.11 -27.15 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.626 -1.296 . . . . 0.0 110.399 -178.685 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.461 ' NE2' ' OD1' ' A' ' 77' ' ' ASN . 3.1 pt20 -95.02 -10.87 29.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 108.854 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 68.2 mt-30 . . . . . 0 N--CA 1.498 1.935 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 -179.785 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.63 HG23 ' N ' ' A' ' 73' ' ' GLY . 16.9 m . . . . . 0 N--CA 1.481 1.122 0 CA-C-O 120.921 0.391 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.63 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.15 -13.41 0.36 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -80.9 -62.07 2.06 Favored Glycine 0 N--CA 1.492 2.392 0 O-C-N 121.213 -1.169 . . . . 0.0 110.666 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.521 ' O ' HD13 ' A' ' 79' ' ' LEU . 25.8 mp0 -73.78 -32.12 63.62 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.882 -1.364 . . . . 0.0 108.8 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.462 ' O ' HG22 ' A' ' 80' ' ' ILE . 39.9 t -66.57 -59.72 3.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -50.46 -30.82 13.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.105 -0.997 . . . . 0.0 109.305 179.206 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 61.1 tp -78.61 -29.81 46.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.077 -1.014 . . . . 0.0 109.654 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -72.7 -35.34 67.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.061 -1.024 . . . . 0.0 109.685 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.24 -42.43 23.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.719 -1.238 . . . . 0.0 109.464 -179.476 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.481 ' NE2' HG23 ' A' ' 80' ' ' ILE . 2.1 mp0 -66.07 -29.59 69.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.952 -1.093 . . . . 0.0 110.394 -179.315 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 pp0? . . . . . 0 N--CA 1.498 1.926 0 O-C-N 120.632 -1.293 . . . . 0.0 109.013 179.407 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.6 m . . . . . 0 N--CA 1.483 1.205 0 CA-C-O 121.385 0.612 . . . . 0.0 109.772 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -46.56 -14.57 0.11 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.86 -53.09 12.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -74.25 -32.45 62.96 Favored 'General case' 0 N--CA 1.485 1.289 0 O-C-N 120.985 -1.303 . . . . 0.0 109.228 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -70.8 -60.0 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.185 -0.947 . . . . 0.0 108.773 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' A' ' 77' ' ' ASN . 29.7 t-20 -55.48 -24.82 33.34 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.095 -1.003 . . . . 0.0 108.973 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.9 tp -81.65 -41.8 20.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.843 -1.161 . . . . 0.0 109.047 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.3 tp -58.9 -35.89 73.79 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.357 -0.84 . . . . 0.0 110.432 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.564 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.21 -49.12 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.853 -1.154 . . . . 0.0 108.891 -179.523 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.454 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 2.5 mp0 -58.57 -12.06 3.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.756 -1.215 . . . . 0.0 108.841 178.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 O-C-N 121.173 -0.954 . . . . 0.0 109.686 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' GLY . 30.5 m . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 121.311 0.577 . . . . 0.0 109.638 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.588 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -44.92 -17.97 0.11 Allowed Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.94 -54.87 25.35 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.516 ' O ' HD13 ' A' ' 79' ' ' LEU . 20.8 mp0 -74.69 -36.01 62.76 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.185 -1.185 . . . . 0.0 109.624 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.403 ' O ' HG22 ' A' ' 80' ' ' ILE . 7.4 t -65.84 -58.91 4.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.027 -1.046 . . . . 0.0 109.053 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.594 ' HB2' HE22 ' A' ' 81' ' ' GLN . 2.7 p30 -54.24 -31.02 52.36 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 108.74 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.3 tp -73.23 -37.79 66.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.183 -0.948 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.516 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -61.64 -40.81 96.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.197 -0.939 . . . . 0.0 109.425 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.754 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -81.92 -46.71 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.777 -1.202 . . . . 0.0 109.957 -179.279 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.594 HE22 ' HB2' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -53.45 -39.88 64.78 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.641 -1.287 . . . . 0.0 109.981 -179.372 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 1.2 pp0? . . . . . 0 N--CA 1.493 1.702 0 O-C-N 120.859 -1.15 . . . . 0.0 110.143 -179.128 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 74' ' ' GLY . 20.4 m . . . . . 0 N--CA 1.485 1.29 0 CA-C-O 121.356 0.598 . . . . 0.0 109.631 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.63 -22.57 0.73 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -61.04 -46.93 93.57 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.4 ' O ' HD13 ' A' ' 79' ' ' LEU . 3.6 mp0 -81.69 -46.55 14.14 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.142 -1.211 . . . . 0.0 109.488 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.449 HG23 ' H ' ' A' ' 76' ' ' VAL . 4.8 t -57.04 -51.33 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.206 -0.934 . . . . 0.0 108.683 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -58.46 -50.17 74.68 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.2 tp -47.9 -36.37 12.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.985 -1.072 . . . . 0.0 109.305 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.2 mp -70.88 -33.94 71.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.184 -0.947 . . . . 0.0 109.926 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -75.8 -31.95 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 120.572 -1.33 . . . . 0.0 109.06 -179.541 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 15.7 mt-30 -74.93 -22.15 58.76 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.177 -0.952 . . . . 0.0 109.317 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.572 179.905 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.59 HG23 ' N ' ' A' ' 73' ' ' GLY . 34.7 m . . . . . 0 N--CA 1.487 1.392 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.606 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -49.35 -10.06 0.17 Allowed Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -75.59 -55.7 4.91 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.624 ' O ' HD23 ' A' ' 79' ' ' LEU . 18.8 mm100 -74.99 -26.33 59.48 Favored 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.202 -1.175 . . . . 0.0 109.702 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.0 t -73.03 -62.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -0.906 . . . . 0.0 108.946 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.606 ' ND2' ' O ' ' A' ' 73' ' ' GLY . 3.2 p30 -51.59 -36.76 46.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.028 -1.045 . . . . 0.0 108.476 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.1 tp -66.7 -43.0 85.51 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.624 HD23 ' O ' ' A' ' 75' ' ' GLN . 0.9 OUTLIER -56.74 -53.91 52.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.305 -0.872 . . . . 0.0 110.057 -179.383 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.706 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -68.11 -38.52 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.887 -1.133 . . . . 0.0 110.134 -178.666 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.406 ' OE1' HG23 ' A' ' 80' ' ' ILE . 1.0 OUTLIER -66.14 -41.22 90.73 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.497 -1.377 . . . . 0.0 109.883 -179.766 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? . . . . . 0 N--CA 1.492 1.638 0 O-C-N 120.717 -1.239 . . . . 0.0 110.102 -179.116 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.559 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.7 m . . . . . 0 N--CA 1.481 1.124 0 CA-C-O 120.895 0.379 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -42.85 -17.63 0.04 OUTLIER Glycine 0 N--CA 1.498 2.83 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.524 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -77.72 -52.54 5.4 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -72.78 -36.56 67.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.135 -1.215 . . . . 0.0 108.839 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.3 t -65.52 -53.45 39.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.1 t30 -51.93 -31.24 27.81 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.425 HD13 ' O ' ' A' ' 74' ' ' GLY . 3.0 mp -72.24 -47.69 48.39 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.117 . . . . 0.0 108.294 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.65 -48.24 49.41 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.576 -0.703 . . . . 0.0 110.286 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.43 ' H ' HG22 ' A' ' 80' ' ' ILE . 0.0 OUTLIER -72.57 -43.83 61.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 120.763 -1.21 . . . . 0.0 109.802 -178.945 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -47.43 -25.26 1.0 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.824 -1.173 . . . . 0.0 108.587 179.303 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 61.4 mt-30 . . . . . 0 N--CA 1.496 1.838 0 O-C-N 121.73 -0.606 . . . . 0.0 109.454 179.438 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.588 HG23 ' N ' ' A' ' 73' ' ' GLY . 22.6 m . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 121.166 0.508 . . . . 0.0 109.872 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.588 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.22 -11.67 0.14 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.939 -1.264 . . . . 0.0 109.939 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -84.45 -64.51 1.57 Allowed Glycine 0 N--CA 1.493 2.447 0 O-C-N 121.197 -1.178 . . . . 0.0 110.208 -179.561 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -70.61 -9.77 57.72 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.004 -1.292 . . . . 0.0 109.242 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 72' ' ' VAL . 56.5 t -93.24 -64.15 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.049 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' A' ' 78' ' ' LEU . 19.6 p-10 -52.19 -20.4 2.57 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.966 -1.084 . . . . 0.0 108.084 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 80' ' ' ILE . 24.5 tp -84.97 -68.44 0.72 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.6 tp -47.0 -11.9 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.098 -1.001 . . . . 0.0 110.74 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -95.11 -55.34 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.795 -1.191 . . . . 0.0 109.53 -179.821 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.492 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -56.69 -21.96 31.48 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.411 -1.431 . . . . 0.0 110.069 179.915 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.543 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.07 0 O-C-N 120.814 -1.179 . . . . 0.0 109.208 178.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.632 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.1 m . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 120.947 0.403 . . . . 0.0 110.477 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.632 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -53.6 -15.52 4.48 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -72.74 -59.25 4.48 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.503 ' O ' HD23 ' A' ' 79' ' ' LEU . 2.3 mp0 -80.64 -41.82 23.2 Favored 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.098 -1.236 . . . . 0.0 109.085 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 72' ' ' VAL . 46.7 t -53.85 -47.53 63.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 108.659 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -62.9 -57.84 9.41 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.237 -0.915 . . . . 0.0 108.709 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.5 tp -51.51 -30.78 21.51 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.056 -1.027 . . . . 0.0 109.958 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.503 HD23 ' O ' ' A' ' 75' ' ' GLN . 3.4 mm? -76.37 -30.23 57.47 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.995 -1.065 . . . . 0.0 110.289 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -77.85 -28.31 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.357 -1.464 . . . . 0.0 110.069 -178.946 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.456 ' NE2' ' CG2' ' A' ' 80' ' ' ILE . 18.7 mp0 -85.97 -36.9 19.54 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.153 -1.592 . . . . 0.0 110.381 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.501 2.093 0 O-C-N 120.68 -1.262 . . . . 0.0 111.738 -178.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.9 m . . . . . 0 N--CA 1.478 0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.596 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -43.91 -21.13 0.19 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -65.31 -47.12 83.18 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.488 ' O ' HD13 ' A' ' 79' ' ' LEU . 1.4 mp0 -79.9 -38.0 33.48 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.324 -1.103 . . . . 0.0 109.654 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.76 -57.64 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 108.994 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.596 ' ND2' ' O ' ' A' ' 73' ' ' GLY . 3.1 p30 -56.54 -51.79 67.24 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.014 -1.054 . . . . 0.0 108.435 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.487 ' N ' ' OD1' ' A' ' 77' ' ' ASN . 28.0 tp -47.31 -35.89 8.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.062 179.457 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.488 HD13 ' O ' ' A' ' 75' ' ' GLN . 3.6 mp -71.46 -26.65 62.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.461 -0.774 . . . . 0.0 109.31 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.51 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -69.77 -34.17 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.896 -1.127 . . . . 0.0 109.651 -179.389 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 12.1 mp0 -87.67 -19.93 27.0 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.878 -1.139 . . . . 0.0 110.09 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 . . . . . 0 N--CA 1.493 1.689 0 O-C-N 121.082 -1.011 . . . . 0.0 108.738 -179.768 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 74' ' ' GLY . 21.2 m . . . . . 0 N--CA 1.479 1.024 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.93 -14.86 0.09 OUTLIER Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.55 -55.48 8.57 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -74.06 -34.47 64.06 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.015 -1.285 . . . . 0.0 109.549 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.46 -61.22 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.738 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -50.67 -31.2 15.62 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.439 -0.788 . . . . 0.0 108.912 179.235 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.42 ' O ' ' OE1' ' A' ' 81' ' ' GLN . 41.0 tp -74.23 -39.61 62.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.346 -0.846 . . . . 0.0 109.172 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 21.6 tp -62.75 -28.12 69.75 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 111.056 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.406 ' H ' HG22 ' A' ' 80' ' ' ILE . 0.0 OUTLIER -91.62 -40.04 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.683 -1.26 . . . . 0.0 110.832 -178.738 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.492 ' OE1' ' N ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -66.67 -23.48 66.15 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.957 -1.089 . . . . 0.0 109.289 -178.885 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.492 ' N ' ' OE1' ' A' ' 81' ' ' GLN . 4.0 tp60 . . . . . 0 N--CA 1.494 1.742 0 O-C-N 120.965 -1.084 . . . . 0.0 108.56 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.509 HG23 ' N ' ' A' ' 73' ' ' GLY . 24.2 m . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 121.262 0.553 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.509 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -45.18 -18.71 0.16 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.65 -46.67 89.29 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -80.71 -41.76 23.09 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.239 -1.154 . . . . 0.0 109.397 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 76' ' ' VAL . 3.6 t -59.17 -53.01 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 108.732 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -57.76 -55.19 38.08 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.0 tp -50.16 -31.71 14.28 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.432 -0.792 . . . . 0.0 109.1 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.2 tp -64.76 -59.7 3.93 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.367 -0.833 . . . . 0.0 110.358 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.44 ' H ' HG22 ' A' ' 80' ' ' ILE . 0.0 OUTLIER -73.01 -21.74 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 110.602 -178.386 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -70.98 -46.5 62.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.507 -1.371 . . . . 0.0 109.341 179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 2.4 pp0? . . . . . 0 N--CA 1.499 1.983 0 O-C-N 121.087 -1.008 . . . . 0.0 110.031 -179.051 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.416 ' C ' ' N ' ' A' ' 74' ' ' GLY . 28.6 m . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.81 -20.5 1.22 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.416 ' N ' ' C ' ' A' ' 72' ' ' VAL . . . -76.77 -39.0 30.04 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -64.41 -33.48 75.96 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.06 -48.2 33.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.409 ' O ' ' OE1' ' A' ' 81' ' ' GLN . 30.9 t30 -56.45 -34.7 67.11 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.9 tp -67.11 -37.24 83.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.248 -0.908 . . . . 0.0 108.789 179.298 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 40.7 tp -60.53 -40.04 90.05 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.154 -0.966 . . . . 0.0 109.947 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -85.53 -50.03 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 120.549 -1.344 . . . . 0.0 109.224 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.439 ' N ' HG23 ' A' ' 80' ' ' ILE . 1.9 mp0 -45.48 -32.0 2.0 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.631 -1.293 . . . . 0.0 110.375 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 1.1 pp0? . . . . . 0 N--CA 1.498 1.96 0 O-C-N 120.828 -1.17 . . . . 0.0 110.045 -179.355 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.551 HG23 ' N ' ' A' ' 73' ' ' GLY . 28.8 m . . . . . 0 N--CA 1.48 1.068 0 CA-C-O 121.078 0.466 . . . . 0.0 109.785 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.551 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.73 -12.8 0.45 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -81.24 -41.9 9.83 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -82.48 -41.8 19.29 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.221 -1.164 . . . . 0.0 108.851 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.4 t -62.43 -55.82 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 60.3 t-20 -56.36 -53.78 53.32 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.4 tp -47.6 -35.65 9.56 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.174 -0.954 . . . . 0.0 108.597 179.002 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -63.59 -38.68 92.03 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.729 -0.607 . . . . 0.0 109.769 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.535 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -76.88 -22.96 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.715 -1.24 . . . . 0.0 109.558 -179.577 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -74.51 -48.45 27.06 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 111.527 -178.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 O-C-N 120.304 -1.497 . . . . 0.0 109.315 -179.285 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.536 HG23 ' N ' ' A' ' 73' ' ' GLY . 20.9 m . . . . . 0 N--CA 1.476 0.866 0 CA-C-O 120.893 0.378 . . . . 0.0 110.019 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.536 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.5 -27.06 0.75 Allowed Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.22 -36.66 26.8 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.481 ' O ' HD13 ' A' ' 79' ' ' LEU . 13.2 mt-30 -66.07 -23.49 66.53 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 178.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.4 t -73.67 -47.16 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -56.11 -49.44 73.88 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 31.8 tp -59.85 -36.33 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.511 -0.743 . . . . 0.0 110.085 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.481 HD13 ' O ' ' A' ' 75' ' ' GLN . 2.5 mp -69.05 -24.74 64.21 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.118 -0.988 . . . . 0.0 111.495 -178.163 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.63 -26.32 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 120.378 -1.451 . . . . 0.0 110.708 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -86.51 -22.02 26.62 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.372 -1.455 . . . . 0.0 109.94 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 . . . . . 0 N--CA 1.494 1.746 0 O-C-N 120.95 -1.093 . . . . 0.0 108.843 179.58 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.8 m . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.313 0.578 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 71' ' ' SER . 2.4 p 175.08 112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 55.8 mt 48.16 11.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.128 -0.982 . . . . 0.0 109.659 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.535 ' N ' ' O ' ' A' ' 69' ' ' VAL . 29.8 t -82.6 118.25 23.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.997 0.903 . . . . 0.0 109.591 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.482 ' C ' ' H ' ' A' ' 74' ' ' GLY . 26.7 m -93.85 -18.33 6.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -51.18 -10.14 0.45 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -72.62 -49.91 16.92 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.9 mp0 -79.27 -39.23 33.51 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.18 -1.188 . . . . 0.0 109.139 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 13.9 t -62.48 -54.5 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 108.585 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -54.5 -49.18 70.77 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.425 ' O ' ' OE1' ' A' ' 82' ' ' GLN . 40.8 tp -48.02 -50.61 27.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.092 -1.005 . . . . 0.0 108.862 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.9 tp -55.88 -31.98 63.29 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 110.973 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -74.32 -38.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.583 -1.323 . . . . 0.0 109.851 -178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -64.87 -53.44 46.59 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.176 -0.953 . . . . 0.0 110.362 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.483 ' N ' ' OE1' ' A' ' 82' ' ' GLN . 6.9 mp0 -56.31 -42.57 77.84 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -64.99 -19.6 66.08 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.757 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.427 ' O ' HG22 ' A' ' 84' ' ' ILE . 3.1 mm -89.1 -6.79 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.09 -1.006 . . . . 0.0 109.153 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -135.65 57.23 18.18 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.376 -0.827 . . . . 0.0 109.798 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -75.85 11.84 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.673 2.249 . . . . 0.0 111.497 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.0 mmmm -58.78 -31.67 68.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.458 -0.776 . . . . 0.0 109.573 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -67.29 0.64 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.322 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 6.7 tp -51.75 -41.82 61.87 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.351 -0.843 . . . . 0.0 109.073 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.742 ' OG ' ' CH2' ' A' ' 99' ' ' TRP . 30.0 t -58.09 -46.22 85.86 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.285 -0.885 . . . . 0.0 109.195 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 6.0 tpp180 -53.7 -32.28 51.23 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.263 -0.898 . . . . 0.0 108.875 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 16.0 mt -82.28 10.24 7.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.808 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 95' ' ' GLY . 32.2 m-85 -141.45 153.98 66.34 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.253 -0.904 . . . . 0.0 109.082 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -39.58 -15.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.708 2.272 . . . . 0.0 113.057 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -44.92 -32.9 3.36 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 120.326 -0.94 . . . . 0.0 110.757 -179.59 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.526 ' O ' ' N ' ' A' ' 98' ' ' ALA . 67.0 p-90 -84.22 -34.9 23.8 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.696 -1.473 . . . . 0.0 110.944 -178.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -49.51 -9.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.163 . . . . 0.0 110.284 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.526 ' N ' ' O ' ' A' ' 96' ' ' TRP . . . -112.81 -19.88 11.83 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.124 -0.985 . . . . 0.0 108.541 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.742 ' CH2' ' OG ' ' A' ' 90' ' ' SER . 23.2 m0 -83.02 -4.66 58.56 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.724 -0.61 . . . . 0.0 109.859 -178.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' A' ' 99' ' ' TRP . 30.9 m . . . . . 0 C--N 1.306 -1.305 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.608 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.499 HG22 ' N ' ' A' ' 69' ' ' VAL . 59.5 m . . . . . 0 N--CA 1.492 1.646 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' A' ' 71' ' ' SER . 0.6 OUTLIER -171.89 -41.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.186 -0.946 . . . . 0.0 109.221 -179.75 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 14.3 mt -45.79 -12.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.579 -0.701 . . . . 0.0 110.303 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.556 ' N ' ' O ' ' A' ' 69' ' ' VAL . 2.6 t -155.01 124.39 6.37 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.027 -1.046 . . . . 0.0 109.562 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.567 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.8 m -79.49 -45.95 23.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-O 121.229 0.538 . . . . 0.0 109.569 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.567 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.47 -15.33 0.44 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -73.18 -51.94 9.47 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.44 ' N ' ' CD ' ' A' ' 75' ' ' GLN . 2.0 mp0 -82.94 -42.28 17.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.169 -1.195 . . . . 0.0 109.528 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 32.9 t -56.61 -52.05 58.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -61.77 -53.35 57.21 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 42.3 tp -50.39 -31.83 15.91 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.117 -0.989 . . . . 0.0 109.143 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.7 tp -75.61 -30.13 59.44 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.273 -0.892 . . . . 0.0 110.539 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.556 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -82.56 -19.95 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 120.831 -1.168 . . . . 0.0 109.526 -179.094 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 -90.46 -35.52 15.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.592 -1.317 . . . . 0.0 110.34 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.9 tp60 -86.61 -36.7 18.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.948 -1.095 . . . . 0.0 108.782 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.48 -11.45 0.86 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.167 -0.958 . . . . 0.0 109.782 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.571 HD12 ' N ' ' A' ' 85' ' ' ASP . 1.9 pp -142.29 -126.29 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 O-C-N 121.068 -1.02 . . . . 0.0 108.675 -179.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.571 ' N ' HD12 ' A' ' 84' ' ' ILE . 74.4 m-20 -89.16 115.9 64.89 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 120.917 -1.114 . . . . 0.0 109.05 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -80.25 5.81 5.78 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.818 1.679 . . . . 0.0 112.128 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.458 ' HB3' ' HZ2' ' A' ' 87' ' ' LYS . 4.2 mtpm? -50.61 -34.32 25.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.193 -0.942 . . . . 0.0 109.336 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.466 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -65.3 -57.25 8.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.369 179.933 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.5 tp -48.1 -31.5 5.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.054 -1.029 . . . . 0.0 109.119 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.4 m -87.69 -19.69 27.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 109.923 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.575 ' HE ' ' CA ' ' A' ' 91' ' ' ARG . 0.0 OUTLIER -77.83 -21.35 51.62 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.009 -1.057 . . . . 0.0 109.655 -179.415 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 16.7 mt -47.29 -16.29 0.05 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.991 -1.068 . . . . 0.0 109.23 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.497 ' N ' ' O ' ' A' ' 91' ' ' ARG . 71.3 m-85 -112.85 90.06 14.67 Favored Pre-proline 0 N--CA 1.496 1.847 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -41.02 -21.55 0.11 Allowed 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 122.033 1.822 . . . . 0.0 112.473 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 99' ' ' TRP . . . -58.91 -9.25 6.84 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.411 ' CD1' ' CE3' ' A' ' 99' ' ' TRP . 7.3 m95 -80.65 -9.54 59.78 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -1.194 . . . . 0.0 109.543 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 13.7 ptpt -66.25 -17.51 64.79 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.084 -1.01 . . . . 0.0 110.328 -179.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.67 -21.52 10.19 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 21.4 m0 -72.86 -2.21 19.81 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 119.524 -0.87 . . . . 0.0 109.368 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m . . . . . 0 C--N 1.305 -1.329 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.68 -179.978 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.7 m . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.281 0.562 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.2 m -86.5 68.04 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.265 -0.897 . . . . 0.0 109.268 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.472 ' O ' ' CB ' ' A' ' 71' ' ' SER . 23.6 mt 65.0 -32.57 0.15 Allowed 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.794 -0.567 . . . . 0.0 110.383 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.539 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.5 OUTLIER 166.2 114.91 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.125 -0.985 . . . . 0.0 109.171 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.531 HG23 ' N ' ' A' ' 73' ' ' GLY . 23.7 m -54.75 -39.61 48.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.531 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.96 -23.73 0.43 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.96 -44.84 54.42 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 19.0 mp0 -62.31 -29.21 70.28 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.7 t -70.33 -44.91 77.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.662 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -60.58 -57.76 11.36 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 33.2 tp -47.94 -28.94 2.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 108.969 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.1 tp -70.7 -40.04 73.1 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.353 -0.842 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -67.9 -38.75 80.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.944 -1.098 . . . . 0.0 109.45 -179.276 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -68.6 -31.99 71.55 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.895 -1.128 . . . . 0.0 108.529 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -53.81 53.29 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.453 -0.779 . . . . 0.0 109.684 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -47.06 -51.34 17.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.47 -0.769 . . . . 0.0 110.375 -179.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.408 ' O ' ' OD2' ' A' ' 85' ' ' ASP . 7.5 mm -46.78 -44.49 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.405 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.591 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 25.5 m-20 -151.51 102.27 2.92 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.218 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -81.58 -2.17 11.36 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.973 1.782 . . . . 0.0 112.323 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.49 -27.63 39.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.109 -0.994 . . . . 0.0 108.886 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.591 ' ND2' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -64.47 -50.62 66.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.214 -0.929 . . . . 0.0 109.028 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.6 tp -57.99 -45.54 86.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.303 -0.873 . . . . 0.0 108.815 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.8 p -70.3 -26.74 63.93 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.345 -0.847 . . . . 0.0 109.417 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' A' ' 93' ' ' PHE . 2.8 tmm_? -69.97 -24.56 63.35 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.331 -0.856 . . . . 0.0 109.808 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 71.9 mt -47.0 -17.84 0.06 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.161 -0.962 . . . . 0.0 109.299 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.475 ' N ' ' O ' ' A' ' 91' ' ' ARG . 1.0 OUTLIER -106.97 100.52 32.49 Favored Pre-proline 0 N--CA 1.497 1.878 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.439 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -42.7 -27.49 0.86 Allowed 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.896 1.731 . . . . 0.0 112.25 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.82 -5.55 14.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 4.9 p-90 -66.86 -12.56 59.63 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.854 -1.38 . . . . 0.0 109.292 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.2 ptpt -60.36 -12.56 9.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -120.23 -21.93 6.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.615 -0.678 . . . . 0.0 109.453 -179.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 22.8 m0 -69.56 -30.61 68.44 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.367 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--N 1.304 -1.389 0 CA-C-O 117.961 -1.018 . . . . 0.0 109.511 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 69' ' ' VAL . 2.7 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.735 HG13 ' H ' ' A' ' 70' ' ' LEU . 4.8 p -172.65 -60.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.141 -0.974 . . . . 0.0 110.038 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.735 ' H ' HG13 ' A' ' 69' ' ' VAL . 45.1 mt -44.17 -38.62 3.83 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.438 -0.788 . . . . 0.0 109.555 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER 26.48 99.02 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.375 0 CA-C-O 121.981 0.896 . . . . 0.0 111.683 179.625 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.561 HG23 ' N ' ' A' ' 73' ' ' GLY . 15.5 m -63.52 -42.89 97.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 CA-C-O 121.375 0.607 . . . . 0.0 109.488 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.561 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.69 -9.82 0.1 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -79.93 -62.68 2.08 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.053 -1.263 . . . . 0.0 110.109 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.492 ' O ' HD13 ' A' ' 79' ' ' LEU . 1.4 mp0 -74.03 -30.32 62.37 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.073 -1.251 . . . . 0.0 108.841 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 72' ' ' VAL . 41.2 t -67.81 -51.57 48.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.493 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -55.11 -36.34 65.61 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.133 -0.979 . . . . 0.0 108.803 178.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.5 tp -73.95 -46.93 40.97 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 120.715 -1.241 . . . . 0.0 108.88 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.492 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.9 mp -65.87 -15.71 63.17 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.567 -0.708 . . . . 0.0 109.298 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.737 HD13 HD11 ' A' ' 84' ' ' ILE . 0.4 OUTLIER -80.33 -54.51 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.819 -1.176 . . . . 0.0 108.306 -179.885 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.489 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 15.9 mt-30 -54.97 -53.82 50.79 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.066 -1.021 . . . . 0.0 110.095 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -39.59 90.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.627 ' HB3' HD13 ' A' ' 84' ' ' ILE . . . -66.23 -37.99 86.86 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.133 -0.979 . . . . 0.0 110.159 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.737 HD11 HD13 ' A' ' 80' ' ' ILE . 0.0 OUTLIER -139.74 88.51 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.13 -0.981 . . . . 0.0 108.484 179.487 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.577 ' N ' ' CD ' ' A' ' 86' ' ' PRO . 0.6 OUTLIER -56.85 -41.69 92.58 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.421 179.689 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.577 ' CD ' ' N ' ' A' ' 85' ' ' ASP . 33.5 Cg_exo -61.4 18.32 0.04 OUTLIER 'Trans proline' 0 N--CA 1.5 1.866 0 C-N-CA 122.583 2.188 . . . . 0.0 112.456 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.523 ' H ' ' C ' ' A' ' 85' ' ' ASP . 47.9 pttt -46.85 -23.57 0.46 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.218 -0.926 . . . . 0.0 109.219 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.445 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 4.5 p30 -74.47 -58.04 3.55 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.445 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 30.7 tp -47.41 -30.14 3.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.576 -0.702 . . . . 0.0 109.322 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 72.3 m -90.04 -26.37 20.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 110.183 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.478 ' O ' ' N ' ' A' ' 93' ' ' PHE . 29.7 ttm180 -85.55 -17.42 36.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.028 -1.045 . . . . 0.0 110.701 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 71.5 mt -47.42 -18.52 0.12 Allowed 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.849 -1.157 . . . . 0.0 108.679 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 95' ' ' GLY . 17.7 m-85 -122.93 86.02 50.56 Favored Pre-proline 0 N--CA 1.494 1.731 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -41.67 -17.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.213 1.942 . . . . 0.0 112.081 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -67.67 -5.21 36.63 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 1.5 p-90 -72.58 -10.09 59.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.897 -1.355 . . . . 0.0 109.361 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -59.83 -9.8 3.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.31 -0.869 . . . . 0.0 109.853 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -124.12 -21.68 4.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 108.906 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.576 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 7.2 m0 -77.95 -2.59 37.68 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.415 -0.803 . . . . 0.0 109.414 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.431 ' H ' HG22 ' A' ' 100' ' ' VAL . 1.8 m . . . . . 0 N--CA 1.488 1.459 0 CA-C-O 117.924 -1.036 . . . . 0.0 109.459 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.237 0.541 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.681 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.9 m -145.06 104.85 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 14.1 mt 50.07 9.09 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.945 -1.097 . . . . 0.0 109.745 -179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 69' ' ' VAL . 26.7 t -74.08 106.43 5.75 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 122.137 0.97 . . . . 0.0 109.116 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 75' ' ' GLN . 18.9 m -79.48 -27.77 12.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -24.71 3.08 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.647 -1.781 . . . . 0.0 108.647 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.401 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -72.57 -42.05 49.05 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.413 ' N ' ' O ' ' A' ' 72' ' ' VAL . 10.9 mp0 -58.64 -21.8 54.91 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 178.521 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.4 ' C ' ' N ' ' A' ' 78' ' ' LEU . 5.1 t -83.87 -53.64 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.401 ' OD1' ' O ' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -57.05 -14.66 3.98 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.632 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 80' ' ' ILE . 65.9 tp -88.0 -66.05 0.95 Allowed 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.453 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -48.97 -13.88 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 110.027 -179.806 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -95.71 -55.0 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.931 -1.105 . . . . 0.0 110.221 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.494 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -55.35 -12.67 1.11 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.072 -1.642 . . . . 0.0 108.256 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.48 ' N ' ' OE1' ' A' ' 81' ' ' GLN . 1.5 tt0 -94.37 -50.71 5.11 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.53 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -51.42 -8.4 0.05 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.793 -0.567 . . . . 0.0 110.307 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.461 ' H ' ' C ' ' A' ' 82' ' ' GLN . 5.4 mm -42.89 -19.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.375 -0.828 . . . . 0.0 109.931 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 87' ' ' LYS . 0.4 OUTLIER -48.87 172.1 0.09 OUTLIER Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.733 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -37.45 -22.89 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.159 1.906 . . . . 0.0 112.354 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.539 ' N ' ' O ' ' A' ' 85' ' ' ASP . 63.0 mmtt -50.38 -26.82 5.38 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.411 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 6.2 p-10 -71.92 -45.45 61.12 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.117 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.411 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 23.9 tp -50.46 -37.74 39.99 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.305 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 87' ' ' LYS . 13.6 p -76.61 -26.91 55.47 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.468 -0.77 . . . . 0.0 109.069 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.439 ' O ' ' N ' ' A' ' 93' ' ' PHE . 7.5 tpt180 -62.7 -35.65 80.39 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.282 -0.886 . . . . 0.0 109.513 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 15.8 mt -46.36 -21.92 0.21 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.173 -0.955 . . . . 0.0 108.892 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.536 ' O ' ' N ' ' A' ' 95' ' ' GLY . 31.5 m-85 -115.05 88.96 18.42 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -42.53 -14.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 122.224 1.949 . . . . 0.0 112.296 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -63.99 -5.23 13.7 Favored Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 1.4 p-90 -64.52 -12.16 41.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.947 -1.325 . . . . 0.0 109.034 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 49.2 mtmt -58.78 -9.69 1.93 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.497 -0.752 . . . . 0.0 110.022 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -123.34 -21.03 5.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.035 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.495 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 23.4 m0 -71.77 -9.07 57.75 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.501 -0.749 . . . . 0.0 109.557 -179.345 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 12.2 m . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.548 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 11.5 m . . . . . 0 N--CA 1.496 1.838 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.528 ' C ' ' H ' ' A' ' 71' ' ' SER . 16.0 m -113.3 45.23 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.54 -0.725 . . . . 0.0 109.113 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 24.5 mt 65.33 -32.49 0.15 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.777 -0.577 . . . . 0.0 110.49 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.528 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.5 p 172.92 107.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.169 -0.957 . . . . 0.0 109.192 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.2 m -57.16 -29.85 33.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 CA-C-O 121.361 0.6 . . . . 0.0 109.531 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -9.37 0.06 OUTLIER Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -74.85 -63.78 2.49 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.848 -1.384 . . . . 0.0 110.387 -179.263 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -75.25 -28.31 59.8 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.02 -1.282 . . . . 0.0 109.744 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 25.7 t -68.7 -57.71 8.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 108.747 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.461 ' OD1' ' NE2' ' A' ' 81' ' ' GLN . 14.5 t-20 -51.98 -44.26 63.97 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.208 -0.932 . . . . 0.0 108.574 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.405 HD13 ' O ' ' A' ' 74' ' ' GLY . 4.3 mp -57.2 -30.39 64.5 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.037 -1.039 . . . . 0.0 108.516 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.534 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -73.65 -29.26 62.23 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.317 -0.864 . . . . 0.0 110.779 -178.81 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.712 ' O ' HD11 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -80.11 -27.15 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.626 -1.296 . . . . 0.0 110.399 -178.685 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.461 ' NE2' ' OD1' ' A' ' 77' ' ' ASN . 3.1 pt20 -95.02 -10.87 29.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 108.854 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.527 ' O ' ' N ' ' A' ' 84' ' ' ILE . 68.2 mt-30 -95.48 -65.72 0.96 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.521 ' C ' HD13 ' A' ' 84' ' ' ILE . . . -44.35 -16.06 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.584 -0.697 . . . . 0.0 111.012 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.841 ' N ' HD13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.37 31.74 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.235 -0.916 . . . . 0.0 109.032 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 84' ' ' ILE . 2.7 m-20 60.96 150.97 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.992 . . . . 0.0 109.22 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.29 -25.32 13.53 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.125 1.883 . . . . 0.0 112.354 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 8.4 ptmt -48.79 -24.49 1.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.354 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.426 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 5.3 p-10 -70.28 -47.81 59.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.317 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.426 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 6.6 tp -64.53 -23.58 67.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.344 -0.847 . . . . 0.0 109.13 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.9 m -79.73 -47.4 15.36 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 93' ' ' PHE . 66.5 mtt85 -75.58 -52.15 11.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.755 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 41.7 mt -46.07 -19.45 0.07 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.179 -0.951 . . . . 0.0 109.032 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.554 ' O ' ' N ' ' A' ' 95' ' ' GLY . 29.9 m-85 -111.05 95.29 24.05 Favored Pre-proline 0 N--CA 1.494 1.769 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -42.43 -12.73 0.04 OUTLIER 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.413 2.075 . . . . 0.0 112.621 -179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -56.69 -18.83 25.76 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 121.236 -0.915 . . . . 0.0 111.105 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 8.0 p-90 -65.54 -20.28 66.27 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.493 -1.592 . . . . 0.0 110.075 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -63.75 -11.52 27.15 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.144 -0.972 . . . . 0.0 109.76 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.27 -21.21 9.43 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.516 ' CD1' ' O ' ' A' ' 95' ' ' GLY . 25.0 m0 -70.64 -15.54 62.74 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.44 -178.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.505 179.914 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.7 m . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.515 ' O ' ' N ' ' A' ' 71' ' ' SER . 7.4 p -172.45 121.46 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.411 -0.805 . . . . 0.0 109.246 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.488 ' O ' HG13 ' A' ' 72' ' ' VAL . 81.8 mt 49.69 10.02 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.113 -0.992 . . . . 0.0 109.944 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 69' ' ' VAL . 53.9 p -43.83 113.5 0.52 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.63 HG23 ' N ' ' A' ' 73' ' ' GLY . 16.9 m -95.38 -50.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.9 -178.021 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.63 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.15 -13.41 0.36 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -80.9 -62.07 2.06 Favored Glycine 0 N--CA 1.492 2.392 0 O-C-N 121.213 -1.169 . . . . 0.0 110.666 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.521 ' O ' HD13 ' A' ' 79' ' ' LEU . 25.8 mp0 -73.78 -32.12 63.62 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.882 -1.364 . . . . 0.0 108.8 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.462 ' O ' HG22 ' A' ' 80' ' ' ILE . 39.9 t -66.57 -59.72 3.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -50.46 -30.82 13.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.105 -0.997 . . . . 0.0 109.305 179.206 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 61.1 tp -78.61 -29.81 46.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.077 -1.014 . . . . 0.0 109.654 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -72.7 -35.34 67.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.061 -1.024 . . . . 0.0 109.685 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.24 -42.43 23.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.719 -1.238 . . . . 0.0 109.464 -179.476 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.481 ' NE2' HG23 ' A' ' 80' ' ' ILE . 2.1 mp0 -66.07 -29.59 69.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.952 -1.093 . . . . 0.0 110.394 -179.315 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.89 -26.97 20.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.632 -1.293 . . . . 0.0 109.013 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.436 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -77.05 -8.61 57.74 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.488 -0.757 . . . . 0.0 110.282 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.436 ' C ' ' O ' ' A' ' 83' ' ' ALA . 6.0 mm -38.28 -57.84 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.428 ' OD2' ' N ' ' A' ' 85' ' ' ASP . 9.0 p30 -171.68 129.07 0.66 Allowed Pre-proline 0 C--N 1.299 -1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.03 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -77.35 7.37 3.79 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.828 1.685 . . . . 0.0 112.17 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 39.4 pttt -50.26 -34.96 25.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.165 -0.959 . . . . 0.0 109.289 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.405 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 5.5 p-10 -74.72 -45.84 41.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.26 -0.9 . . . . 0.0 108.993 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.405 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 32.0 tp -59.93 -42.0 93.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.571 -0.706 . . . . 0.0 109.668 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 6.0 m -75.53 -21.75 57.67 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.254 -0.904 . . . . 0.0 110.266 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.513 ' O ' ' N ' ' A' ' 93' ' ' PHE . 57.2 ttm-85 -76.27 -28.71 57.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.032 -1.042 . . . . 0.0 109.71 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 18.3 mt -46.87 -16.77 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.016 -1.052 . . . . 0.0 108.962 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.552 ' O ' ' N ' ' A' ' 95' ' ' GLY . 21.8 m-85 -124.37 84.75 56.19 Favored Pre-proline 0 N--CA 1.492 1.634 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.285 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -39.82 -17.08 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.645 2.23 . . . . 0.0 112.586 -178.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -62.62 -5.82 9.87 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.6 p-90 -68.1 -10.78 56.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.588 -1.536 . . . . 0.0 109.44 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -61.83 -12.68 18.61 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.461 -0.774 . . . . 0.0 110.174 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -121.85 -21.07 6.18 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.542 -0.723 . . . . 0.0 109.276 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.519 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.7 m0 -71.32 -14.46 62.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.364 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.434 ' OXT' ' O ' ' A' ' 99' ' ' TRP . 3.5 m . . . . . 0 C--N 1.305 -1.362 0 CA-C-O 118.078 -0.963 . . . . 0.0 109.602 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.416 HG22 ' N ' ' A' ' 69' ' ' VAL . 98.9 m . . . . . 0 N--CA 1.497 1.911 0 CA-C-O 121.274 0.559 . . . . 0.0 110.49 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.593 ' C ' ' H ' ' A' ' 71' ' ' SER . 32.8 m -76.5 120.79 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 121.3 -0.875 . . . . 0.0 109.143 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.445 ' O ' ' O ' ' A' ' 71' ' ' SER . 21.3 mt 60.7 -13.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.385 -0.822 . . . . 0.0 110.141 -179.174 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.593 ' H ' ' C ' ' A' ' 69' ' ' VAL . 29.8 t 47.3 98.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.158 -0.964 . . . . 0.0 110.162 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.6 m -45.26 -25.68 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 CA-C-O 121.385 0.612 . . . . 0.0 109.772 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -46.56 -14.57 0.11 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.86 -53.09 12.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -74.25 -32.45 62.96 Favored 'General case' 0 N--CA 1.485 1.289 0 O-C-N 120.985 -1.303 . . . . 0.0 109.228 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -70.8 -60.0 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.185 -0.947 . . . . 0.0 108.773 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' A' ' 77' ' ' ASN . 29.7 t-20 -55.48 -24.82 33.34 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.095 -1.003 . . . . 0.0 108.973 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.9 tp -81.65 -41.8 20.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.843 -1.161 . . . . 0.0 109.047 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.3 tp -58.9 -35.89 73.79 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.357 -0.84 . . . . 0.0 110.432 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.564 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.21 -49.12 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.853 -1.154 . . . . 0.0 108.891 -179.523 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.454 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 2.5 mp0 -58.57 -12.06 3.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.756 -1.215 . . . . 0.0 108.841 178.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -88.85 -55.39 3.72 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.173 -0.954 . . . . 0.0 109.686 -178.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.467 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -48.78 -71.76 0.06 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.82 -1.175 . . . . 0.0 109.867 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.467 ' C ' ' O ' ' A' ' 83' ' ' ALA . 9.7 mm 28.03 69.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 CA-C-O 121.224 0.535 . . . . 0.0 112.095 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' A' ' 84' ' ' ILE . 0.2 OUTLIER 177.66 -53.08 0.0 OUTLIER Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.878 . . . . 0.0 109.46 179.504 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 88' ' ' ASN . 89.5 Cg_endo -82.81 -51.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.035 1.823 . . . . 0.0 111.966 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 10.7 pttm -48.59 -16.74 0.12 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.24 -0.913 . . . . 0.0 109.11 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.488 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -73.63 -61.2 1.92 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.488 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 3.3 tt -54.8 -22.97 16.02 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.109 -0.994 . . . . 0.0 108.742 179.48 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.447 ' O ' ' N ' ' A' ' 95' ' ' GLY . 8.5 t -87.26 -34.49 18.91 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.309 -0.869 . . . . 0.0 110.271 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -72.82 -20.42 61.14 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.057 -1.027 . . . . 0.0 110.002 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.494 ' O ' ' CD1' ' A' ' 93' ' ' PHE . 82.0 mt -76.61 -2.03 30.57 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.917 -1.114 . . . . 0.0 110.863 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' A' ' 92' ' ' LEU . 11.1 m-85 -159.95 -72.93 0.01 OUTLIER Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 120.542 -1.349 . . . . 0.0 111.485 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 96' ' ' TRP . 73.5 Cg_endo -69.6 -53.26 0.29 Allowed 'Trans proline' 0 N--CA 1.5 1.86 0 C-N-CA 121.53 1.487 . . . . 0.0 112.751 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 90' ' ' SER . . . -46.63 -11.69 0.05 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.119 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.612 ' NE1' ' CH2' ' A' ' 99' ' ' TRP . 26.3 m0 -50.02 -19.56 0.75 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.584 ' HZ2' ' HA ' ' A' ' 97' ' ' LYS . 3.4 mmpm? -58.6 -8.4 1.25 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.91 -17.29 19.33 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 120.877 -1.139 . . . . 0.0 108.331 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.612 ' CH2' ' NE1' ' A' ' 96' ' ' TRP . 31.2 m0 -73.43 -25.64 60.6 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.117 -178.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 C--N 1.304 -1.393 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.645 -179.92 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.521 HG22 ' H ' ' A' ' 69' ' ' VAL . 1.7 m . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.521 ' H ' HG22 ' A' ' 68' ' ' THR . 34.5 m -83.66 53.34 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.488 -0.757 . . . . 0.0 109.505 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 22.0 mt 60.17 6.07 0.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.521 -0.737 . . . . 0.0 109.076 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.413 ' H ' ' C ' ' A' ' 69' ' ' VAL . 16.0 m -173.49 115.83 0.25 Allowed 'General case' 0 N--CA 1.487 1.396 0 CA-C-O 121.964 0.888 . . . . 0.0 109.212 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' GLY . 30.5 m -71.16 -28.02 31.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 CA-C-O 121.311 0.577 . . . . 0.0 109.638 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.588 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -44.92 -17.97 0.11 Allowed Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.94 -54.87 25.35 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.516 ' O ' HD13 ' A' ' 79' ' ' LEU . 20.8 mp0 -74.69 -36.01 62.76 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.185 -1.185 . . . . 0.0 109.624 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.403 ' O ' HG22 ' A' ' 80' ' ' ILE . 7.4 t -65.84 -58.91 4.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.027 -1.046 . . . . 0.0 109.053 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.594 ' HB2' HE22 ' A' ' 81' ' ' GLN . 2.7 p30 -54.24 -31.02 52.36 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 108.74 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.3 tp -73.23 -37.79 66.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.183 -0.948 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.516 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -61.64 -40.81 96.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.197 -0.939 . . . . 0.0 109.425 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.754 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -81.92 -46.71 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.777 -1.202 . . . . 0.0 109.957 -179.279 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.594 HE22 ' HB2' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -53.45 -39.88 64.78 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.641 -1.287 . . . . 0.0 109.981 -179.372 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 1.2 pp0? -80.87 -31.7 35.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.859 -1.15 . . . . 0.0 110.143 -179.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -65.62 -9.97 31.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.125 -0.984 . . . . 0.0 111.112 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.605 ' C ' HD12 ' A' ' 84' ' ' ILE . 2.7 pp -112.43 17.9 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.365 0 O-C-N 121.035 -1.041 . . . . 0.0 110.767 -179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.439 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 10.7 p30 -158.67 150.08 16.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 120.905 -1.122 . . . . 0.0 109.501 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -72.35 24.33 0.27 Allowed 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 122.166 1.911 . . . . 0.0 111.636 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.415 ' H ' ' C ' ' A' ' 85' ' ' ASP . 21.4 mmtm -50.65 -36.78 37.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.21 -0.931 . . . . 0.0 109.11 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 41.7 p-10 -59.7 -26.3 65.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.403 -0.811 . . . . 0.0 109.137 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.472 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 7.5 tt -81.53 -57.77 3.32 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.377 -0.827 . . . . 0.0 109.019 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 7.8 p -53.92 -23.02 11.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.249 -0.907 . . . . 0.0 109.091 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.528 ' O ' ' CD1' ' A' ' 96' ' ' TRP . 12.6 mtp180 -76.15 -63.37 1.33 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.437 -0.789 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 44.1 mt -51.27 -25.12 5.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -0.947 . . . . 0.0 109.499 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.547 ' O ' ' N ' ' A' ' 95' ' ' GLY . 2.1 m-85 -57.25 158.21 10.66 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.118 -0.989 . . . . 0.0 108.818 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_exo -40.44 -14.07 0.03 OUTLIER 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.804 2.336 . . . . 0.0 113.245 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -48.13 -44.62 26.54 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.611 ' NE1' ' CZ3' ' A' ' 99' ' ' TRP . 13.6 m0 -58.19 -22.52 52.06 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.121 -1.223 . . . . 0.0 110.071 -179.282 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.7 mmpt? -59.34 -9.38 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.153 -0.967 . . . . 0.0 110.412 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.22 -20.57 12.27 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.611 ' CZ3' ' NE1' ' A' ' 96' ' ' TRP . 23.7 m0 -76.88 -16.95 59.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.346 -179.186 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 1.1 t . . . . . 0 C--N 1.306 -1.299 0 CA-C-O 117.929 -1.034 . . . . 0.0 108.869 -179.857 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.631 HG23 ' H ' ' A' ' 71' ' ' SER . 34.5 m -129.2 2.09 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.197 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.443 ' O ' ' O ' ' A' ' 71' ' ' SER . 17.1 mt 58.93 -6.9 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.43 -0.794 . . . . 0.0 110.468 179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.631 ' H ' HG23 ' A' ' 69' ' ' VAL . 8.6 t 55.83 110.25 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 122.202 1.001 . . . . 0.0 109.98 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 74' ' ' GLY . 20.4 m -95.67 -26.18 4.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 CA-C-O 121.356 0.598 . . . . 0.0 109.631 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.63 -22.57 0.73 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -61.04 -46.93 93.57 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.4 ' O ' HD13 ' A' ' 79' ' ' LEU . 3.6 mp0 -81.69 -46.55 14.14 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.142 -1.211 . . . . 0.0 109.488 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.449 HG23 ' H ' ' A' ' 76' ' ' VAL . 4.8 t -57.04 -51.33 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.206 -0.934 . . . . 0.0 108.683 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -58.46 -50.17 74.68 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.2 tp -47.9 -36.37 12.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.985 -1.072 . . . . 0.0 109.305 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.2 mp -70.88 -33.94 71.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.184 -0.947 . . . . 0.0 109.926 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -75.8 -31.95 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 120.572 -1.33 . . . . 0.0 109.06 -179.541 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 15.7 mt-30 -74.93 -22.15 58.76 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.177 -0.952 . . . . 0.0 109.317 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.433 ' O ' HD12 ' A' ' 84' ' ' ILE . 20.7 mt-30 -79.82 -56.77 4.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.572 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.584 ' C ' ' H ' ' A' ' 85' ' ' ASP . . . -78.28 -40.81 35.85 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.279 -0.888 . . . . 0.0 110.034 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.433 HD12 ' O ' ' A' ' 82' ' ' GLN . 1.3 mp 57.45 -16.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.386 -0.821 . . . . 0.0 111.564 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.584 ' H ' ' C ' ' A' ' 83' ' ' ALA . 2.1 p30 -83.51 129.89 58.3 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 120.318 -1.489 . . . . 0.0 109.328 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -79.05 -2.35 12.33 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.941 1.76 . . . . 0.0 111.951 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.473 ' NZ ' ' CG ' ' A' ' 85' ' ' ASP . 23.4 pttm -69.32 -21.09 63.87 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.306 -0.871 . . . . 0.0 108.935 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 0.2 OUTLIER -90.43 -62.84 1.37 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.833 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.48 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 34.3 tp -48.48 -25.17 1.54 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.107 -0.995 . . . . 0.0 109.442 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.458 ' OG ' ' CB ' ' A' ' 96' ' ' TRP . 5.2 t -94.28 -46.24 7.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 110.278 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 93' ' ' PHE . 55.5 ttt180 -56.27 -38.76 71.62 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.147 -0.97 . . . . 0.0 109.912 -179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.8 mt -49.62 -11.44 0.05 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.957 -1.089 . . . . 0.0 109.444 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.558 ' O ' ' N ' ' A' ' 95' ' ' GLY . 64.2 m-85 -146.02 119.0 5.16 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.279 -0.888 . . . . 0.0 108.847 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.16 -11.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.103 1.869 . . . . 0.0 112.782 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -61.72 -3.25 4.21 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 120.272 -0.966 . . . . 0.0 110.885 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.458 ' CB ' ' OG ' ' A' ' 90' ' ' SER . 2.3 p-90 -69.2 -10.11 56.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.642 -1.505 . . . . 0.0 109.188 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 7.9 ptpt -61.39 -9.98 6.5 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.592 -0.693 . . . . 0.0 110.768 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.89 -19.96 13.58 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.774 0.797 . . . . 0.0 109.007 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.438 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 20.3 m95 -77.27 6.36 6.87 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.743 -0.598 . . . . 0.0 109.898 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.579 -179.995 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.57 ' O ' ' N ' ' A' ' 71' ' ' SER . 0.2 OUTLIER -167.16 -31.38 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.069 -1.02 . . . . 0.0 108.505 -179.587 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 69' ' ' VAL . 9.7 mt -30.93 -31.51 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.253 0 CA-C-O 121.057 0.456 . . . . 0.0 111.372 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.57 ' N ' ' O ' ' A' ' 69' ' ' VAL . 51.7 m -163.56 126.77 2.67 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.033 -1.042 . . . . 0.0 110.207 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.59 HG23 ' N ' ' A' ' 73' ' ' GLY . 34.7 m -95.29 -51.21 11.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.705 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.606 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -49.35 -10.06 0.17 Allowed Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -75.59 -55.7 4.91 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.624 ' O ' HD23 ' A' ' 79' ' ' LEU . 18.8 mm100 -74.99 -26.33 59.48 Favored 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.202 -1.175 . . . . 0.0 109.702 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.0 t -73.03 -62.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -0.906 . . . . 0.0 108.946 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.606 ' ND2' ' O ' ' A' ' 73' ' ' GLY . 3.2 p30 -51.59 -36.76 46.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.028 -1.045 . . . . 0.0 108.476 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.1 tp -66.7 -43.0 85.51 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.624 HD23 ' O ' ' A' ' 75' ' ' GLN . 0.9 OUTLIER -56.74 -53.91 52.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.305 -0.872 . . . . 0.0 110.057 -179.383 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.706 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -68.11 -38.52 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.887 -1.133 . . . . 0.0 110.134 -178.666 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.406 ' OE1' HG23 ' A' ' 80' ' ' ILE . 1.0 OUTLIER -66.14 -41.22 90.73 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.497 -1.377 . . . . 0.0 109.883 -179.766 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -83.37 -32.58 26.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.717 -1.239 . . . . 0.0 110.102 -179.116 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -74.32 -63.27 1.27 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.117 -0.989 . . . . 0.0 111.221 -178.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 3.9 mt 43.72 55.86 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 O-C-N 121.093 -1.004 . . . . 0.0 110.079 -178.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.752 ' H ' ' CD ' ' A' ' 86' ' ' PRO . 2.0 t70 -157.11 -39.08 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.263 -0.898 . . . . 0.0 110.826 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.752 ' CD ' ' H ' ' A' ' 85' ' ' ASP . 59.8 Cg_endo -93.83 36.1 0.19 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.422 2.081 . . . . 0.0 111.531 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -54.3 -27.22 33.95 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.374 -0.829 . . . . 0.0 108.839 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -77.09 -68.95 0.56 Allowed 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.489 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 3.9 tt -49.73 -26.21 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.355 -0.841 . . . . 0.0 109.405 -179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.442 ' OG ' ' CZ2' ' A' ' 96' ' ' TRP . 60.5 p -77.26 -51.39 10.99 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.226 -0.921 . . . . 0.0 109.759 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 63.3 mtm180 -50.13 -29.73 9.71 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.958 -1.089 . . . . 0.0 109.289 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.1 mt -58.29 -32.76 68.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.079 -1.013 . . . . 0.0 109.118 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -67.36 153.3 95.06 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.172 -0.955 . . . . 0.0 108.478 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -75.16 -14.48 20.79 Favored 'Trans proline' 0 N--CA 1.493 1.477 0 C-N-CA 122.207 1.938 . . . . 0.0 112.868 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.07 -11.43 66.94 Favored Glycine 0 N--CA 1.497 2.73 0 C-N-CA 119.97 -1.11 . . . . 0.0 110.414 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.442 ' CZ2' ' OG ' ' A' ' 90' ' ' SER . 26.9 m95 -89.44 -7.14 55.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.177 -1.19 . . . . 0.0 110.088 -179.497 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.28 -23.24 2.17 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.164 -0.96 . . . . 0.0 111.244 -178.733 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.63 -20.06 10.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.939 . . . . 0.0 109.408 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.503 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 23.0 m0 -73.61 -12.41 60.74 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.836 -178.598 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.2 m . . . . . 0 C--N 1.304 -1.372 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.366 179.998 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 121.344 0.592 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 71' ' ' SER . 2.2 p -175.1 -49.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.88 . . . . 0.0 109.152 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.486 ' O ' ' CB ' ' A' ' 71' ' ' SER . 53.7 mt -48.19 -10.16 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.534 -0.728 . . . . 0.0 109.828 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 69' ' ' VAL . 1.4 p 76.89 126.75 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.22 -0.925 . . . . 0.0 109.161 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.559 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.7 m -60.22 -25.48 33.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.17 -179.533 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -42.85 -17.63 0.04 OUTLIER Glycine 0 N--CA 1.498 2.83 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.524 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -77.72 -52.54 5.4 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -72.78 -36.56 67.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.135 -1.215 . . . . 0.0 108.839 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.3 t -65.52 -53.45 39.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.1 t30 -51.93 -31.24 27.81 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.425 HD13 ' O ' ' A' ' 74' ' ' GLY . 3.0 mp -72.24 -47.69 48.39 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.117 . . . . 0.0 108.294 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.65 -48.24 49.41 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.576 -0.703 . . . . 0.0 110.286 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.477 ' O ' ' N ' ' A' ' 84' ' ' ILE . 0.0 OUTLIER -72.57 -43.83 61.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 120.763 -1.21 . . . . 0.0 109.802 -178.945 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -47.43 -25.26 1.0 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.824 -1.173 . . . . 0.0 108.587 179.303 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 61.4 mt-30 -95.58 -33.34 12.42 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.73 -0.606 . . . . 0.0 109.454 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.568 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -91.3 -8.57 47.84 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.421 -0.8 . . . . 0.0 111.047 -178.181 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.542 ' C ' ' O ' ' A' ' 83' ' ' ALA . 0.4 OUTLIER 2.88 -69.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.428 0 C-N-CA 123.632 0.773 . . . . 0.0 111.994 -179.568 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.568 ' N ' ' O ' ' A' ' 83' ' ' ALA . 30.5 t70 37.55 62.04 3.79 Favored Pre-proline 0 N--CA 1.498 1.933 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.113 179.168 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -82.56 -8.37 11.47 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.775 2.316 . . . . 0.0 112.068 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.4 ptmt -58.75 -22.61 58.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 110.145 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 85' ' ' ASP . 3.0 p30 -75.59 -53.62 8.31 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.111 -0.993 . . . . 0.0 109.89 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.482 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 59.8 tp -71.87 -21.82 61.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.558 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 16.2 m -83.56 -47.21 11.55 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.234 -0.916 . . . . 0.0 110.621 -179.196 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.458 ' C ' ' H ' ' A' ' 93' ' ' PHE . 0.1 OUTLIER -66.58 -37.41 84.87 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.903 -1.123 . . . . 0.0 110.256 -179.029 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.0 mt -68.85 8.2 0.56 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.896 -1.127 . . . . 0.0 109.641 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.524 ' O ' ' N ' ' A' ' 95' ' ' GLY . 59.1 m-85 -150.23 151.39 31.5 Favored Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.149 -0.969 . . . . 0.0 109.858 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -37.76 -22.13 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.739 2.293 . . . . 0.0 112.76 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.526 ' O ' ' NE1' ' A' ' 99' ' ' TRP . . . -39.14 -42.21 1.6 Allowed Glycine 0 N--CA 1.491 2.342 0 O-C-N 121.807 -0.558 . . . . 0.0 112.26 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.679 ' HE1' ' CE ' ' A' ' 97' ' ' LYS . 0.6 OUTLIER -91.8 -29.12 16.93 Favored 'General case' 0 N--CA 1.504 2.25 0 O-C-N 120.667 -1.49 . . . . 0.0 111.896 -177.903 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.679 ' CE ' ' HE1' ' A' ' 96' ' ' TRP . 24.7 mmtp -50.63 -9.0 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.526 -1.359 . . . . 0.0 109.808 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.51 ' N ' ' O ' ' A' ' 96' ' ' TRP . . . -106.01 -19.8 13.62 Favored 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.119 -0.988 . . . . 0.0 108.838 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.526 ' NE1' ' O ' ' A' ' 95' ' ' GLY . 26.2 m0 -74.62 -26.05 59.64 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.814 -0.754 . . . . 0.0 109.55 -178.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 C--N 1.305 -1.344 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.564 179.87 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.1 m . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.765 0.793 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.738 HG23 ' H ' ' A' ' 71' ' ' SER . 10.3 m -147.25 169.11 4.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.683 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 71' ' ' SER . 20.1 mt -57.42 10.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.287 -0.883 . . . . 0.0 110.645 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.738 ' H ' HG23 ' A' ' 69' ' ' VAL . 0.7 OUTLIER 76.56 107.83 0.08 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 122.125 0.964 . . . . 0.0 109.691 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.588 HG23 ' N ' ' A' ' 73' ' ' GLY . 22.6 m -95.45 -46.66 13.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.872 -179.548 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.588 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.22 -11.67 0.14 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.939 -1.264 . . . . 0.0 109.939 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -84.45 -64.51 1.57 Allowed Glycine 0 N--CA 1.493 2.447 0 O-C-N 121.197 -1.178 . . . . 0.0 110.208 -179.561 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -70.61 -9.77 57.72 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.004 -1.292 . . . . 0.0 109.242 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 72' ' ' VAL . 56.5 t -93.24 -64.15 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.049 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' A' ' 78' ' ' LEU . 19.6 p-10 -52.19 -20.4 2.57 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.966 -1.084 . . . . 0.0 108.084 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 80' ' ' ILE . 24.5 tp -84.97 -68.44 0.72 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.6 tp -47.0 -11.9 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.098 -1.001 . . . . 0.0 110.74 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -95.11 -55.34 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.795 -1.191 . . . . 0.0 109.53 -179.821 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.492 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -56.69 -21.96 31.48 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.411 -1.431 . . . . 0.0 110.069 179.915 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.617 ' NE2' ' N ' ' A' ' 83' ' ' ALA . 0.0 OUTLIER -93.49 -49.8 5.74 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 120.814 -1.179 . . . . 0.0 109.208 178.927 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.617 ' N ' ' NE2' ' A' ' 82' ' ' GLN . . . -66.04 -66.12 0.59 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.221 -0.924 . . . . 0.0 110.134 -179.378 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.489 ' O ' ' CB ' ' A' ' 85' ' ' ASP . 3.4 mt 65.87 -44.24 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 O-C-N 121.79 -0.569 . . . . 0.0 109.993 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.604 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 0.0 OUTLIER 164.69 -60.14 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.554 -0.716 . . . . 0.0 109.349 178.713 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.404 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 92.2 Cg_exo -33.39 -26.12 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.521 2.147 . . . . 0.0 113.548 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.551 ' N ' ' O ' ' A' ' 85' ' ' ASP . 26.4 pttt -46.43 -23.09 0.32 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.016 -1.053 . . . . 0.0 109.771 -179.326 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.604 ' ND2' ' O ' ' A' ' 85' ' ' ASP . 0.4 OUTLIER -88.87 -70.73 0.63 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.315 -0.866 . . . . 0.0 109.847 -179.708 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.3 tp -47.61 -15.9 0.06 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.927 -1.108 . . . . 0.0 109.57 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 95' ' ' GLY . 12.3 m -95.27 -67.85 0.83 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.438 -0.789 . . . . 0.0 110.672 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 43.2 ttt180 -56.89 -26.12 58.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.212 -0.93 . . . . 0.0 111.214 -178.1 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.55 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 66.6 mt -56.42 -36.43 68.96 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.824 -1.172 . . . . 0.0 110.348 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 4.5 m-85 -163.26 -66.96 0.01 OUTLIER Pre-proline 0 N--CA 1.497 1.923 0 C-N-CA 118.533 -1.267 . . . . 0.0 111.493 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.439 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 27.5 Cg_endo -60.21 -34.38 94.1 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 122.202 1.934 . . . . 0.0 112.743 -178.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . . . -47.08 -24.83 2.26 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 16.6 m95 -56.11 -9.63 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.203 -1.175 . . . . 0.0 109.657 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -64.35 -10.39 24.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.345 -0.847 . . . . 0.0 110.626 -179.442 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.78 -19.2 16.1 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.438 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.3 m95 -76.99 7.69 4.61 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.2 0.524 . . . . 0.0 109.898 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.405 ' H ' HG22 ' A' ' 100' ' ' VAL . 4.3 m . . . . . 0 C--N 1.304 -1.394 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.357 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 53.6 m . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.376 0.607 . . . . 0.0 109.892 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.535 HG23 ' N ' ' A' ' 70' ' ' LEU . 14.3 m -146.66 -47.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.535 ' N ' HG23 ' A' ' 69' ' ' VAL . 7.4 mt -71.08 5.1 2.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -0.981 . . . . 0.0 108.645 178.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.409 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.2 m 65.89 109.32 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.937 0.875 . . . . 0.0 108.819 -179.145 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.632 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.1 m -60.87 -56.68 16.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.477 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.632 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -53.6 -15.52 4.48 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -72.74 -59.25 4.48 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.503 ' O ' HD23 ' A' ' 79' ' ' LEU . 2.3 mp0 -80.64 -41.82 23.2 Favored 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.098 -1.236 . . . . 0.0 109.085 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 72' ' ' VAL . 46.7 t -53.85 -47.53 63.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 108.659 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -62.9 -57.84 9.41 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.237 -0.915 . . . . 0.0 108.709 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.5 tp -51.51 -30.78 21.51 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.056 -1.027 . . . . 0.0 109.958 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.503 HD23 ' O ' ' A' ' 75' ' ' GLN . 3.4 mm? -76.37 -30.23 57.47 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.995 -1.065 . . . . 0.0 110.289 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.701 ' O ' HD11 ' A' ' 84' ' ' ILE . 0.3 OUTLIER -77.85 -28.31 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.357 -1.464 . . . . 0.0 110.069 -178.946 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.456 ' NE2' ' CG2' ' A' ' 80' ' ' ILE . 18.7 mp0 -85.97 -36.9 19.54 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.153 -1.592 . . . . 0.0 110.381 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -90.95 -40.44 11.69 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.68 -1.262 . . . . 0.0 111.738 -178.044 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.495 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -53.72 -71.37 0.07 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.279 -178.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.701 HD11 ' O ' ' A' ' 80' ' ' ILE . 34.1 mm 25.94 65.94 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 122.14 -0.35 . . . . 0.0 111.633 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.531 ' O ' ' O ' ' A' ' 84' ' ' ILE . 3.9 p-10 39.3 103.68 0.02 OUTLIER Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.84 -0.537 . . . . 0.0 111.155 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_endo -77.14 27.78 0.44 Allowed 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.568 1.512 . . . . 0.0 111.902 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -51.83 -36.85 49.54 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.279 -0.888 . . . . 0.0 108.88 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 9.2 p-10 -57.13 -48.61 78.24 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.386 -0.821 . . . . 0.0 108.852 179.481 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.456 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 62.5 tp -56.88 -47.14 81.16 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.52 -0.737 . . . . 0.0 109.109 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 35.5 t -73.53 -14.37 61.2 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.309 -0.87 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.571 ' NH2' ' NE1' ' A' ' 96' ' ' TRP . 18.0 tpt85 -71.03 -49.61 43.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.184 -0.947 . . . . 0.0 109.508 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 31.3 mt -50.77 -11.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.444 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.572 ' O ' ' N ' ' A' ' 95' ' ' GLY . 64.8 m-85 -119.09 111.82 36.72 Favored Pre-proline 0 N--CA 1.498 1.958 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_exo -42.77 -11.41 0.03 OUTLIER 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 122.123 1.882 . . . . 0.0 112.617 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -43.22 -33.99 2.11 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.571 ' NE1' ' NH2' ' A' ' 91' ' ' ARG . 69.2 p-90 -52.64 -9.14 0.11 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.884 -1.362 . . . . 0.0 110.499 -178.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.435 ' H ' ' C ' ' A' ' 95' ' ' GLY . 25.7 pttt -58.3 -15.93 12.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.056 -1.027 . . . . 0.0 110.581 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.18 -18.81 14.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 108.814 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.441 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 13.6 m95 -75.56 -3.95 37.13 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.222 0.534 . . . . 0.0 109.908 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.2 m . . . . . 0 C--N 1.305 -1.359 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.621 -179.996 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 63.1 m . . . . . 0 N--CA 1.494 1.751 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.3 m -146.52 -19.14 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.3 -0.875 . . . . 0.0 109.077 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' A' ' 71' ' ' SER . 22.7 mt -61.71 1.39 0.25 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.351 -0.843 . . . . 0.0 108.996 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.523 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.3 t 74.08 114.13 0.06 Allowed 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 122.025 0.916 . . . . 0.0 109.49 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.9 m -70.46 -25.29 26.65 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.596 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -43.91 -21.13 0.19 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -65.31 -47.12 83.18 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.488 ' O ' HD13 ' A' ' 79' ' ' LEU . 1.4 mp0 -79.9 -38.0 33.48 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.324 -1.103 . . . . 0.0 109.654 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.76 -57.64 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 108.994 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.596 ' ND2' ' O ' ' A' ' 73' ' ' GLY . 3.1 p30 -56.54 -51.79 67.24 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.014 -1.054 . . . . 0.0 108.435 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.487 ' N ' ' OD1' ' A' ' 77' ' ' ASN . 28.0 tp -47.31 -35.89 8.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.062 179.457 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.488 HD13 ' O ' ' A' ' 75' ' ' GLN . 3.6 mp -71.46 -26.65 62.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.461 -0.774 . . . . 0.0 109.31 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.51 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -69.77 -34.17 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.896 -1.127 . . . . 0.0 109.651 -179.389 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.49 ' O ' HD11 ' A' ' 84' ' ' ILE . 12.1 mp0 -87.67 -19.93 27.0 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.878 -1.139 . . . . 0.0 110.09 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -93.4 -34.45 13.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.082 -1.011 . . . . 0.0 108.738 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -61.71 -21.29 64.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.25 -0.906 . . . . 0.0 110.051 -179.464 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.622 ' C ' HD12 ' A' ' 84' ' ' ILE . 2.3 pp -89.4 -1.39 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.154 -0.966 . . . . 0.0 109.951 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.598 ' N ' HD12 ' A' ' 84' ' ' ILE . 7.6 t0 -98.98 126.76 37.18 Favored Pre-proline 0 N--CA 1.497 1.89 0 O-C-N 121.213 -0.93 . . . . 0.0 108.784 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -38.11 -39.73 1.0 Allowed 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 122.237 1.958 . . . . 0.0 113.261 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -50.92 -16.93 0.49 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.928 -1.108 . . . . 0.0 109.279 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.446 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 4.7 p-10 -76.37 -50.05 15.23 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.278 -0.889 . . . . 0.0 109.04 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.446 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 3.3 tt -62.09 -21.42 64.95 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.323 -0.861 . . . . 0.0 108.821 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.581 ' C ' ' HE1' ' A' ' 96' ' ' TRP . 11.0 p -95.53 -33.02 12.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.135 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 93' ' ' PHE . 0.0 OUTLIER -76.76 -43.14 38.23 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.141 -0.974 . . . . 0.0 110.633 -178.732 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 64.2 mt -44.31 -19.15 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.223 -0.923 . . . . 0.0 109.387 -179.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.537 ' O ' ' N ' ' A' ' 95' ' ' GLY . 92.5 m-85 -106.77 102.73 43.67 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.497 ' O ' ' N ' ' A' ' 96' ' ' TRP . 81.6 Cg_exo -45.21 -9.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 122.036 1.824 . . . . 0.0 112.095 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.0 -14.73 0.14 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.581 ' HE1' ' C ' ' A' ' 90' ' ' SER . 3.7 m95 -47.9 -14.46 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.997 -1.296 . . . . 0.0 109.176 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.504 ' N ' ' O ' ' A' ' 95' ' ' GLY . 50.5 mtmt -69.09 -9.19 51.46 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.305 -0.872 . . . . 0.0 110.168 -179.63 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.26 -19.49 14.09 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.261 -0.899 . . . . 0.0 108.581 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.425 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 22.3 m95 -76.04 -8.86 57.95 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.243 0.544 . . . . 0.0 110.005 -178.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 C--N 1.305 -1.333 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.541 -179.898 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.664 HG22 HG12 ' A' ' 69' ' ' VAL . 90.2 m . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.749 HG22 ' H ' ' A' ' 70' ' ' LEU . 3.4 p -170.97 -118.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.749 ' H ' HG22 ' A' ' 69' ' ' VAL . 20.4 mt -64.61 3.61 0.49 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.269 -1.52 . . . . 0.0 108.883 179.316 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.521 ' H ' ' C ' ' A' ' 69' ' ' VAL . 38.8 m 55.4 110.81 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.195 0.998 . . . . 0.0 109.966 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 74' ' ' GLY . 21.2 m -83.47 -16.51 11.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.93 -14.86 0.09 OUTLIER Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.55 -55.48 8.57 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -74.06 -34.47 64.06 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.015 -1.285 . . . . 0.0 109.549 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.46 -61.22 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.738 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -50.67 -31.2 15.62 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.439 -0.788 . . . . 0.0 108.912 179.235 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.42 ' O ' ' OE1' ' A' ' 81' ' ' GLN . 41.0 tp -74.23 -39.61 62.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.346 -0.846 . . . . 0.0 109.172 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 21.6 tp -62.75 -28.12 69.75 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 111.056 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.406 HG22 ' H ' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -91.62 -40.04 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.683 -1.26 . . . . 0.0 110.832 -178.738 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.492 ' OE1' ' N ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -66.67 -23.48 66.15 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.957 -1.089 . . . . 0.0 109.289 -178.885 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.492 ' N ' ' OE1' ' A' ' 81' ' ' GLN . 4.0 tp60 -95.12 -36.96 11.29 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.965 -1.084 . . . . 0.0 108.56 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.514 ' C ' ' H ' ' A' ' 85' ' ' ASP . . . -62.19 -11.7 15.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.209 -0.932 . . . . 0.0 110.733 -179.089 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 85' ' ' ASP . 27.0 mm -52.66 -4.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.725 -1.235 . . . . 0.0 110.216 -179.716 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.527 ' C ' ' H ' ' A' ' 87' ' ' LYS . 0.4 OUTLIER -47.43 170.3 0.1 OUTLIER Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 120.924 -1.11 . . . . 0.0 109.104 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.95 8.92 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 1.99 0 C-N-CA 122.571 2.181 . . . . 0.0 113.653 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 85' ' ' ASP . 22.8 pttp -48.27 -21.21 0.47 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.683 -1.26 . . . . 0.0 109.545 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' CG ' ' H ' ' A' ' 89' ' ' LEU . 3.8 p30 -71.19 -61.25 1.83 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.298 -0.876 . . . . 0.0 109.227 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.456 ' H ' ' CG ' ' A' ' 88' ' ' ASN . 1.9 tt -51.86 -27.88 14.17 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 16.1 t -89.52 -24.27 21.82 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.431 -0.793 . . . . 0.0 109.734 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.404 ' O ' ' N ' ' A' ' 93' ' ' PHE . 15.9 tpp85 -70.46 -23.72 62.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.109 -0.994 . . . . 0.0 109.318 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.512 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 84.0 mt -47.84 -19.19 0.21 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.147 -0.971 . . . . 0.0 109.748 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.512 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 5.3 m-85 -160.0 -66.63 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.975 . . . . 0.0 110.02 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.44 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 77.2 Cg_exo -31.95 -52.7 0.33 Allowed 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 122.591 2.194 . . . . 0.0 113.238 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.526 ' O ' ' CE2' ' A' ' 99' ' ' TRP . . . -47.26 -41.92 16.76 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.429 ' CD1' ' N ' ' A' ' 96' ' ' TRP . 14.6 m95 -85.55 -9.89 56.72 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.1 -1.235 . . . . 0.0 110.425 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 7.2 mmpt? -72.75 -9.43 58.64 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.949 -1.095 . . . . 0.0 110.189 -179.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.13 -20.59 9.21 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.526 ' CE2' ' O ' ' A' ' 95' ' ' GLY . 23.9 m0 -74.77 -22.6 58.68 Favored 'General case' 0 C--N 1.3 -1.577 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.765 -178.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 100' ' ' VAL . 5.6 m . . . . . 0 C--N 1.304 -1.378 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.453 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.574 HG22 ' N ' ' A' ' 69' ' ' VAL . 94.1 m . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.574 ' N ' HG22 ' A' ' 68' ' ' THR . 35.9 m -62.21 -143.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.234 -0.916 . . . . 0.0 109.205 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 15.5 mt -55.81 -4.38 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.991 -1.068 . . . . 0.0 109.53 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.497 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.6 m 62.56 111.63 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.292 -0.88 . . . . 0.0 109.668 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.509 HG23 ' N ' ' A' ' 73' ' ' GLY . 24.2 m -48.27 -40.36 9.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-O 121.262 0.553 . . . . 0.0 109.622 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.509 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -45.18 -18.71 0.16 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.65 -46.67 89.29 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -80.71 -41.76 23.09 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.239 -1.154 . . . . 0.0 109.397 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 76' ' ' VAL . 3.6 t -59.17 -53.01 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 108.732 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -57.76 -55.19 38.08 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.0 tp -50.16 -31.71 14.28 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.432 -0.792 . . . . 0.0 109.1 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.58 ' O ' ' HB3' ' A' ' 83' ' ' ALA . 5.2 tp -64.76 -59.7 3.93 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.367 -0.833 . . . . 0.0 110.358 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.44 HG22 ' H ' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -73.01 -21.74 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 110.602 -178.386 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -70.98 -46.5 62.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.507 -1.371 . . . . 0.0 109.341 179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.427 ' O ' HD12 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -92.13 -30.33 16.03 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.087 -1.008 . . . . 0.0 110.031 -179.051 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.58 ' HB3' ' O ' ' A' ' 79' ' ' LEU . . . -86.51 -32.98 20.46 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.063 -1.023 . . . . 0.0 109.813 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.427 HD12 ' O ' ' A' ' 82' ' ' GLN . 1.2 mp 41.27 22.11 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 CA-C-O 121.58 0.705 . . . . 0.0 110.073 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 83' ' ' ALA . 67.5 m-20 46.38 87.57 0.12 Allowed Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.301 -0.874 . . . . 0.0 110.024 179.22 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.54 -8.99 9.99 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 122.428 2.085 . . . . 0.0 112.095 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -47.14 -22.09 0.33 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.335 -0.853 . . . . 0.0 109.532 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.494 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 6.4 p-10 -69.93 -54.42 13.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.325 -0.86 . . . . 0.0 109.811 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.494 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 2.0 tt -59.66 -33.56 71.69 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.256 -0.903 . . . . 0.0 108.889 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 76.9 p -79.39 -33.33 42.88 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.307 -0.871 . . . . 0.0 109.475 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' C ' ' N ' ' A' ' 93' ' ' PHE . 35.0 ttm180 -56.16 -42.27 76.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.254 -0.904 . . . . 0.0 109.555 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 61.2 mt -48.23 -20.01 0.34 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.119 -0.988 . . . . 0.0 109.252 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.55 ' O ' ' N ' ' A' ' 95' ' ' GLY . 1.8 m-85 -116.69 121.97 32.28 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.352 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 96' ' ' TRP . 74.1 Cg_exo -40.63 -16.99 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.138 1.892 . . . . 0.0 112.472 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.84 -9.39 0.06 OUTLIER Glycine 0 N--CA 1.489 2.192 0 C-N-CA 120.392 -0.909 . . . . 0.0 110.93 -179.419 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.53 ' N ' ' O ' ' A' ' 94' ' ' PRO . 62.0 p-90 -73.05 -11.73 60.66 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.798 -1.413 . . . . 0.0 109.963 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.529 ' CB ' ' NZ ' ' A' ' 97' ' ' LYS . 0.1 OUTLIER -61.75 -9.02 5.47 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.172 -0.955 . . . . 0.0 110.313 -179.73 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.76 -19.83 13.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.184 -0.948 . . . . 0.0 109.199 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.439 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.4 m95 -76.22 6.93 4.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.765 -0.584 . . . . 0.0 110.149 -178.573 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 100' ' ' VAL . 21.0 m . . . . . 0 N--CA 1.487 1.411 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.613 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.453 HG22 ' H ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.601 HG21 HE22 ' A' ' 75' ' ' GLN . 5.7 m -86.43 10.55 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.099 -1.001 . . . . 0.0 109.676 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 19.2 mt 56.79 7.05 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.93 . . . . 0.0 109.793 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.454 ' H ' HG23 ' A' ' 69' ' ' VAL . 76.9 p -171.18 115.49 0.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.416 ' C ' ' N ' ' A' ' 74' ' ' GLY . 28.6 m -53.99 -28.34 17.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.81 -20.5 1.22 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.416 ' N ' ' C ' ' A' ' 72' ' ' VAL . . . -76.77 -39.0 30.04 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.601 HE22 HG21 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -64.41 -33.48 75.96 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.954 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.06 -48.2 33.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.409 ' O ' ' OE1' ' A' ' 81' ' ' GLN . 30.9 t30 -56.45 -34.7 67.11 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.9 tp -67.11 -37.24 83.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.248 -0.908 . . . . 0.0 108.789 179.298 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 40.7 tp -60.53 -40.04 90.05 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.154 -0.966 . . . . 0.0 109.947 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -85.53 -50.03 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 120.549 -1.344 . . . . 0.0 109.224 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.439 ' N ' HG23 ' A' ' 80' ' ' ILE . 1.9 mp0 -45.48 -32.0 2.0 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.631 -1.293 . . . . 0.0 110.375 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 1.1 pp0? -94.36 -30.53 14.45 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.828 -1.17 . . . . 0.0 110.045 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.83 -9.84 2.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.124 -0.985 . . . . 0.0 111.183 -178.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.495 ' CD1' ' N ' ' A' ' 85' ' ' ASP . 1.6 pp -124.57 -120.74 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.989 -1.069 . . . . 0.0 108.908 -179.495 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.495 ' N ' ' CD1' ' A' ' 84' ' ' ILE . 0.1 OUTLIER -172.9 -58.72 0.0 OUTLIER Pre-proline 0 C--N 1.3 -1.549 0 O-C-N 120.799 -1.188 . . . . 0.0 109.898 179.625 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.449 ' O ' ' N ' ' A' ' 88' ' ' ASN . 86.6 Cg_endo -77.2 -49.46 0.1 Allowed 'Trans proline' 0 N--CA 1.5 1.873 0 C-N-CA 122.044 1.829 . . . . 0.0 112.351 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.417 ' HG2' ' H ' ' A' ' 87' ' ' LYS . 7.8 mmmm -49.54 -14.85 0.12 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.308 -0.87 . . . . 0.0 109.188 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 0.6 OUTLIER -70.06 -51.78 29.23 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.234 -0.986 . . . . 0.0 108.43 179.836 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.478 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 10.9 tp -67.66 -22.91 65.28 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.334 -0.853 . . . . 0.0 108.887 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 m -77.39 -47.07 20.78 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.41 -0.806 . . . . 0.0 110.376 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.504 ' O ' ' N ' ' A' ' 93' ' ' PHE . 78.0 mtt-85 -85.63 -45.26 11.88 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.019 -1.051 . . . . 0.0 110.57 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 63.5 mt -45.79 -19.28 0.05 Allowed 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.975 -1.078 . . . . 0.0 108.982 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.554 ' O ' ' N ' ' A' ' 95' ' ' GLY . 52.8 m-85 -114.71 87.57 14.82 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 178.584 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -41.62 -12.81 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.6 2.2 . . . . 0.0 112.718 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -59.98 -11.89 20.0 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 59.8 p-90 -59.11 -19.72 47.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.579 -1.542 . . . . 0.0 109.556 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -64.6 -8.86 15.79 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.29 -0.881 . . . . 0.0 109.641 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.81 -17.5 16.86 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.455 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 31.9 m0 -71.8 7.46 1.53 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.317 -178.317 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.002 179.936 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.437 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.483 ' C ' ' H ' ' A' ' 71' ' ' SER . 4.6 m -98.61 12.75 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.141 -0.974 . . . . 0.0 109.692 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.3 mt 53.09 8.19 0.1 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.0 -1.062 . . . . 0.0 109.257 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.483 ' H ' ' C ' ' A' ' 69' ' ' VAL . 15.4 m -69.33 113.73 6.93 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.999 0.904 . . . . 0.0 108.962 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.551 HG23 ' N ' ' A' ' 73' ' ' GLY . 28.8 m -88.15 -45.98 15.81 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.785 -179.009 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.551 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.73 -12.8 0.45 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -81.24 -41.9 9.83 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -82.48 -41.8 19.29 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.221 -1.164 . . . . 0.0 108.851 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.4 t -62.43 -55.82 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 60.3 t-20 -56.36 -53.78 53.32 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.4 tp -47.6 -35.65 9.56 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.174 -0.954 . . . . 0.0 108.597 179.002 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -63.59 -38.68 92.03 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.729 -0.607 . . . . 0.0 109.769 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.535 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -76.88 -22.96 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.715 -1.24 . . . . 0.0 109.558 -179.577 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -74.51 -48.45 27.06 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 111.527 -178.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.431 ' CD ' ' N ' ' A' ' 83' ' ' ALA . 0.5 OUTLIER -85.01 -19.14 32.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.304 -1.497 . . . . 0.0 109.315 -179.285 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.837 ' O ' HD12 ' A' ' 84' ' ' ILE . . . -83.58 -66.28 0.91 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.161 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.837 HD12 ' O ' ' A' ' 83' ' ' ALA . 0.5 OUTLIER 29.93 77.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 CA-C-O 121.662 0.744 . . . . 0.0 110.612 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.589 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 42.3 t0 51.43 65.08 6.97 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.199 -0.938 . . . . 0.0 109.331 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.439 ' O ' ' OG ' ' A' ' 90' ' ' SER . 76.9 Cg_endo -76.23 -7.29 17.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.636 2.224 . . . . 0.0 112.183 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' A' ' 87' ' ' LYS . 0.1 OUTLIER -61.31 -26.42 67.78 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.164 -0.96 . . . . 0.0 108.554 179.555 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.589 ' ND2' ' O ' ' A' ' 85' ' ' ASP . 0.4 OUTLIER -86.69 -67.7 0.8 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.436 -0.79 . . . . 0.0 109.061 179.7 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 10.9 tp -45.96 -28.93 1.26 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.218 -0.926 . . . . 0.0 109.399 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.439 ' OG ' ' O ' ' A' ' 86' ' ' PRO . 95.6 p -83.07 -40.85 19.33 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.424 -0.797 . . . . 0.0 110.35 -179.481 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 2.8 ttp-105 -79.82 -20.27 46.51 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.623 -1.298 . . . . 0.0 110.678 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.522 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 39.5 mt -89.62 6.96 38.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.02 -1.05 . . . . 0.0 110.875 -178.749 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.522 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 14.4 m-85 -154.24 -74.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 120.583 -1.323 . . . . 0.0 111.275 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 95.1 Cg_endo -74.49 -45.5 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 121.567 1.512 . . . . 0.0 113.237 -179.426 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 99' ' ' TRP . . . -41.62 -39.89 2.7 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.347 -0.846 . . . . 0.0 111.317 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.439 ' CD1' ' CE3' ' A' ' 99' ' ' TRP . 23.7 m0 -82.97 -23.38 33.41 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.698 -1.472 . . . . 0.0 110.196 -178.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 3.3 mmpp? -64.05 -9.05 13.87 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.137 -0.977 . . . . 0.0 110.337 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.58 -20.01 10.9 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 108.599 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.552 ' CD1' ' O ' ' A' ' 95' ' ' GLY . 22.1 m0 -80.98 -4.6 55.63 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.634 -178.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.5 m . . . . . 0 C--N 1.305 -1.349 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.537 -179.957 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.544 HG22 ' N ' ' A' ' 69' ' ' VAL . 28.1 m . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.109 -0.701 . . . . 0.0 109.109 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.544 ' N ' HG22 ' A' ' 68' ' ' THR . 6.7 p -160.75 117.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 O-C-N 121.121 -0.987 . . . . 0.0 110.159 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 50.4 mt 50.56 5.01 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -0.803 . . . . 0.0 110.537 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.529 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -84.94 105.49 15.75 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.846 -1.159 . . . . 0.0 108.636 179.528 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.536 HG23 ' N ' ' A' ' 73' ' ' GLY . 20.9 m -79.41 -41.99 22.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.019 -179.01 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.536 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.5 -27.06 0.75 Allowed Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.22 -36.66 26.8 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.481 ' O ' HD13 ' A' ' 79' ' ' LEU . 13.2 mt-30 -66.07 -23.49 66.53 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 178.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.4 t -73.67 -47.16 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -56.11 -49.44 73.88 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 31.8 tp -59.85 -36.33 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.511 -0.743 . . . . 0.0 110.085 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.481 HD13 ' O ' ' A' ' 75' ' ' GLN . 2.5 mp -69.05 -24.74 64.21 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.118 -0.988 . . . . 0.0 111.495 -178.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.63 -26.32 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 120.378 -1.451 . . . . 0.0 110.708 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -86.51 -22.02 26.62 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.372 -1.455 . . . . 0.0 109.94 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -95.19 -42.12 8.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.95 -1.093 . . . . 0.0 108.843 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.849 ' C ' HD12 ' A' ' 84' ' ' ILE . . . -98.01 -27.39 14.26 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.216 -0.927 . . . . 0.0 111.459 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.849 HD12 ' C ' ' A' ' 83' ' ' ALA . 0.1 OUTLIER 36.9 32.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.296 0 O-C-N 121.635 -0.666 . . . . 0.0 110.274 -177.8 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 84' ' ' ILE . 5.4 p-10 39.11 95.13 0.04 OUTLIER Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 121.863 -0.523 . . . . 0.0 110.543 179.296 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -80.23 23.26 0.7 Allowed 'Trans proline' 0 N--CA 1.491 1.344 0 C-N-CA 121.896 1.731 . . . . 0.0 111.948 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 28.5 mtmm -58.5 -32.82 69.17 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.222 -0.924 . . . . 0.0 109.219 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.466 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 3.3 p30 -63.7 -25.29 68.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.317 -0.864 . . . . 0.0 108.96 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 2.5 tt -80.89 -45.16 17.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.962 . . . . 0.0 108.598 179.322 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 93' ' ' PHE . 16.6 t -69.73 -20.62 63.51 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.828 ' HE ' ' HE1' ' A' ' 96' ' ' TRP . 0.0 OUTLIER -78.09 -54.52 6.18 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.283 -0.886 . . . . 0.0 109.656 -179.782 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 32.4 mt -65.4 7.75 0.2 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.199 -0.938 . . . . 0.0 109.715 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' GLY . 31.1 m-85 -146.3 157.4 49.24 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.091 -1.006 . . . . 0.0 109.463 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.548 ' O ' ' N ' ' A' ' 96' ' ' TRP . 90.6 Cg_exo -43.4 -6.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 122.651 2.234 . . . . 0.0 112.975 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.27 -11.19 0.07 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' TRP . . . . . 0.828 ' HE1' ' HE ' ' A' ' 91' ' ' ARG . 5.3 m0 -44.94 -16.58 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.269 -1.136 . . . . 0.0 109.374 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' A' ' 95' ' ' GLY . 0.1 OUTLIER -62.35 -8.49 6.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.85 . . . . 0.0 110.218 179.829 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -94.49 -19.23 20.73 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.845 -1.159 . . . . 0.0 108.118 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.446 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 20.0 m95 -76.07 -13.0 60.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.261 0.553 . . . . 0.0 109.78 -178.785 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.6 m . . . . . 0 C--N 1.304 -1.373 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.489 179.917 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.482 ' C ' ' H ' ' A' ' 74' ' ' GLY . 26.7 m . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -51.18 -10.14 0.45 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -72.62 -49.91 16.92 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.9 mp0 -79.27 -39.23 33.51 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.18 -1.188 . . . . 0.0 109.139 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 13.9 t -62.48 -54.5 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 108.585 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -54.5 -49.18 70.77 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.58 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 40.8 tp -48.02 -50.61 27.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.092 -1.005 . . . . 0.0 108.862 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.9 tp -55.88 -31.98 63.29 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 110.973 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -74.32 -38.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.583 -1.323 . . . . 0.0 109.851 -178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -64.87 -53.44 46.59 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.176 -0.953 . . . . 0.0 110.362 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.876 HE21 ' H ' ' A' ' 82' ' ' GLN . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.567 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.8 m . . . . . 0 N--CA 1.481 1.109 0 CA-C-O 121.229 0.538 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.567 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.47 -15.33 0.44 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -73.18 -51.94 9.47 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.568 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 2.6 mp0 -82.94 -42.28 17.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.169 -1.195 . . . . 0.0 109.528 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 32.9 t -56.61 -52.05 58.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.474 ' C ' HE21 ' A' ' 81' ' ' GLN . 8.1 t-20 -61.77 -53.35 57.21 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 42.3 tp -50.39 -31.83 15.91 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.117 -0.989 . . . . 0.0 109.143 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.7 tp -75.61 -30.13 59.44 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.273 -0.892 . . . . 0.0 110.539 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.556 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -82.56 -19.95 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 120.831 -1.168 . . . . 0.0 109.526 -179.094 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.474 HE21 ' C ' ' A' ' 77' ' ' ASN . 6.7 mt-30 -90.46 -35.52 15.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.592 -1.317 . . . . 0.0 110.34 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.9 tp60 . . . . . 0 N--CA 1.488 1.465 0 O-C-N 120.948 -1.095 . . . . 0.0 108.782 -179.521 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.531 HG23 ' N ' ' A' ' 73' ' ' GLY . 23.7 m . . . . . 0 N--CA 1.481 1.099 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.531 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.96 -23.73 0.43 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.96 -44.84 54.42 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.659 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 2.3 mp0 -62.31 -29.21 70.28 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.7 t -70.33 -44.91 77.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.524 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 9.1 t-20 -60.58 -57.76 11.36 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 33.2 tp -47.94 -28.94 2.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 108.969 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.1 tp -70.7 -40.04 73.1 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.353 -0.842 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -67.9 -38.75 80.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.944 -1.098 . . . . 0.0 109.45 -179.276 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 2.5 mp0 -68.6 -31.99 71.55 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.895 -1.128 . . . . 0.0 108.529 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.399 0 O-C-N 121.453 -0.779 . . . . 0.0 109.684 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.561 HG23 ' N ' ' A' ' 73' ' ' GLY . 15.5 m . . . . . 0 N--CA 1.477 0.922 0 CA-C-O 121.375 0.607 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.561 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.69 -9.82 0.1 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -79.93 -62.68 2.08 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.053 -1.263 . . . . 0.0 110.109 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.566 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 0.6 OUTLIER -74.03 -30.32 62.37 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.073 -1.251 . . . . 0.0 108.841 -179.638 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 72' ' ' VAL . 41.2 t -67.81 -51.57 48.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 14.7 t-20 -55.11 -36.34 65.61 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.133 -0.979 . . . . 0.0 108.803 178.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.5 tp -73.95 -46.93 40.97 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 120.715 -1.241 . . . . 0.0 108.88 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.492 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.9 mp -65.87 -15.71 63.17 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.567 -0.708 . . . . 0.0 109.298 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.489 ' CG2' ' N ' ' A' ' 81' ' ' GLN . 0.4 OUTLIER -80.33 -54.51 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.819 -1.176 . . . . 0.0 108.306 -179.885 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 4.6 mt-30 -54.97 -53.82 50.79 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.066 -1.021 . . . . 0.0 110.095 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 75' ' ' GLN . 18.9 m . . . . . 0 N--CA 1.476 0.836 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -24.71 3.08 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.647 -1.781 . . . . 0.0 108.647 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.551 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -72.57 -42.05 49.05 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.413 ' N ' ' O ' ' A' ' 72' ' ' VAL . 10.9 mp0 -58.64 -21.8 54.91 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 178.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.4 ' C ' ' N ' ' A' ' 78' ' ' LEU . 5.1 t -83.87 -53.64 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.593 HD22 ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -57.05 -14.66 3.98 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.632 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.593 ' N ' HD22 ' A' ' 77' ' ' ASN . 65.9 tp -88.0 -66.05 0.95 Allowed 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.453 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -48.97 -13.88 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 110.027 -179.806 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -95.71 -55.0 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.931 -1.105 . . . . 0.0 110.221 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.622 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 2.3 pp0? -55.35 -12.67 1.11 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.072 -1.642 . . . . 0.0 108.256 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.622 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 178.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.2 m . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 121.361 0.6 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -9.37 0.06 OUTLIER Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -74.85 -63.78 2.49 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.848 -1.384 . . . . 0.0 110.387 -179.263 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -75.25 -28.31 59.8 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.02 -1.282 . . . . 0.0 109.744 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 25.7 t -68.7 -57.71 8.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 108.747 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.82 HD22 HE22 ' A' ' 81' ' ' GLN . 8.7 t30 -51.98 -44.26 63.97 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.208 -0.932 . . . . 0.0 108.574 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.405 HD13 ' O ' ' A' ' 74' ' ' GLY . 4.3 mp -57.2 -30.39 64.5 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.037 -1.039 . . . . 0.0 108.516 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.534 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -73.65 -29.26 62.23 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.317 -0.864 . . . . 0.0 110.779 -178.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.42 ' H ' HG23 ' A' ' 80' ' ' ILE . 0.9 OUTLIER -80.11 -27.15 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.626 -1.296 . . . . 0.0 110.399 -178.685 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.82 HE22 HD22 ' A' ' 77' ' ' ASN . 3.1 pt20 -95.02 -10.87 29.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 108.854 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 15.9 mt-30 . . . . . 0 N--CA 1.498 1.935 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 -179.785 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.63 HG23 ' N ' ' A' ' 73' ' ' GLY . 16.9 m . . . . . 0 N--CA 1.481 1.122 0 CA-C-O 120.921 0.391 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.63 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.15 -13.41 0.36 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -80.9 -62.07 2.06 Favored Glycine 0 N--CA 1.492 2.392 0 O-C-N 121.213 -1.169 . . . . 0.0 110.666 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.541 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 3.4 mp0 -73.78 -32.12 63.62 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.882 -1.364 . . . . 0.0 108.8 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.462 ' O ' HG22 ' A' ' 80' ' ' ILE . 39.9 t -66.57 -59.72 3.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -50.46 -30.82 13.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.105 -0.997 . . . . 0.0 109.305 179.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 61.1 tp -78.61 -29.81 46.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.077 -1.014 . . . . 0.0 109.654 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -72.7 -35.34 67.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.061 -1.024 . . . . 0.0 109.685 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.24 -42.43 23.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.719 -1.238 . . . . 0.0 109.464 -179.476 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.481 ' NE2' HG23 ' A' ' 80' ' ' ILE . 2.1 mp0 -66.07 -29.59 69.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.952 -1.093 . . . . 0.0 110.394 -179.315 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 pp0? . . . . . 0 N--CA 1.498 1.926 0 O-C-N 120.632 -1.293 . . . . 0.0 109.013 179.407 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.6 m . . . . . 0 N--CA 1.483 1.205 0 CA-C-O 121.385 0.612 . . . . 0.0 109.772 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -46.56 -14.57 0.11 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.86 -53.09 12.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -74.25 -32.45 62.96 Favored 'General case' 0 N--CA 1.485 1.289 0 O-C-N 120.985 -1.303 . . . . 0.0 109.228 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -70.8 -60.0 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.185 -0.947 . . . . 0.0 108.773 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 29.7 t-20 -55.48 -24.82 33.34 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.095 -1.003 . . . . 0.0 108.973 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.9 tp -81.65 -41.8 20.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.843 -1.161 . . . . 0.0 109.047 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.3 tp -58.9 -35.89 73.79 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.357 -0.84 . . . . 0.0 110.432 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.564 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.21 -49.12 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.853 -1.154 . . . . 0.0 108.891 -179.523 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 0.1 OUTLIER -58.57 -12.06 3.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.756 -1.215 . . . . 0.0 108.841 178.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 . . . . . 0 N--CA 1.487 1.418 0 O-C-N 121.173 -0.954 . . . . 0.0 109.686 -178.98 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' GLY . 30.5 m . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 121.311 0.577 . . . . 0.0 109.638 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -44.92 -17.97 0.11 Allowed Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.94 -54.87 25.35 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.671 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 2.1 mp0 -74.69 -36.01 62.76 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.185 -1.185 . . . . 0.0 109.624 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.403 ' O ' HG22 ' A' ' 80' ' ' ILE . 7.4 t -65.84 -58.91 4.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.027 -1.046 . . . . 0.0 109.053 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.486 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -54.24 -31.02 52.36 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 108.74 179.726 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.3 tp -73.23 -37.79 66.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.183 -0.948 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.516 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -61.64 -40.81 96.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.197 -0.939 . . . . 0.0 109.425 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.754 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -81.92 -46.71 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.777 -1.202 . . . . 0.0 109.957 -179.279 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.698 HE21 ' N ' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -53.45 -39.88 64.78 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.641 -1.287 . . . . 0.0 109.981 -179.372 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.493 ' NE2' ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.702 0 O-C-N 120.859 -1.15 . . . . 0.0 110.143 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 74' ' ' GLY . 20.4 m . . . . . 0 N--CA 1.485 1.29 0 CA-C-O 121.356 0.598 . . . . 0.0 109.631 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.63 -22.57 0.73 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -61.04 -46.93 93.57 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.4 ' O ' HD13 ' A' ' 79' ' ' LEU . 3.6 mp0 -81.69 -46.55 14.14 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.142 -1.211 . . . . 0.0 109.488 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.449 HG23 ' H ' ' A' ' 76' ' ' VAL . 4.8 t -57.04 -51.33 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.206 -0.934 . . . . 0.0 108.683 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.592 ' C ' HE21 ' A' ' 81' ' ' GLN . 6.6 t-20 -58.46 -50.17 74.68 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.2 tp -47.9 -36.37 12.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.985 -1.072 . . . . 0.0 109.305 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.2 mp -70.88 -33.94 71.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.184 -0.947 . . . . 0.0 109.926 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -75.8 -31.95 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 120.572 -1.33 . . . . 0.0 109.06 -179.541 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.592 HE21 ' C ' ' A' ' 77' ' ' ASN . 6.0 mt-30 -74.93 -22.15 58.76 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.177 -0.952 . . . . 0.0 109.317 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.572 179.905 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.59 HG23 ' N ' ' A' ' 73' ' ' GLY . 34.7 m . . . . . 0 N--CA 1.487 1.392 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.59 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.35 -10.06 0.17 Allowed Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -75.59 -55.7 4.91 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.624 ' O ' HD23 ' A' ' 79' ' ' LEU . 68.6 mm-40 -74.99 -26.33 59.48 Favored 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.202 -1.175 . . . . 0.0 109.702 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.0 t -73.03 -62.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -0.906 . . . . 0.0 108.946 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.497 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -51.59 -36.76 46.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.028 -1.045 . . . . 0.0 108.476 179.405 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.443 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 11.1 tp -66.7 -43.0 85.51 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.624 HD23 ' O ' ' A' ' 75' ' ' GLN . 0.9 OUTLIER -56.74 -53.91 52.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.305 -0.872 . . . . 0.0 110.057 -179.383 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.706 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -68.11 -38.52 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.887 -1.133 . . . . 0.0 110.134 -178.666 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.634 HE21 ' N ' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -66.14 -41.22 90.73 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.497 -1.377 . . . . 0.0 109.883 -179.766 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.508 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.638 0 O-C-N 120.717 -1.239 . . . . 0.0 110.102 -179.116 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.559 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.7 m . . . . . 0 N--CA 1.481 1.124 0 CA-C-O 120.895 0.379 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -42.85 -17.63 0.04 OUTLIER Glycine 0 N--CA 1.498 2.83 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -77.72 -52.54 5.4 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -72.78 -36.56 67.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.135 -1.215 . . . . 0.0 108.839 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.3 t -65.52 -53.45 39.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.615 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.3 t-20 -51.93 -31.24 27.81 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.425 HD13 ' O ' ' A' ' 74' ' ' GLY . 3.0 mp -72.24 -47.69 48.39 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.117 . . . . 0.0 108.294 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.65 -48.24 49.41 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.576 -0.703 . . . . 0.0 110.286 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.451 HG23 ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -72.57 -43.83 61.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 120.763 -1.21 . . . . 0.0 109.802 -178.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.615 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 0.0 OUTLIER -47.43 -25.26 1.0 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.824 -1.173 . . . . 0.0 108.587 179.303 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 . . . . . 0 N--CA 1.496 1.838 0 O-C-N 121.73 -0.606 . . . . 0.0 109.454 179.438 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.588 HG23 ' N ' ' A' ' 73' ' ' GLY . 22.6 m . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 121.166 0.508 . . . . 0.0 109.872 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.588 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.22 -11.67 0.14 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.939 -1.264 . . . . 0.0 109.939 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -84.45 -64.51 1.57 Allowed Glycine 0 N--CA 1.493 2.447 0 O-C-N 121.197 -1.178 . . . . 0.0 110.208 -179.561 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -70.61 -9.77 57.72 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.004 -1.292 . . . . 0.0 109.242 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 72' ' ' VAL . 56.5 t -93.24 -64.15 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.049 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.68 HD22 ' N ' ' A' ' 78' ' ' LEU . 0.1 OUTLIER -52.19 -20.4 2.57 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.966 -1.084 . . . . 0.0 108.084 178.945 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.68 ' N ' HD22 ' A' ' 77' ' ' ASN . 24.5 tp -84.97 -68.44 0.72 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.6 tp -47.0 -11.9 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.098 -1.001 . . . . 0.0 110.74 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -95.11 -55.34 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.795 -1.191 . . . . 0.0 109.53 -179.821 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.492 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 3.2 pp0? -56.69 -21.96 31.48 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.411 -1.431 . . . . 0.0 110.069 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.543 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.07 0 O-C-N 120.814 -1.179 . . . . 0.0 109.208 178.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.632 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.1 m . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 120.947 0.403 . . . . 0.0 110.477 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.632 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -53.6 -15.52 4.48 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -72.74 -59.25 4.48 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.503 ' O ' HD23 ' A' ' 79' ' ' LEU . 1.7 mp0 -80.64 -41.82 23.2 Favored 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.098 -1.236 . . . . 0.0 109.085 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 72' ' ' VAL . 46.7 t -53.85 -47.53 63.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 108.659 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.631 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.8 t30 -62.9 -57.84 9.41 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.237 -0.915 . . . . 0.0 108.709 179.027 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.5 tp -51.51 -30.78 21.51 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.056 -1.027 . . . . 0.0 109.958 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.503 HD23 ' O ' ' A' ' 75' ' ' GLN . 3.4 mm? -76.37 -30.23 57.47 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.995 -1.065 . . . . 0.0 110.289 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -77.85 -28.31 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.357 -1.464 . . . . 0.0 110.069 -178.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.631 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -85.97 -36.9 19.54 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.153 -1.592 . . . . 0.0 110.381 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.497 ' NE2' ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.501 2.093 0 O-C-N 120.68 -1.262 . . . . 0.0 111.738 -178.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.9 m . . . . . 0 N--CA 1.478 0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -43.91 -21.13 0.19 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -65.31 -47.12 83.18 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.488 ' O ' HD13 ' A' ' 79' ' ' LEU . 1.4 mp0 -79.9 -38.0 33.48 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.324 -1.103 . . . . 0.0 109.654 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.76 -57.64 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 108.994 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.796 HD22 HE22 ' A' ' 81' ' ' GLN . 0.2 OUTLIER -56.54 -51.79 67.24 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.014 -1.054 . . . . 0.0 108.435 179.712 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.618 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 28.0 tp -47.31 -35.89 8.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.062 179.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.488 HD13 ' O ' ' A' ' 75' ' ' GLN . 3.6 mp -71.46 -26.65 62.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.461 -0.774 . . . . 0.0 109.31 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.51 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -69.77 -34.17 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.896 -1.127 . . . . 0.0 109.651 -179.389 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.796 HE22 HD22 ' A' ' 77' ' ' ASN . 0.0 OUTLIER -87.67 -19.93 27.0 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.878 -1.139 . . . . 0.0 110.09 -179.8 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 . . . . . 0 N--CA 1.493 1.689 0 O-C-N 121.082 -1.011 . . . . 0.0 108.738 -179.768 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 74' ' ' GLY . 21.2 m . . . . . 0 N--CA 1.479 1.024 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.93 -14.86 0.09 OUTLIER Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.55 -55.48 8.57 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -74.06 -34.47 64.06 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.015 -1.285 . . . . 0.0 109.549 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.46 -61.22 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.738 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -50.67 -31.2 15.62 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.439 -0.788 . . . . 0.0 108.912 179.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.57 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 41.0 tp -74.23 -39.61 62.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.346 -0.846 . . . . 0.0 109.172 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 21.6 tp -62.75 -28.12 69.75 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 111.056 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.406 ' H ' HG22 ' A' ' 80' ' ' ILE . 0.0 OUTLIER -91.62 -40.04 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.683 -1.26 . . . . 0.0 110.832 -178.738 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.64 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -66.67 -23.48 66.15 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.957 -1.089 . . . . 0.0 109.289 -178.885 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.64 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 4.0 tp60 . . . . . 0 N--CA 1.494 1.742 0 O-C-N 120.965 -1.084 . . . . 0.0 108.56 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.509 HG23 ' N ' ' A' ' 73' ' ' GLY . 24.2 m . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 121.262 0.553 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.509 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -45.18 -18.71 0.16 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.65 -46.67 89.29 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.443 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 1.9 mp0 -80.71 -41.76 23.09 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.239 -1.154 . . . . 0.0 109.397 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 76' ' ' VAL . 3.6 t -59.17 -53.01 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 108.732 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.554 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 23.1 t-20 -57.76 -55.19 38.08 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.0 tp -50.16 -31.71 14.28 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.432 -0.792 . . . . 0.0 109.1 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.2 tp -64.76 -59.7 3.93 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.367 -0.833 . . . . 0.0 110.358 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.448 HG23 ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -73.01 -21.74 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 110.602 -178.386 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.554 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 1.4 mp0 -70.98 -46.5 62.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.507 -1.371 . . . . 0.0 109.341 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 2.4 pp0? . . . . . 0 N--CA 1.499 1.983 0 O-C-N 121.087 -1.008 . . . . 0.0 110.031 -179.051 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.416 ' C ' ' N ' ' A' ' 74' ' ' GLY . 28.6 m . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.81 -20.5 1.22 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.416 ' N ' ' C ' ' A' ' 72' ' ' VAL . . . -76.77 -39.0 30.04 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.54 ' N ' ' NE2' ' A' ' 75' ' ' GLN . 0.5 OUTLIER -64.41 -33.48 75.96 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.954 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.06 -48.2 33.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.577 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 7.2 t-20 -56.45 -34.7 67.11 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.9 tp -67.11 -37.24 83.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.248 -0.908 . . . . 0.0 108.789 179.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 40.7 tp -60.53 -40.04 90.05 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.154 -0.966 . . . . 0.0 109.947 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -85.53 -50.03 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 120.549 -1.344 . . . . 0.0 109.224 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.577 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -45.48 -32.0 2.0 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.631 -1.293 . . . . 0.0 110.375 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.63 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 O-C-N 120.828 -1.17 . . . . 0.0 110.045 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.551 HG23 ' N ' ' A' ' 73' ' ' GLY . 28.8 m . . . . . 0 N--CA 1.48 1.068 0 CA-C-O 121.078 0.466 . . . . 0.0 109.785 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.551 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.73 -12.8 0.45 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -81.24 -41.9 9.83 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -82.48 -41.8 19.29 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.221 -1.164 . . . . 0.0 108.851 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.4 t -62.43 -55.82 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.623 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 0.5 OUTLIER -56.36 -53.78 53.32 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.542 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 27.4 tp -47.6 -35.65 9.56 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.174 -0.954 . . . . 0.0 108.597 179.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.661 ' C ' HE22 ' A' ' 82' ' ' GLN . 0.7 OUTLIER -63.59 -38.68 92.03 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.729 -0.607 . . . . 0.0 109.769 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.535 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -76.88 -22.96 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.715 -1.24 . . . . 0.0 109.558 -179.577 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.623 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 8.0 mt-30 -74.51 -48.45 27.06 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 111.527 -178.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.834 HE21 ' H ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 O-C-N 120.304 -1.497 . . . . 0.0 109.315 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.536 HG23 ' N ' ' A' ' 73' ' ' GLY . 20.9 m . . . . . 0 N--CA 1.476 0.866 0 CA-C-O 120.893 0.378 . . . . 0.0 110.019 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.536 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.5 -27.06 0.75 Allowed Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.22 -36.66 26.8 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.481 ' O ' HD13 ' A' ' 79' ' ' LEU . 11.3 mt-30 -66.07 -23.49 66.53 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 178.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.4 t -73.67 -47.16 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.415 ' C ' HE21 ' A' ' 81' ' ' GLN . 2.3 t-20 -56.11 -49.44 73.88 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 31.8 tp -59.85 -36.33 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.511 -0.743 . . . . 0.0 110.085 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.481 HD13 ' O ' ' A' ' 75' ' ' GLN . 2.5 mp -69.05 -24.74 64.21 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.118 -0.988 . . . . 0.0 111.495 -178.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.63 -26.32 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 120.378 -1.451 . . . . 0.0 110.708 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.415 HE21 ' C ' ' A' ' 77' ' ' ASN . 4.1 pt20 -86.51 -22.02 26.62 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.372 -1.455 . . . . 0.0 109.94 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 . . . . . 0 N--CA 1.494 1.746 0 O-C-N 120.95 -1.093 . . . . 0.0 108.843 179.58 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.8 m . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.313 0.578 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 71' ' ' SER . 2.4 p 175.08 112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 55.8 mt 48.16 11.24 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.128 -0.982 . . . . 0.0 109.659 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.535 ' N ' ' O ' ' A' ' 69' ' ' VAL . 29.8 t -82.6 118.25 23.16 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.997 0.903 . . . . 0.0 109.591 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.482 ' C ' ' H ' ' A' ' 74' ' ' GLY . 26.7 m -93.85 -18.33 6.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -51.18 -10.14 0.45 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 72' ' ' VAL . . . -72.62 -49.91 16.92 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.9 mp0 -79.27 -39.23 33.51 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.18 -1.188 . . . . 0.0 109.139 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 13.9 t -62.48 -54.5 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 108.585 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -54.5 -49.18 70.77 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.58 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 40.8 tp -48.02 -50.61 27.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.092 -1.005 . . . . 0.0 108.862 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.9 tp -55.88 -31.98 63.29 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.281 -0.887 . . . . 0.0 110.973 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -74.32 -38.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.583 -1.323 . . . . 0.0 109.851 -178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -64.87 -53.44 46.59 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.176 -0.953 . . . . 0.0 110.362 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.876 ' H ' HE21 ' A' ' 82' ' ' GLN . 0.1 OUTLIER -56.31 -42.57 77.84 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.425 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -64.99 -19.6 66.08 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.757 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.427 ' O ' HG22 ' A' ' 84' ' ' ILE . 3.1 mm -89.1 -6.79 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.09 -1.006 . . . . 0.0 109.153 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -135.65 57.23 18.18 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.376 -0.827 . . . . 0.0 109.798 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -75.85 11.84 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.673 2.249 . . . . 0.0 111.497 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.0 mmmm -58.78 -31.67 68.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.458 -0.776 . . . . 0.0 109.573 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.785 HD22 ' H ' ' A' ' 89' ' ' LEU . 0.2 OUTLIER -74.57 -67.29 0.64 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.322 -179.788 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.785 ' H ' HD22 ' A' ' 88' ' ' ASN . 6.7 tp -51.75 -41.82 61.87 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.351 -0.843 . . . . 0.0 109.073 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.742 ' OG ' ' CH2' ' A' ' 99' ' ' TRP . 30.0 t -58.09 -46.22 85.86 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.285 -0.885 . . . . 0.0 109.195 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 6.0 tpp180 -53.7 -32.28 51.23 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.263 -0.898 . . . . 0.0 108.875 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 16.0 mt -82.28 10.24 7.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.808 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.575 ' O ' ' N ' ' A' ' 95' ' ' GLY . 32.2 m-85 -141.45 153.98 66.34 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.253 -0.904 . . . . 0.0 109.082 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -39.58 -15.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.708 2.272 . . . . 0.0 113.057 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -44.92 -32.9 3.36 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 120.326 -0.94 . . . . 0.0 110.757 -179.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.526 ' O ' ' N ' ' A' ' 98' ' ' ALA . 67.0 p-90 -84.22 -34.9 23.8 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.696 -1.473 . . . . 0.0 110.944 -178.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -49.51 -9.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.163 . . . . 0.0 110.284 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.526 ' N ' ' O ' ' A' ' 96' ' ' TRP . . . -112.81 -19.88 11.83 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.124 -0.985 . . . . 0.0 108.541 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.742 ' CH2' ' OG ' ' A' ' 90' ' ' SER . 23.2 m0 -83.02 -4.66 58.56 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.724 -0.61 . . . . 0.0 109.859 -178.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.424 ' O ' ' O ' ' A' ' 99' ' ' TRP . 30.9 m . . . . . 0 C--N 1.306 -1.305 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.608 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.524 HG21 HE22 ' A' ' 75' ' ' GLN . 59.5 m . . . . . 0 N--CA 1.492 1.646 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' A' ' 71' ' ' SER . 0.6 OUTLIER -171.89 -41.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.186 -0.946 . . . . 0.0 109.221 -179.75 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 14.3 mt -45.79 -12.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.579 -0.701 . . . . 0.0 110.303 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.556 ' N ' ' O ' ' A' ' 69' ' ' VAL . 2.6 t -155.01 124.39 6.37 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.027 -1.046 . . . . 0.0 109.562 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.567 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.8 m -79.49 -45.95 23.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-O 121.229 0.538 . . . . 0.0 109.569 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.567 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.47 -15.33 0.44 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -73.18 -51.94 9.47 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.568 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 2.6 mp0 -82.94 -42.28 17.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.169 -1.195 . . . . 0.0 109.528 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 32.9 t -56.61 -52.05 58.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.474 ' C ' HE21 ' A' ' 81' ' ' GLN . 8.1 t-20 -61.77 -53.35 57.21 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 42.3 tp -50.39 -31.83 15.91 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.117 -0.989 . . . . 0.0 109.143 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.7 tp -75.61 -30.13 59.44 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.273 -0.892 . . . . 0.0 110.539 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.556 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -82.56 -19.95 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 120.831 -1.168 . . . . 0.0 109.526 -179.094 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.474 HE21 ' C ' ' A' ' 77' ' ' ASN . 6.7 mt-30 -90.46 -35.52 15.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.592 -1.317 . . . . 0.0 110.34 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 4.9 tp60 -86.61 -36.7 18.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.948 -1.095 . . . . 0.0 108.782 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.48 -11.45 0.86 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.167 -0.958 . . . . 0.0 109.782 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.571 HD12 ' N ' ' A' ' 85' ' ' ASP . 1.9 pp -142.29 -126.29 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 O-C-N 121.068 -1.02 . . . . 0.0 108.675 -179.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.571 ' N ' HD12 ' A' ' 84' ' ' ILE . 74.4 m-20 -89.16 115.9 64.89 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 120.917 -1.114 . . . . 0.0 109.05 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -80.25 5.81 5.78 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.818 1.679 . . . . 0.0 112.128 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.458 ' HB3' ' HZ2' ' A' ' 87' ' ' LYS . 4.2 mtpm? -50.61 -34.32 25.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.193 -0.942 . . . . 0.0 109.336 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.806 HD22 ' H ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -65.3 -57.25 8.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.369 179.933 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.806 ' H ' HD22 ' A' ' 88' ' ' ASN . 30.5 tp -48.1 -31.5 5.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.054 -1.029 . . . . 0.0 109.119 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.4 m -87.69 -19.69 27.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 109.923 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.575 ' HE ' ' CA ' ' A' ' 91' ' ' ARG . 0.0 OUTLIER -77.83 -21.35 51.62 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.009 -1.057 . . . . 0.0 109.655 -179.415 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 16.7 mt -47.29 -16.29 0.05 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.991 -1.068 . . . . 0.0 109.23 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.497 ' N ' ' O ' ' A' ' 91' ' ' ARG . 71.3 m-85 -112.85 90.06 14.67 Favored Pre-proline 0 N--CA 1.496 1.847 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -41.02 -21.55 0.11 Allowed 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 122.033 1.822 . . . . 0.0 112.473 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 99' ' ' TRP . . . -58.91 -9.25 6.84 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.411 ' CD1' ' CE3' ' A' ' 99' ' ' TRP . 7.3 m95 -80.65 -9.54 59.78 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -1.194 . . . . 0.0 109.543 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 13.7 ptpt -66.25 -17.51 64.79 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.084 -1.01 . . . . 0.0 110.328 -179.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.67 -21.52 10.19 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 21.4 m0 -72.86 -2.21 19.81 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 119.524 -0.87 . . . . 0.0 109.368 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m . . . . . 0 C--N 1.305 -1.329 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.68 -179.978 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.7 m . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.281 0.562 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.2 m -86.5 68.04 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.265 -0.897 . . . . 0.0 109.268 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.472 ' O ' ' CB ' ' A' ' 71' ' ' SER . 23.6 mt 65.0 -32.57 0.15 Allowed 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.794 -0.567 . . . . 0.0 110.383 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.539 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.5 OUTLIER 166.2 114.91 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.125 -0.985 . . . . 0.0 109.171 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.531 HG23 ' N ' ' A' ' 73' ' ' GLY . 23.7 m -54.75 -39.61 48.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.531 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.96 -23.73 0.43 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.96 -44.84 54.42 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.659 ' NE2' ' H ' ' A' ' 75' ' ' GLN . 2.3 mp0 -62.31 -29.21 70.28 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.7 t -70.33 -44.91 77.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.524 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 9.1 t-20 -60.58 -57.76 11.36 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 33.2 tp -47.94 -28.94 2.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 108.969 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.1 tp -70.7 -40.04 73.1 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.353 -0.842 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -67.9 -38.75 80.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.944 -1.098 . . . . 0.0 109.45 -179.276 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 2.5 mp0 -68.6 -31.99 71.55 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.895 -1.128 . . . . 0.0 108.529 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -53.81 53.29 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.453 -0.779 . . . . 0.0 109.684 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -47.06 -51.34 17.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.47 -0.769 . . . . 0.0 110.375 -179.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.408 ' O ' ' OD2' ' A' ' 85' ' ' ASP . 7.5 mm -46.78 -44.49 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.405 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 88' ' ' ASN . 25.5 m-20 -151.51 102.27 2.92 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -81.58 -2.17 11.36 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.973 1.782 . . . . 0.0 112.323 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.49 -27.63 39.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.109 -0.994 . . . . 0.0 108.886 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.621 ' ND2' ' N ' ' A' ' 89' ' ' LEU . 2.0 p-10 -64.47 -50.62 66.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.214 -0.929 . . . . 0.0 109.028 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.621 ' N ' ' ND2' ' A' ' 88' ' ' ASN . 9.6 tp -57.99 -45.54 86.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.303 -0.873 . . . . 0.0 108.815 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.8 p -70.3 -26.74 63.93 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.345 -0.847 . . . . 0.0 109.417 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' A' ' 93' ' ' PHE . 2.8 tmm_? -69.97 -24.56 63.35 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.331 -0.856 . . . . 0.0 109.808 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 71.9 mt -47.0 -17.84 0.06 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.161 -0.962 . . . . 0.0 109.299 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.475 ' N ' ' O ' ' A' ' 91' ' ' ARG . 1.0 OUTLIER -106.97 100.52 32.49 Favored Pre-proline 0 N--CA 1.497 1.878 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.439 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -42.7 -27.49 0.86 Allowed 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.896 1.731 . . . . 0.0 112.25 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.82 -5.55 14.15 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 4.9 p-90 -66.86 -12.56 59.63 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.854 -1.38 . . . . 0.0 109.292 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.2 ptpt -60.36 -12.56 9.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -120.23 -21.93 6.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.615 -0.678 . . . . 0.0 109.453 -179.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 22.8 m0 -69.56 -30.61 68.44 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.367 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--N 1.304 -1.389 0 CA-C-O 117.961 -1.018 . . . . 0.0 109.511 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 69' ' ' VAL . 2.7 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.735 HG13 ' H ' ' A' ' 70' ' ' LEU . 4.8 p -172.65 -60.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.141 -0.974 . . . . 0.0 110.038 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.735 ' H ' HG13 ' A' ' 69' ' ' VAL . 45.1 mt -44.17 -38.62 3.83 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.438 -0.788 . . . . 0.0 109.555 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER 26.48 99.02 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.375 0 CA-C-O 121.981 0.896 . . . . 0.0 111.683 179.625 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.561 HG23 ' N ' ' A' ' 73' ' ' GLY . 15.5 m -63.52 -42.89 97.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 CA-C-O 121.375 0.607 . . . . 0.0 109.488 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.561 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.69 -9.82 0.1 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -79.93 -62.68 2.08 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.053 -1.263 . . . . 0.0 110.109 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.566 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 0.6 OUTLIER -74.03 -30.32 62.37 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.073 -1.251 . . . . 0.0 108.841 -179.638 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 72' ' ' VAL . 41.2 t -67.81 -51.57 48.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 14.7 t-20 -55.11 -36.34 65.61 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.133 -0.979 . . . . 0.0 108.803 178.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.5 tp -73.95 -46.93 40.97 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 120.715 -1.241 . . . . 0.0 108.88 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.492 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.9 mp -65.87 -15.71 63.17 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.567 -0.708 . . . . 0.0 109.298 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.737 HD13 HD11 ' A' ' 84' ' ' ILE . 0.4 OUTLIER -80.33 -54.51 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.819 -1.176 . . . . 0.0 108.306 -179.885 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 4.6 mt-30 -54.97 -53.82 50.79 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.066 -1.021 . . . . 0.0 110.095 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -39.59 90.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.627 ' HB3' HD13 ' A' ' 84' ' ' ILE . . . -66.23 -37.99 86.86 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.133 -0.979 . . . . 0.0 110.159 -179.322 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.737 HD11 HD13 ' A' ' 80' ' ' ILE . 0.0 OUTLIER -139.74 88.51 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.13 -0.981 . . . . 0.0 108.484 179.487 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.577 ' N ' ' CD ' ' A' ' 86' ' ' PRO . 0.6 OUTLIER -56.85 -41.69 92.58 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.421 179.689 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.577 ' CD ' ' N ' ' A' ' 85' ' ' ASP . 33.5 Cg_exo -61.4 18.32 0.04 OUTLIER 'Trans proline' 0 N--CA 1.5 1.866 0 C-N-CA 122.583 2.188 . . . . 0.0 112.456 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.523 ' H ' ' C ' ' A' ' 85' ' ' ASP . 47.9 pttt -46.85 -23.57 0.46 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.218 -0.926 . . . . 0.0 109.219 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.636 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 2.6 p-10 -74.47 -58.04 3.55 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.636 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 30.7 tp -47.41 -30.14 3.11 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.576 -0.702 . . . . 0.0 109.322 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 72.3 m -90.04 -26.37 20.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 110.183 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.478 ' O ' ' N ' ' A' ' 93' ' ' PHE . 29.7 ttm180 -85.55 -17.42 36.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.028 -1.045 . . . . 0.0 110.701 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 71.5 mt -47.42 -18.52 0.12 Allowed 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.849 -1.157 . . . . 0.0 108.679 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 95' ' ' GLY . 17.7 m-85 -122.93 86.02 50.56 Favored Pre-proline 0 N--CA 1.494 1.731 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -41.67 -17.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.213 1.942 . . . . 0.0 112.081 -179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -67.67 -5.21 36.63 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 1.5 p-90 -72.58 -10.09 59.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.897 -1.355 . . . . 0.0 109.361 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -59.83 -9.8 3.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.31 -0.869 . . . . 0.0 109.853 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -124.12 -21.68 4.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 108.906 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.576 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 7.2 m0 -77.95 -2.59 37.68 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.415 -0.803 . . . . 0.0 109.414 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.431 ' H ' HG22 ' A' ' 100' ' ' VAL . 1.8 m . . . . . 0 N--CA 1.488 1.459 0 CA-C-O 117.924 -1.036 . . . . 0.0 109.459 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.237 0.541 . . . . 0.0 109.602 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.681 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.9 m -145.06 104.85 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 14.1 mt 50.07 9.09 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.945 -1.097 . . . . 0.0 109.745 -179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 69' ' ' VAL . 26.7 t -74.08 106.43 5.75 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 122.137 0.97 . . . . 0.0 109.116 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.413 ' O ' ' N ' ' A' ' 75' ' ' GLN . 18.9 m -79.48 -27.77 12.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -24.71 3.08 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.647 -1.781 . . . . 0.0 108.647 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.551 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -72.57 -42.05 49.05 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.413 ' N ' ' O ' ' A' ' 72' ' ' VAL . 10.9 mp0 -58.64 -21.8 54.91 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 178.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.4 ' C ' ' N ' ' A' ' 78' ' ' LEU . 5.1 t -83.87 -53.64 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.593 HD22 ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -57.05 -14.66 3.98 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 179.632 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.593 ' N ' HD22 ' A' ' 77' ' ' ASN . 65.9 tp -88.0 -66.05 0.95 Allowed 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.453 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -48.97 -13.88 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 110.027 -179.806 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.2 OUTLIER -95.71 -55.0 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.931 -1.105 . . . . 0.0 110.221 -179.387 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.622 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 2.3 pp0? -55.35 -12.67 1.11 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.072 -1.642 . . . . 0.0 108.256 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.622 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -94.37 -50.71 5.11 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 178.832 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.53 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -51.42 -8.4 0.05 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.793 -0.567 . . . . 0.0 110.307 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.461 ' H ' ' C ' ' A' ' 82' ' ' GLN . 5.4 mm -42.89 -19.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.375 -0.828 . . . . 0.0 109.931 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 87' ' ' LYS . 0.4 OUTLIER -48.87 172.1 0.09 OUTLIER Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.733 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -37.45 -22.89 0.05 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.159 1.906 . . . . 0.0 112.354 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.539 ' N ' ' O ' ' A' ' 85' ' ' ASP . 63.0 mmtt -50.38 -26.82 5.38 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.419 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.9 OUTLIER -71.92 -45.45 61.12 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.117 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.419 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 23.9 tp -50.46 -37.74 39.99 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 87' ' ' LYS . 13.6 p -76.61 -26.91 55.47 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.468 -0.77 . . . . 0.0 109.069 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.439 ' O ' ' N ' ' A' ' 93' ' ' PHE . 7.5 tpt180 -62.7 -35.65 80.39 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.282 -0.886 . . . . 0.0 109.513 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 15.8 mt -46.36 -21.92 0.21 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.173 -0.955 . . . . 0.0 108.892 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.536 ' O ' ' N ' ' A' ' 95' ' ' GLY . 31.5 m-85 -115.05 88.96 18.42 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -42.53 -14.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 122.224 1.949 . . . . 0.0 112.296 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -63.99 -5.23 13.7 Favored Glycine 0 N--CA 1.487 2.059 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 1.4 p-90 -64.52 -12.16 41.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.947 -1.325 . . . . 0.0 109.034 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 49.2 mtmt -58.78 -9.69 1.93 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.497 -0.752 . . . . 0.0 110.022 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -123.34 -21.03 5.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.035 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.495 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 23.4 m0 -71.77 -9.07 57.75 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.501 -0.749 . . . . 0.0 109.557 -179.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 12.2 m . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.548 179.975 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 11.5 m . . . . . 0 N--CA 1.496 1.838 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.528 ' C ' ' H ' ' A' ' 71' ' ' SER . 16.0 m -113.3 45.23 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.54 -0.725 . . . . 0.0 109.113 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 24.5 mt 65.33 -32.49 0.15 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.777 -0.577 . . . . 0.0 110.49 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.528 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.5 p 172.92 107.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.169 -0.957 . . . . 0.0 109.192 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.2 m -57.16 -29.85 33.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 CA-C-O 121.361 0.6 . . . . 0.0 109.531 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.76 -9.37 0.06 OUTLIER Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -74.85 -63.78 2.49 Favored Glycine 0 N--CA 1.49 2.251 0 O-C-N 120.848 -1.384 . . . . 0.0 110.387 -179.263 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -75.25 -28.31 59.8 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.02 -1.282 . . . . 0.0 109.744 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 25.7 t -68.7 -57.71 8.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 108.747 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.82 HD22 HE22 ' A' ' 81' ' ' GLN . 8.7 t30 -51.98 -44.26 63.97 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.208 -0.932 . . . . 0.0 108.574 179.065 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.405 HD13 ' O ' ' A' ' 74' ' ' GLY . 4.3 mp -57.2 -30.39 64.5 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.037 -1.039 . . . . 0.0 108.516 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.534 HD13 ' O ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -73.65 -29.26 62.23 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.317 -0.864 . . . . 0.0 110.779 -178.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.712 ' O ' HD11 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -80.11 -27.15 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.626 -1.296 . . . . 0.0 110.399 -178.685 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.82 HE22 HD22 ' A' ' 77' ' ' ASN . 3.1 pt20 -95.02 -10.87 29.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 108.854 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.527 ' O ' ' N ' ' A' ' 84' ' ' ILE . 15.9 mt-30 -95.48 -65.72 0.96 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.521 ' C ' HD13 ' A' ' 84' ' ' ILE . . . -44.35 -16.06 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.584 -0.697 . . . . 0.0 111.012 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.841 ' N ' HD13 ' A' ' 84' ' ' ILE . 0.0 OUTLIER -129.37 31.74 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.235 -0.916 . . . . 0.0 109.032 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.523 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 2.7 m-20 60.96 150.97 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.992 . . . . 0.0 109.22 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.29 -25.32 13.53 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.125 1.883 . . . . 0.0 112.354 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 8.4 ptmt -48.79 -24.49 1.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.354 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.662 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -70.28 -47.81 59.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.317 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.662 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 6.6 tp -64.53 -23.58 67.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.344 -0.847 . . . . 0.0 109.13 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.9 m -79.73 -47.4 15.36 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 93' ' ' PHE . 66.5 mtt85 -75.58 -52.15 11.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.755 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 41.7 mt -46.07 -19.45 0.07 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.179 -0.951 . . . . 0.0 109.032 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.554 ' O ' ' N ' ' A' ' 95' ' ' GLY . 29.9 m-85 -111.05 95.29 24.05 Favored Pre-proline 0 N--CA 1.494 1.769 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -42.43 -12.73 0.04 OUTLIER 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.413 2.075 . . . . 0.0 112.621 -179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -56.69 -18.83 25.76 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 121.236 -0.915 . . . . 0.0 111.105 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 8.0 p-90 -65.54 -20.28 66.27 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.493 -1.592 . . . . 0.0 110.075 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -63.75 -11.52 27.15 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.144 -0.972 . . . . 0.0 109.76 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.27 -21.21 9.43 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.516 ' CD1' ' O ' ' A' ' 95' ' ' GLY . 25.0 m0 -70.64 -15.54 62.74 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.44 -178.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.505 179.914 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.7 m . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.515 ' O ' ' N ' ' A' ' 71' ' ' SER . 7.4 p -172.45 121.46 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.411 -0.805 . . . . 0.0 109.246 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.488 ' O ' HG13 ' A' ' 72' ' ' VAL . 81.8 mt 49.69 10.02 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.113 -0.992 . . . . 0.0 109.944 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 69' ' ' VAL . 53.9 p -43.83 113.5 0.52 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.63 HG23 ' N ' ' A' ' 73' ' ' GLY . 16.9 m -95.38 -50.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.9 -178.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.63 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.15 -13.41 0.36 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -80.9 -62.07 2.06 Favored Glycine 0 N--CA 1.492 2.392 0 O-C-N 121.213 -1.169 . . . . 0.0 110.666 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.541 ' H ' ' NE2' ' A' ' 75' ' ' GLN . 3.4 mp0 -73.78 -32.12 63.62 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.882 -1.364 . . . . 0.0 108.8 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.462 ' O ' HG22 ' A' ' 80' ' ' ILE . 39.9 t -66.57 -59.72 3.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -50.46 -30.82 13.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.105 -0.997 . . . . 0.0 109.305 179.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 61.1 tp -78.61 -29.81 46.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.077 -1.014 . . . . 0.0 109.654 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.521 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -72.7 -35.34 67.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.061 -1.024 . . . . 0.0 109.685 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.24 -42.43 23.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.719 -1.238 . . . . 0.0 109.464 -179.476 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.481 ' NE2' HG23 ' A' ' 80' ' ' ILE . 2.1 mp0 -66.07 -29.59 69.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.952 -1.093 . . . . 0.0 110.394 -179.315 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.432 HE21 ' HB2' ' A' ' 83' ' ' ALA . 3.4 pp0? -89.89 -26.97 20.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.632 -1.293 . . . . 0.0 109.013 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.436 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -77.05 -8.61 57.74 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.488 -0.757 . . . . 0.0 110.282 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.436 ' C ' ' O ' ' A' ' 83' ' ' ALA . 6.0 mm -38.28 -57.84 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.428 ' OD2' ' N ' ' A' ' 85' ' ' ASP . 9.0 p30 -171.68 129.07 0.66 Allowed Pre-proline 0 C--N 1.299 -1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.03 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -77.35 7.37 3.79 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.828 1.685 . . . . 0.0 112.17 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 39.4 pttt -50.26 -34.96 25.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.165 -0.959 . . . . 0.0 109.289 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.405 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 2.4 p30 -74.72 -45.84 41.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.26 -0.9 . . . . 0.0 108.993 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.405 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 32.0 tp -59.93 -42.0 93.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.571 -0.706 . . . . 0.0 109.668 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 6.0 m -75.53 -21.75 57.67 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.254 -0.904 . . . . 0.0 110.266 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.513 ' O ' ' N ' ' A' ' 93' ' ' PHE . 57.2 ttm-85 -76.27 -28.71 57.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.032 -1.042 . . . . 0.0 109.71 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 18.3 mt -46.87 -16.77 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.016 -1.052 . . . . 0.0 108.962 179.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.552 ' O ' ' N ' ' A' ' 95' ' ' GLY . 21.8 m-85 -124.37 84.75 56.19 Favored Pre-proline 0 N--CA 1.492 1.634 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -39.82 -17.08 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.645 2.23 . . . . 0.0 112.586 -178.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.552 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -62.62 -5.82 9.87 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 47.6 p-90 -68.1 -10.78 56.63 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.588 -1.536 . . . . 0.0 109.44 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -61.83 -12.68 18.61 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.461 -0.774 . . . . 0.0 110.174 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -121.85 -21.07 6.18 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.542 -0.723 . . . . 0.0 109.276 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.519 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.7 m0 -71.32 -14.46 62.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.364 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.434 ' OXT' ' O ' ' A' ' 99' ' ' TRP . 3.5 m . . . . . 0 C--N 1.305 -1.362 0 CA-C-O 118.078 -0.963 . . . . 0.0 109.602 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.416 HG22 ' N ' ' A' ' 69' ' ' VAL . 98.9 m . . . . . 0 N--CA 1.497 1.911 0 CA-C-O 121.274 0.559 . . . . 0.0 110.49 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.593 ' C ' ' H ' ' A' ' 71' ' ' SER . 32.8 m -76.5 120.79 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 121.3 -0.875 . . . . 0.0 109.143 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.445 ' O ' ' O ' ' A' ' 71' ' ' SER . 21.3 mt 60.7 -13.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.385 -0.822 . . . . 0.0 110.141 -179.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.593 ' H ' ' C ' ' A' ' 69' ' ' VAL . 29.8 t 47.3 98.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.158 -0.964 . . . . 0.0 110.162 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.6 m -45.26 -25.68 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 CA-C-O 121.385 0.612 . . . . 0.0 109.772 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -46.56 -14.57 0.11 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.86 -53.09 12.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -74.25 -32.45 62.96 Favored 'General case' 0 N--CA 1.485 1.289 0 O-C-N 120.985 -1.303 . . . . 0.0 109.228 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -70.8 -60.0 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.185 -0.947 . . . . 0.0 108.773 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.518 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 29.7 t-20 -55.48 -24.82 33.34 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.095 -1.003 . . . . 0.0 108.973 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.9 tp -81.65 -41.8 20.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.843 -1.161 . . . . 0.0 109.047 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 5.3 tp -58.9 -35.89 73.79 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.357 -0.84 . . . . 0.0 110.432 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.564 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -79.21 -49.12 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.853 -1.154 . . . . 0.0 108.891 -179.523 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' A' ' 77' ' ' ASN . 0.1 OUTLIER -58.57 -12.06 3.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.756 -1.215 . . . . 0.0 108.841 178.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -88.85 -55.39 3.72 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.173 -0.954 . . . . 0.0 109.686 -178.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.467 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -48.78 -71.76 0.06 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.82 -1.175 . . . . 0.0 109.867 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.467 ' C ' ' O ' ' A' ' 83' ' ' ALA . 9.7 mm 28.03 69.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 CA-C-O 121.224 0.535 . . . . 0.0 112.095 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.425 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 0.2 OUTLIER 177.66 -53.08 0.0 OUTLIER Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.878 . . . . 0.0 109.46 179.504 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 88' ' ' ASN . 89.5 Cg_endo -82.81 -51.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.035 1.823 . . . . 0.0 111.966 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 10.7 pttm -48.59 -16.74 0.12 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.24 -0.913 . . . . 0.0 109.11 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.7 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -73.63 -61.2 1.92 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.7 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 3.3 tt -54.8 -22.97 16.02 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.109 -0.994 . . . . 0.0 108.742 179.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.447 ' O ' ' N ' ' A' ' 95' ' ' GLY . 8.5 t -87.26 -34.49 18.91 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.309 -0.869 . . . . 0.0 110.271 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -72.82 -20.42 61.14 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.057 -1.027 . . . . 0.0 110.002 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.494 ' O ' ' CD1' ' A' ' 93' ' ' PHE . 82.0 mt -76.61 -2.03 30.57 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.917 -1.114 . . . . 0.0 110.863 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' A' ' 92' ' ' LEU . 11.1 m-85 -159.95 -72.93 0.01 OUTLIER Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 120.542 -1.349 . . . . 0.0 111.485 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 96' ' ' TRP . 73.5 Cg_endo -69.6 -53.26 0.29 Allowed 'Trans proline' 0 N--CA 1.5 1.86 0 C-N-CA 121.53 1.487 . . . . 0.0 112.751 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 90' ' ' SER . . . -46.63 -11.69 0.05 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.612 ' NE1' ' CH2' ' A' ' 99' ' ' TRP . 26.3 m0 -50.02 -19.56 0.75 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.584 ' HZ2' ' HA ' ' A' ' 97' ' ' LYS . 3.4 mmpm? -58.6 -8.4 1.25 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.91 -17.29 19.33 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 120.877 -1.139 . . . . 0.0 108.331 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.612 ' CH2' ' NE1' ' A' ' 96' ' ' TRP . 31.2 m0 -73.43 -25.64 60.6 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.117 -178.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 C--N 1.304 -1.393 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.645 -179.92 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.521 HG22 ' H ' ' A' ' 69' ' ' VAL . 1.7 m . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.521 ' H ' HG22 ' A' ' 68' ' ' THR . 34.5 m -83.66 53.34 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.488 -0.757 . . . . 0.0 109.505 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 22.0 mt 60.17 6.07 0.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.521 -0.737 . . . . 0.0 109.076 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.413 ' H ' ' C ' ' A' ' 69' ' ' VAL . 16.0 m -173.49 115.83 0.25 Allowed 'General case' 0 N--CA 1.487 1.396 0 CA-C-O 121.964 0.888 . . . . 0.0 109.212 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' GLY . 30.5 m -71.16 -28.02 31.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 CA-C-O 121.311 0.577 . . . . 0.0 109.638 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.438 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -44.92 -17.97 0.11 Allowed Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.94 -54.87 25.35 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.671 ' H ' ' NE2' ' A' ' 75' ' ' GLN . 2.1 mp0 -74.69 -36.01 62.76 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.185 -1.185 . . . . 0.0 109.624 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.403 ' O ' HG22 ' A' ' 80' ' ' ILE . 7.4 t -65.84 -58.91 4.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.027 -1.046 . . . . 0.0 109.053 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.486 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -54.24 -31.02 52.36 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 108.74 179.726 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.3 tp -73.23 -37.79 66.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.183 -0.948 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.516 HD13 ' O ' ' A' ' 75' ' ' GLN . 4.6 mp -61.64 -40.81 96.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.197 -0.939 . . . . 0.0 109.425 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.754 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -81.92 -46.71 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.777 -1.202 . . . . 0.0 109.957 -179.279 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.698 ' N ' HE21 ' A' ' 81' ' ' GLN . 0.0 OUTLIER -53.45 -39.88 64.78 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 120.641 -1.287 . . . . 0.0 109.981 -179.372 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.493 ' C ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -80.87 -31.7 35.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.859 -1.15 . . . . 0.0 110.143 -179.128 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -65.62 -9.97 31.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.125 -0.984 . . . . 0.0 111.112 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.605 ' C ' HD12 ' A' ' 84' ' ' ILE . 2.7 pp -112.43 17.9 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.365 0 O-C-N 121.035 -1.041 . . . . 0.0 110.767 -179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.439 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 10.7 p30 -158.67 150.08 16.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 120.905 -1.122 . . . . 0.0 109.501 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -72.35 24.33 0.27 Allowed 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 122.166 1.911 . . . . 0.0 111.636 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.415 ' H ' ' C ' ' A' ' 85' ' ' ASP . 21.4 mmtm -50.65 -36.78 37.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.21 -0.931 . . . . 0.0 109.11 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.726 HD22 ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -59.7 -26.3 65.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.403 -0.811 . . . . 0.0 109.137 179.555 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.726 ' H ' HD22 ' A' ' 88' ' ' ASN . 7.5 tt -81.53 -57.77 3.32 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.377 -0.827 . . . . 0.0 109.019 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 7.8 p -53.92 -23.02 11.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.249 -0.907 . . . . 0.0 109.091 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.528 ' O ' ' CD1' ' A' ' 96' ' ' TRP . 12.6 mtp180 -76.15 -63.37 1.33 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.437 -0.789 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 44.1 mt -51.27 -25.12 5.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -0.947 . . . . 0.0 109.499 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.547 ' O ' ' N ' ' A' ' 95' ' ' GLY . 2.1 m-85 -57.25 158.21 10.66 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.118 -0.989 . . . . 0.0 108.818 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_exo -40.44 -14.07 0.03 OUTLIER 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 122.804 2.336 . . . . 0.0 113.245 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -48.13 -44.62 26.54 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.611 ' NE1' ' CZ3' ' A' ' 99' ' ' TRP . 13.6 m0 -58.19 -22.52 52.06 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.121 -1.223 . . . . 0.0 110.071 -179.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.7 mmpt? -59.34 -9.38 2.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.153 -0.967 . . . . 0.0 110.412 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.22 -20.57 12.27 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.611 ' CZ3' ' NE1' ' A' ' 96' ' ' TRP . 23.7 m0 -76.88 -16.95 59.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.346 -179.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 1.1 t . . . . . 0 C--N 1.306 -1.299 0 CA-C-O 117.929 -1.034 . . . . 0.0 108.869 -179.857 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.631 HG23 ' H ' ' A' ' 71' ' ' SER . 34.5 m -129.2 2.09 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.329 -0.857 . . . . 0.0 109.197 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.443 ' O ' ' O ' ' A' ' 71' ' ' SER . 17.1 mt 58.93 -6.9 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.43 -0.794 . . . . 0.0 110.468 179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.631 ' H ' HG23 ' A' ' 69' ' ' VAL . 8.6 t 55.83 110.25 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 122.202 1.001 . . . . 0.0 109.98 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 74' ' ' GLY . 20.4 m -95.67 -26.18 4.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 CA-C-O 121.356 0.598 . . . . 0.0 109.631 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.63 -22.57 0.73 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -61.04 -46.93 93.57 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.4 ' O ' HD13 ' A' ' 79' ' ' LEU . 3.6 mp0 -81.69 -46.55 14.14 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.142 -1.211 . . . . 0.0 109.488 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.449 HG23 ' H ' ' A' ' 76' ' ' VAL . 4.8 t -57.04 -51.33 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.206 -0.934 . . . . 0.0 108.683 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.592 ' C ' HE21 ' A' ' 81' ' ' GLN . 6.6 t-20 -58.46 -50.17 74.68 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 27.2 tp -47.9 -36.37 12.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.985 -1.072 . . . . 0.0 109.305 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 75' ' ' GLN . 7.2 mp -70.88 -33.94 71.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.184 -0.947 . . . . 0.0 109.926 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -75.8 -31.95 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 120.572 -1.33 . . . . 0.0 109.06 -179.541 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.592 HE21 ' C ' ' A' ' 77' ' ' ASN . 6.0 mt-30 -74.93 -22.15 58.76 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.177 -0.952 . . . . 0.0 109.317 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.433 ' O ' HD12 ' A' ' 84' ' ' ILE . 20.7 mt-30 -79.82 -56.77 4.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.302 -0.874 . . . . 0.0 109.572 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.584 ' C ' ' H ' ' A' ' 85' ' ' ASP . . . -78.28 -40.81 35.85 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.279 -0.888 . . . . 0.0 110.034 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.433 HD12 ' O ' ' A' ' 82' ' ' GLN . 1.3 mp 57.45 -16.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.386 -0.821 . . . . 0.0 111.564 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.584 ' H ' ' C ' ' A' ' 83' ' ' ALA . 2.1 p30 -83.51 129.89 58.3 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 120.318 -1.489 . . . . 0.0 109.328 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -79.05 -2.35 12.33 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.941 1.76 . . . . 0.0 111.951 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.473 ' NZ ' ' CG ' ' A' ' 85' ' ' ASP . 23.4 pttm -69.32 -21.09 63.87 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.306 -0.871 . . . . 0.0 108.935 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.63 ' ND2' ' N ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -90.43 -62.84 1.37 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.833 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.63 ' N ' ' ND2' ' A' ' 88' ' ' ASN . 34.3 tp -48.48 -25.17 1.54 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.107 -0.995 . . . . 0.0 109.442 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.458 ' OG ' ' CB ' ' A' ' 96' ' ' TRP . 5.2 t -94.28 -46.24 7.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 110.278 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 93' ' ' PHE . 55.5 ttt180 -56.27 -38.76 71.62 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.147 -0.97 . . . . 0.0 109.912 -179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.8 mt -49.62 -11.44 0.05 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.957 -1.089 . . . . 0.0 109.444 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.558 ' O ' ' N ' ' A' ' 95' ' ' GLY . 64.2 m-85 -146.02 119.0 5.16 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.279 -0.888 . . . . 0.0 108.847 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.16 -11.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.103 1.869 . . . . 0.0 112.782 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -61.72 -3.25 4.21 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 120.272 -0.966 . . . . 0.0 110.885 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.458 ' CB ' ' OG ' ' A' ' 90' ' ' SER . 2.3 p-90 -69.2 -10.11 56.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.642 -1.505 . . . . 0.0 109.188 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 7.9 ptpt -61.39 -9.98 6.5 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.592 -0.693 . . . . 0.0 110.768 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.89 -19.96 13.58 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.774 0.797 . . . . 0.0 109.007 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.438 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 20.3 m95 -77.27 6.36 6.87 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.743 -0.598 . . . . 0.0 109.898 -178.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.579 -179.995 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.57 ' O ' ' N ' ' A' ' 71' ' ' SER . 0.2 OUTLIER -167.16 -31.38 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.069 -1.02 . . . . 0.0 108.505 -179.587 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 69' ' ' VAL . 9.7 mt -30.93 -31.51 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.253 0 CA-C-O 121.057 0.456 . . . . 0.0 111.372 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.57 ' N ' ' O ' ' A' ' 69' ' ' VAL . 51.7 m -163.56 126.77 2.67 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.033 -1.042 . . . . 0.0 110.207 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.59 HG23 ' N ' ' A' ' 73' ' ' GLY . 34.7 m -95.29 -51.21 11.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.705 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.59 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.35 -10.06 0.17 Allowed Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -75.59 -55.7 4.91 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.948 -1.261 . . . . 0.0 109.948 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.624 ' O ' HD23 ' A' ' 79' ' ' LEU . 68.6 mm-40 -74.99 -26.33 59.48 Favored 'General case' 0 N--CA 1.485 1.322 0 O-C-N 121.202 -1.175 . . . . 0.0 109.702 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.0 t -73.03 -62.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -0.906 . . . . 0.0 108.946 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.497 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 0.1 OUTLIER -51.59 -36.76 46.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.028 -1.045 . . . . 0.0 108.476 179.405 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.443 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 11.1 tp -66.7 -43.0 85.51 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.624 HD23 ' O ' ' A' ' 75' ' ' GLN . 0.9 OUTLIER -56.74 -53.91 52.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.305 -0.872 . . . . 0.0 110.057 -179.383 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.706 ' O ' HD12 ' A' ' 80' ' ' ILE . 0.1 OUTLIER -68.11 -38.52 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.887 -1.133 . . . . 0.0 110.134 -178.666 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.634 ' N ' HE21 ' A' ' 81' ' ' GLN . 0.0 OUTLIER -66.14 -41.22 90.73 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.497 -1.377 . . . . 0.0 109.883 -179.766 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.508 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -83.37 -32.58 26.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.717 -1.239 . . . . 0.0 110.102 -179.116 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -74.32 -63.27 1.27 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.117 -0.989 . . . . 0.0 111.221 -178.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 3.9 mt 43.72 55.86 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 O-C-N 121.093 -1.004 . . . . 0.0 110.079 -178.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.752 ' H ' ' CD ' ' A' ' 86' ' ' PRO . 2.0 t70 -157.11 -39.08 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.263 -0.898 . . . . 0.0 110.826 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.752 ' CD ' ' H ' ' A' ' 85' ' ' ASP . 59.8 Cg_endo -93.83 36.1 0.19 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.422 2.081 . . . . 0.0 111.531 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -54.3 -27.22 33.95 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.374 -0.829 . . . . 0.0 108.839 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.638 ' ND2' ' N ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -77.09 -68.95 0.56 Allowed 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.638 ' N ' ' ND2' ' A' ' 88' ' ' ASN . 3.9 tt -49.73 -26.21 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.355 -0.841 . . . . 0.0 109.405 -179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.442 ' OG ' ' CZ2' ' A' ' 96' ' ' TRP . 60.5 p -77.26 -51.39 10.99 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.226 -0.921 . . . . 0.0 109.759 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 63.3 mtm180 -50.13 -29.73 9.71 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.958 -1.089 . . . . 0.0 109.289 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.1 mt -58.29 -32.76 68.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.079 -1.013 . . . . 0.0 109.118 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -67.36 153.3 95.06 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.172 -0.955 . . . . 0.0 108.478 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -75.16 -14.48 20.79 Favored 'Trans proline' 0 N--CA 1.493 1.477 0 C-N-CA 122.207 1.938 . . . . 0.0 112.868 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.07 -11.43 66.94 Favored Glycine 0 N--CA 1.497 2.73 0 C-N-CA 119.97 -1.11 . . . . 0.0 110.414 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.442 ' CZ2' ' OG ' ' A' ' 90' ' ' SER . 26.9 m95 -89.44 -7.14 55.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.177 -1.19 . . . . 0.0 110.088 -179.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.28 -23.24 2.17 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.164 -0.96 . . . . 0.0 111.244 -178.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.63 -20.06 10.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.939 . . . . 0.0 109.408 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.503 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 23.0 m0 -73.61 -12.41 60.74 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.836 -178.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 5.2 m . . . . . 0 C--N 1.304 -1.372 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.366 179.998 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.3 m . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 121.344 0.592 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 71' ' ' SER . 2.2 p -175.1 -49.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.88 . . . . 0.0 109.152 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.486 ' O ' ' CB ' ' A' ' 71' ' ' SER . 53.7 mt -48.19 -10.16 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.534 -0.728 . . . . 0.0 109.828 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 69' ' ' VAL . 1.4 p 76.89 126.75 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.22 -0.925 . . . . 0.0 109.161 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.559 ' O ' ' N ' ' A' ' 74' ' ' GLY . 33.7 m -60.22 -25.48 33.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.17 -179.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -42.85 -17.63 0.04 OUTLIER Glycine 0 N--CA 1.498 2.83 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -77.72 -52.54 5.4 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -72.78 -36.56 67.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.135 -1.215 . . . . 0.0 108.839 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.3 t -65.52 -53.45 39.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.615 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.3 t-20 -51.93 -31.24 27.81 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.425 HD13 ' O ' ' A' ' 74' ' ' GLY . 3.0 mp -72.24 -47.69 48.39 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.117 . . . . 0.0 108.294 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -49.65 -48.24 49.41 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.576 -0.703 . . . . 0.0 110.286 -179.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.477 ' O ' ' N ' ' A' ' 84' ' ' ILE . 0.0 OUTLIER -72.57 -43.83 61.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 120.763 -1.21 . . . . 0.0 109.802 -178.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.615 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 0.0 OUTLIER -47.43 -25.26 1.0 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.824 -1.173 . . . . 0.0 108.587 179.303 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 -95.58 -33.34 12.42 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.73 -0.606 . . . . 0.0 109.454 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.568 ' O ' ' N ' ' A' ' 85' ' ' ASP . . . -91.3 -8.57 47.84 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.421 -0.8 . . . . 0.0 111.047 -178.181 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.542 ' C ' ' O ' ' A' ' 83' ' ' ALA . 0.4 OUTLIER 2.88 -69.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.428 0 C-N-CA 123.632 0.773 . . . . 0.0 111.994 -179.568 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.568 ' N ' ' O ' ' A' ' 83' ' ' ALA . 30.5 t70 37.55 62.04 3.79 Favored Pre-proline 0 N--CA 1.498 1.933 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.113 179.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -82.56 -8.37 11.47 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.775 2.316 . . . . 0.0 112.068 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.4 ptmt -58.75 -22.61 58.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 110.145 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 85' ' ' ASP . 3.0 p30 -75.59 -53.62 8.31 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.111 -0.993 . . . . 0.0 109.89 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.482 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 59.8 tp -71.87 -21.82 61.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.558 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 16.2 m -83.56 -47.21 11.55 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.234 -0.916 . . . . 0.0 110.621 -179.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.458 ' C ' ' H ' ' A' ' 93' ' ' PHE . 0.1 OUTLIER -66.58 -37.41 84.87 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.903 -1.123 . . . . 0.0 110.256 -179.029 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 45.0 mt -68.85 8.2 0.56 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.896 -1.127 . . . . 0.0 109.641 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.524 ' O ' ' N ' ' A' ' 95' ' ' GLY . 59.1 m-85 -150.23 151.39 31.5 Favored Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.149 -0.969 . . . . 0.0 109.858 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -37.76 -22.13 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.739 2.293 . . . . 0.0 112.76 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.526 ' O ' ' NE1' ' A' ' 99' ' ' TRP . . . -39.14 -42.21 1.6 Allowed Glycine 0 N--CA 1.491 2.342 0 O-C-N 121.807 -0.558 . . . . 0.0 112.26 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.679 ' HE1' ' CE ' ' A' ' 97' ' ' LYS . 0.6 OUTLIER -91.8 -29.12 16.93 Favored 'General case' 0 N--CA 1.504 2.25 0 O-C-N 120.667 -1.49 . . . . 0.0 111.896 -177.903 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.679 ' CE ' ' HE1' ' A' ' 96' ' ' TRP . 24.7 mmtp -50.63 -9.0 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.526 -1.359 . . . . 0.0 109.808 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.51 ' N ' ' O ' ' A' ' 96' ' ' TRP . . . -106.01 -19.8 13.62 Favored 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.119 -0.988 . . . . 0.0 108.838 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.526 ' NE1' ' O ' ' A' ' 95' ' ' GLY . 26.2 m0 -74.62 -26.05 59.64 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.814 -0.754 . . . . 0.0 109.55 -178.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 C--N 1.305 -1.344 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.564 179.87 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.1 m . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.765 0.793 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.738 HG23 ' H ' ' A' ' 71' ' ' SER . 10.3 m -147.25 169.11 4.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 71' ' ' SER . 20.1 mt -57.42 10.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.287 -0.883 . . . . 0.0 110.645 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.738 ' H ' HG23 ' A' ' 69' ' ' VAL . 0.7 OUTLIER 76.56 107.83 0.08 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 122.125 0.964 . . . . 0.0 109.691 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.588 HG23 ' N ' ' A' ' 73' ' ' GLY . 22.6 m -95.45 -46.66 13.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.872 -179.548 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.588 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -48.22 -11.67 0.14 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.939 -1.264 . . . . 0.0 109.939 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 77' ' ' ASN . . . -84.45 -64.51 1.57 Allowed Glycine 0 N--CA 1.493 2.447 0 O-C-N 121.197 -1.178 . . . . 0.0 110.208 -179.561 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -70.61 -9.77 57.72 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.004 -1.292 . . . . 0.0 109.242 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 72' ' ' VAL . 56.5 t -93.24 -64.15 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.262 -0.899 . . . . 0.0 109.049 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.68 HD22 ' N ' ' A' ' 78' ' ' LEU . 0.1 OUTLIER -52.19 -20.4 2.57 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.966 -1.084 . . . . 0.0 108.084 178.945 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.68 ' N ' HD22 ' A' ' 77' ' ' ASN . 24.5 tp -84.97 -68.44 0.72 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.6 tp -47.0 -11.9 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.098 -1.001 . . . . 0.0 110.74 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -95.11 -55.34 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.795 -1.191 . . . . 0.0 109.53 -179.821 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.492 ' N ' ' CG2' ' A' ' 80' ' ' ILE . 3.2 pp0? -56.69 -21.96 31.48 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.411 -1.431 . . . . 0.0 110.069 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.617 ' NE2' ' N ' ' A' ' 83' ' ' ALA . 0.0 OUTLIER -93.49 -49.8 5.74 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 120.814 -1.179 . . . . 0.0 109.208 178.927 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.617 ' N ' ' NE2' ' A' ' 82' ' ' GLN . . . -66.04 -66.12 0.59 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.221 -0.924 . . . . 0.0 110.134 -179.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.489 ' O ' ' CB ' ' A' ' 85' ' ' ASP . 3.4 mt 65.87 -44.24 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 O-C-N 121.79 -0.569 . . . . 0.0 109.993 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' A' ' 87' ' ' LYS . 0.0 OUTLIER 164.69 -60.14 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.554 -0.716 . . . . 0.0 109.349 178.713 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.404 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 92.2 Cg_exo -33.39 -26.12 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.521 2.147 . . . . 0.0 113.548 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.551 ' N ' ' O ' ' A' ' 85' ' ' ASP . 26.4 pttt -46.43 -23.09 0.32 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.016 -1.053 . . . . 0.0 109.771 -179.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.875 HD22 ' H ' ' A' ' 89' ' ' LEU . 0.2 OUTLIER -88.87 -70.73 0.63 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.315 -0.866 . . . . 0.0 109.847 -179.708 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.875 ' H ' HD22 ' A' ' 88' ' ' ASN . 7.3 tp -47.61 -15.9 0.06 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.927 -1.108 . . . . 0.0 109.57 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 95' ' ' GLY . 12.3 m -95.27 -67.85 0.83 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.438 -0.789 . . . . 0.0 110.672 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 43.2 ttt180 -56.89 -26.12 58.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.212 -0.93 . . . . 0.0 111.214 -178.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.55 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 66.6 mt -56.42 -36.43 68.96 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.824 -1.172 . . . . 0.0 110.348 -179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 4.5 m-85 -163.26 -66.96 0.01 OUTLIER Pre-proline 0 N--CA 1.497 1.923 0 C-N-CA 118.533 -1.267 . . . . 0.0 111.493 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.439 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 27.5 Cg_endo -60.21 -34.38 94.1 Favored 'Trans proline' 0 N--CA 1.499 1.823 0 C-N-CA 122.202 1.934 . . . . 0.0 112.743 -178.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . . . -47.08 -24.83 2.26 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 16.6 m95 -56.11 -9.63 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.203 -1.175 . . . . 0.0 109.657 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -64.35 -10.39 24.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.345 -0.847 . . . . 0.0 110.626 -179.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.78 -19.2 16.1 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.438 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.3 m95 -76.99 7.69 4.61 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.2 0.524 . . . . 0.0 109.898 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.405 ' H ' HG22 ' A' ' 100' ' ' VAL . 4.3 m . . . . . 0 C--N 1.304 -1.394 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.357 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 53.6 m . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.376 0.607 . . . . 0.0 109.892 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.535 HG23 ' N ' ' A' ' 70' ' ' LEU . 14.3 m -146.66 -47.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.535 ' N ' HG23 ' A' ' 69' ' ' VAL . 7.4 mt -71.08 5.1 2.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -0.981 . . . . 0.0 108.645 178.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.409 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.2 m 65.89 109.32 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.937 0.875 . . . . 0.0 108.819 -179.145 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.632 HG23 ' N ' ' A' ' 73' ' ' GLY . 33.1 m -60.87 -56.68 16.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.477 -178.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.632 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -53.6 -15.52 4.48 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -72.74 -59.25 4.48 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.503 ' O ' HD23 ' A' ' 79' ' ' LEU . 1.7 mp0 -80.64 -41.82 23.2 Favored 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.098 -1.236 . . . . 0.0 109.085 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 72' ' ' VAL . 46.7 t -53.85 -47.53 63.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 108.659 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.631 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 2.8 t30 -62.9 -57.84 9.41 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.237 -0.915 . . . . 0.0 108.709 179.027 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.5 tp -51.51 -30.78 21.51 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.056 -1.027 . . . . 0.0 109.958 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.503 HD23 ' O ' ' A' ' 75' ' ' GLN . 3.4 mm? -76.37 -30.23 57.47 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.995 -1.065 . . . . 0.0 110.289 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.701 ' O ' HD11 ' A' ' 84' ' ' ILE . 0.3 OUTLIER -77.85 -28.31 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.357 -1.464 . . . . 0.0 110.069 -178.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.631 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -85.97 -36.9 19.54 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.153 -1.592 . . . . 0.0 110.381 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.497 ' C ' ' NE2' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -90.95 -40.44 11.69 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.68 -1.262 . . . . 0.0 111.738 -178.044 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.495 ' O ' ' C ' ' A' ' 84' ' ' ILE . . . -53.72 -71.37 0.07 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.279 -178.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.701 HD11 ' O ' ' A' ' 80' ' ' ILE . 34.1 mm 25.94 65.94 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 122.14 -0.35 . . . . 0.0 111.633 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.531 ' O ' ' O ' ' A' ' 84' ' ' ILE . 3.9 p-10 39.3 103.68 0.02 OUTLIER Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.84 -0.537 . . . . 0.0 111.155 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_endo -77.14 27.78 0.44 Allowed 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.568 1.512 . . . . 0.0 111.902 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -51.83 -36.85 49.54 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.279 -0.888 . . . . 0.0 108.88 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.456 ' CG ' ' N ' ' A' ' 89' ' ' LEU . 1.3 p30 -57.13 -48.61 78.24 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.386 -0.821 . . . . 0.0 108.852 179.481 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.456 ' N ' ' CG ' ' A' ' 88' ' ' ASN . 62.5 tp -56.88 -47.14 81.16 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.52 -0.737 . . . . 0.0 109.109 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 35.5 t -73.53 -14.37 61.2 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.309 -0.87 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.571 ' NH2' ' NE1' ' A' ' 96' ' ' TRP . 18.0 tpt85 -71.03 -49.61 43.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.184 -0.947 . . . . 0.0 109.508 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 31.3 mt -50.77 -11.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.444 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.572 ' O ' ' N ' ' A' ' 95' ' ' GLY . 64.8 m-85 -119.09 111.82 36.72 Favored Pre-proline 0 N--CA 1.498 1.958 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_exo -42.77 -11.41 0.03 OUTLIER 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 122.123 1.882 . . . . 0.0 112.617 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -43.22 -33.99 2.11 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.571 ' NE1' ' NH2' ' A' ' 91' ' ' ARG . 69.2 p-90 -52.64 -9.14 0.11 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.884 -1.362 . . . . 0.0 110.499 -178.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.435 ' H ' ' C ' ' A' ' 95' ' ' GLY . 25.7 pttt -58.3 -15.93 12.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.056 -1.027 . . . . 0.0 110.581 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.18 -18.81 14.01 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 108.814 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.441 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 13.6 m95 -75.56 -3.95 37.13 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.222 0.534 . . . . 0.0 109.908 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.2 m . . . . . 0 C--N 1.305 -1.359 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.621 -179.996 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 63.1 m . . . . . 0 N--CA 1.494 1.751 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' C ' ' H ' ' A' ' 71' ' ' SER . 5.3 m -146.52 -19.14 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.3 -0.875 . . . . 0.0 109.077 179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' A' ' 71' ' ' SER . 22.7 mt -61.71 1.39 0.25 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.351 -0.843 . . . . 0.0 108.996 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.523 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.3 t 74.08 114.13 0.06 Allowed 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 122.025 0.916 . . . . 0.0 109.49 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.9 m -70.46 -25.29 26.65 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 77' ' ' ASN . . . -43.91 -21.13 0.19 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -65.31 -47.12 83.18 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.488 ' O ' HD13 ' A' ' 79' ' ' LEU . 1.4 mp0 -79.9 -38.0 33.48 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.324 -1.103 . . . . 0.0 109.654 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.76 -57.64 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.234 -0.916 . . . . 0.0 108.994 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.796 HD22 HE22 ' A' ' 81' ' ' GLN . 0.2 OUTLIER -56.54 -51.79 67.24 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.014 -1.054 . . . . 0.0 108.435 179.712 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.618 ' N ' ' ND2' ' A' ' 77' ' ' ASN . 28.0 tp -47.31 -35.89 8.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.062 179.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.488 HD13 ' O ' ' A' ' 75' ' ' GLN . 3.6 mp -71.46 -26.65 62.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.461 -0.774 . . . . 0.0 109.31 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.51 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -69.77 -34.17 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.896 -1.127 . . . . 0.0 109.651 -179.389 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.796 HE22 HD22 ' A' ' 77' ' ' ASN . 0.0 OUTLIER -87.67 -19.93 27.0 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 120.878 -1.139 . . . . 0.0 110.09 -179.8 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -93.4 -34.45 13.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.082 -1.011 . . . . 0.0 108.738 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -61.71 -21.29 64.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.25 -0.906 . . . . 0.0 110.051 -179.464 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.622 ' C ' HD12 ' A' ' 84' ' ' ILE . 2.3 pp -89.4 -1.39 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.154 -0.966 . . . . 0.0 109.951 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.598 ' N ' HD12 ' A' ' 84' ' ' ILE . 7.6 t0 -98.98 126.76 37.18 Favored Pre-proline 0 N--CA 1.497 1.89 0 O-C-N 121.213 -0.93 . . . . 0.0 108.784 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -38.11 -39.73 1.0 Allowed 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 122.237 1.958 . . . . 0.0 113.261 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -50.92 -16.93 0.49 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.928 -1.108 . . . . 0.0 109.279 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.687 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.1 OUTLIER -76.37 -50.05 15.23 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.278 -0.889 . . . . 0.0 109.04 179.546 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.687 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 3.3 tt -62.09 -21.42 64.95 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.323 -0.861 . . . . 0.0 108.821 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.581 ' C ' ' HE1' ' A' ' 96' ' ' TRP . 11.0 p -95.53 -33.02 12.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.135 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 93' ' ' PHE . 0.0 OUTLIER -76.76 -43.14 38.23 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.141 -0.974 . . . . 0.0 110.633 -178.732 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 64.2 mt -44.31 -19.15 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.223 -0.923 . . . . 0.0 109.387 -179.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.537 ' O ' ' N ' ' A' ' 95' ' ' GLY . 92.5 m-85 -106.77 102.73 43.67 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.497 ' O ' ' N ' ' A' ' 96' ' ' TRP . 81.6 Cg_exo -45.21 -9.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 122.036 1.824 . . . . 0.0 112.095 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.0 -14.73 0.14 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.581 ' HE1' ' C ' ' A' ' 90' ' ' SER . 3.7 m95 -47.9 -14.46 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.997 -1.296 . . . . 0.0 109.176 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.504 ' N ' ' O ' ' A' ' 95' ' ' GLY . 50.5 mtmt -69.09 -9.19 51.46 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.305 -0.872 . . . . 0.0 110.168 -179.63 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.26 -19.49 14.09 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.261 -0.899 . . . . 0.0 108.581 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.425 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 22.3 m95 -76.04 -8.86 57.95 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.243 0.544 . . . . 0.0 110.005 -178.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 C--N 1.305 -1.333 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.541 -179.898 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.664 HG22 HG12 ' A' ' 69' ' ' VAL . 90.2 m . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.749 HG22 ' H ' ' A' ' 70' ' ' LEU . 3.4 p -170.97 -118.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.749 ' H ' HG22 ' A' ' 69' ' ' VAL . 20.4 mt -64.61 3.61 0.49 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.269 -1.52 . . . . 0.0 108.883 179.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.521 ' H ' ' C ' ' A' ' 69' ' ' VAL . 38.8 m 55.4 110.81 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 CA-C-O 122.195 0.998 . . . . 0.0 109.966 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 74' ' ' GLY . 21.2 m -83.47 -16.51 11.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -45.93 -14.86 0.09 OUTLIER Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -70.55 -55.48 8.57 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -74.06 -34.47 64.06 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.015 -1.285 . . . . 0.0 109.549 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.46 -61.22 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.738 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -50.67 -31.2 15.62 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.439 -0.788 . . . . 0.0 108.912 179.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.57 ' O ' ' NE2' ' A' ' 81' ' ' GLN . 41.0 tp -74.23 -39.61 62.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.346 -0.846 . . . . 0.0 109.172 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 21.6 tp -62.75 -28.12 69.75 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 111.056 -179.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.406 HG22 ' H ' ' A' ' 80' ' ' ILE . 0.0 OUTLIER -91.62 -40.04 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.683 -1.26 . . . . 0.0 110.832 -178.738 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.64 ' NE2' ' N ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -66.67 -23.48 66.15 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.957 -1.089 . . . . 0.0 109.289 -178.885 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.64 ' N ' ' NE2' ' A' ' 81' ' ' GLN . 4.0 tp60 -95.12 -36.96 11.29 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.965 -1.084 . . . . 0.0 108.56 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.514 ' C ' ' H ' ' A' ' 85' ' ' ASP . . . -62.19 -11.7 15.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.209 -0.932 . . . . 0.0 110.733 -179.089 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 85' ' ' ASP . 27.0 mm -52.66 -4.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.725 -1.235 . . . . 0.0 110.216 -179.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.527 ' C ' ' H ' ' A' ' 87' ' ' LYS . 0.4 OUTLIER -47.43 170.3 0.1 OUTLIER Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 120.924 -1.11 . . . . 0.0 109.104 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.95 8.92 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 1.99 0 C-N-CA 122.571 2.181 . . . . 0.0 113.653 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 85' ' ' ASP . 22.8 pttp -48.27 -21.21 0.47 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.683 -1.26 . . . . 0.0 109.545 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.71 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 2.6 p-10 -71.19 -61.25 1.83 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.298 -0.876 . . . . 0.0 109.227 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.71 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 1.9 tt -51.86 -27.88 14.17 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 16.1 t -89.52 -24.27 21.82 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.431 -0.793 . . . . 0.0 109.734 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.404 ' O ' ' N ' ' A' ' 93' ' ' PHE . 15.9 tpp85 -70.46 -23.72 62.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.109 -0.994 . . . . 0.0 109.318 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.512 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 84.0 mt -47.84 -19.19 0.21 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.147 -0.971 . . . . 0.0 109.748 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.512 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 5.3 m-85 -160.0 -66.63 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.975 . . . . 0.0 110.02 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.44 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 77.2 Cg_exo -31.95 -52.7 0.33 Allowed 'Trans proline' 0 N--CA 1.492 1.429 0 C-N-CA 122.591 2.194 . . . . 0.0 113.238 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.526 ' O ' ' CE2' ' A' ' 99' ' ' TRP . . . -47.26 -41.92 16.76 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.429 ' CD1' ' N ' ' A' ' 96' ' ' TRP . 14.6 m95 -85.55 -9.89 56.72 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.1 -1.235 . . . . 0.0 110.425 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 7.2 mmpt? -72.75 -9.43 58.64 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.949 -1.095 . . . . 0.0 110.189 -179.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.13 -20.59 9.21 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.526 ' CE2' ' O ' ' A' ' 95' ' ' GLY . 23.9 m0 -74.77 -22.6 58.68 Favored 'General case' 0 C--N 1.3 -1.577 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.765 -178.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 100' ' ' VAL . 5.6 m . . . . . 0 C--N 1.304 -1.378 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.453 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.574 HG22 ' N ' ' A' ' 69' ' ' VAL . 94.1 m . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.574 ' N ' HG22 ' A' ' 68' ' ' THR . 35.9 m -62.21 -143.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.234 -0.916 . . . . 0.0 109.205 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 15.5 mt -55.81 -4.38 0.11 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.991 -1.068 . . . . 0.0 109.53 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.497 ' H ' ' C ' ' A' ' 69' ' ' VAL . 1.6 m 62.56 111.63 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.292 -0.88 . . . . 0.0 109.668 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.509 HG23 ' N ' ' A' ' 73' ' ' GLY . 24.2 m -48.27 -40.36 9.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-O 121.262 0.553 . . . . 0.0 109.622 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.509 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -45.18 -18.71 0.16 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -64.65 -46.67 89.29 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.443 ' NE2' ' N ' ' A' ' 75' ' ' GLN . 1.9 mp0 -80.71 -41.76 23.09 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.239 -1.154 . . . . 0.0 109.397 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 76' ' ' VAL . 3.6 t -59.17 -53.01 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 108.732 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.554 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 23.1 t-20 -57.76 -55.19 38.08 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 179.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.0 tp -50.16 -31.71 14.28 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.432 -0.792 . . . . 0.0 109.1 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.58 ' O ' ' HB3' ' A' ' 83' ' ' ALA . 5.2 tp -64.76 -59.7 3.93 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.367 -0.833 . . . . 0.0 110.358 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.448 HG23 ' NE2' ' A' ' 81' ' ' GLN . 0.0 OUTLIER -73.01 -21.74 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 110.602 -178.386 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.554 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 1.4 mp0 -70.98 -46.5 62.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.507 -1.371 . . . . 0.0 109.341 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.498 HE21 ' HB2' ' A' ' 83' ' ' ALA . 2.4 pp0? -92.13 -30.33 16.03 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.087 -1.008 . . . . 0.0 110.031 -179.051 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.58 ' HB3' ' O ' ' A' ' 79' ' ' LEU . . . -86.51 -32.98 20.46 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.063 -1.023 . . . . 0.0 109.813 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.427 HD12 ' O ' ' A' ' 82' ' ' GLN . 1.2 mp 41.27 22.11 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 CA-C-O 121.58 0.705 . . . . 0.0 110.073 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 83' ' ' ALA . 67.5 m-20 46.38 87.57 0.12 Allowed Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.301 -0.874 . . . . 0.0 110.024 179.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -60.54 -8.99 9.99 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 122.428 2.085 . . . . 0.0 112.095 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -47.14 -22.09 0.33 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.335 -0.853 . . . . 0.0 109.532 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.665 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.3 OUTLIER -69.93 -54.42 13.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.325 -0.86 . . . . 0.0 109.811 -179.671 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.665 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 2.0 tt -59.66 -33.56 71.69 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.256 -0.903 . . . . 0.0 108.889 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 76.9 p -79.39 -33.33 42.88 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.307 -0.871 . . . . 0.0 109.475 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' C ' ' N ' ' A' ' 93' ' ' PHE . 35.0 ttm180 -56.16 -42.27 76.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.254 -0.904 . . . . 0.0 109.555 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 61.2 mt -48.23 -20.01 0.34 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.119 -0.988 . . . . 0.0 109.252 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.55 ' O ' ' N ' ' A' ' 95' ' ' GLY . 1.8 m-85 -116.69 121.97 32.28 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 96' ' ' TRP . 74.1 Cg_exo -40.63 -16.99 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.138 1.892 . . . . 0.0 112.472 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.84 -9.39 0.06 OUTLIER Glycine 0 N--CA 1.489 2.192 0 C-N-CA 120.392 -0.909 . . . . 0.0 110.93 -179.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.53 ' N ' ' O ' ' A' ' 94' ' ' PRO . 62.0 p-90 -73.05 -11.73 60.66 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.798 -1.413 . . . . 0.0 109.963 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.529 ' CB ' ' NZ ' ' A' ' 97' ' ' LYS . 0.1 OUTLIER -61.75 -9.02 5.47 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.172 -0.955 . . . . 0.0 110.313 -179.73 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.76 -19.83 13.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.184 -0.948 . . . . 0.0 109.199 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.439 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 19.4 m95 -76.22 6.93 4.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.765 -0.584 . . . . 0.0 110.149 -178.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 100' ' ' VAL . 21.0 m . . . . . 0 N--CA 1.487 1.411 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.613 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.453 HG22 ' H ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.601 HG21 HE22 ' A' ' 75' ' ' GLN . 5.7 m -86.43 10.55 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.099 -1.001 . . . . 0.0 109.676 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 19.2 mt 56.79 7.05 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.93 . . . . 0.0 109.793 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.454 ' H ' HG23 ' A' ' 69' ' ' VAL . 76.9 p -171.18 115.49 0.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.416 ' C ' ' N ' ' A' ' 74' ' ' GLY . 28.6 m -53.99 -28.34 17.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -47.81 -20.5 1.22 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.416 ' N ' ' C ' ' A' ' 72' ' ' VAL . . . -76.77 -39.0 30.04 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.601 HE22 HG21 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -64.41 -33.48 75.96 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.954 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.06 -48.2 33.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.577 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 7.2 t-20 -56.45 -34.7 67.11 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.9 tp -67.11 -37.24 83.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.248 -0.908 . . . . 0.0 108.789 179.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 40.7 tp -60.53 -40.04 90.05 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.154 -0.966 . . . . 0.0 109.947 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.1 OUTLIER -85.53 -50.03 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 120.549 -1.344 . . . . 0.0 109.224 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.577 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 2.2 mp0 -45.48 -32.0 2.0 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.631 -1.293 . . . . 0.0 110.375 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.63 HE21 ' C ' ' A' ' 82' ' ' GLN . 0.0 OUTLIER -94.36 -30.53 14.45 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.828 -1.17 . . . . 0.0 110.045 -179.355 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.83 -9.84 2.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.124 -0.985 . . . . 0.0 111.183 -178.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.495 ' CD1' ' N ' ' A' ' 85' ' ' ASP . 1.6 pp -124.57 -120.74 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.989 -1.069 . . . . 0.0 108.908 -179.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.574 ' O ' ' ND2' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -172.9 -58.72 0.0 OUTLIER Pre-proline 0 C--N 1.3 -1.549 0 O-C-N 120.799 -1.188 . . . . 0.0 109.898 179.625 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.449 ' O ' ' N ' ' A' ' 88' ' ' ASN . 86.6 Cg_endo -77.2 -49.46 0.1 Allowed 'Trans proline' 0 N--CA 1.5 1.873 0 C-N-CA 122.044 1.829 . . . . 0.0 112.351 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.417 ' HG2' ' H ' ' A' ' 87' ' ' LYS . 7.8 mmmm -49.54 -14.85 0.12 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.308 -0.87 . . . . 0.0 109.188 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.731 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -70.06 -51.78 29.23 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.234 -0.986 . . . . 0.0 108.43 179.836 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.731 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 10.9 tp -67.66 -22.91 65.28 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.334 -0.853 . . . . 0.0 108.887 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 m -77.39 -47.07 20.78 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.41 -0.806 . . . . 0.0 110.376 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.504 ' O ' ' N ' ' A' ' 93' ' ' PHE . 78.0 mtt-85 -85.63 -45.26 11.88 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.019 -1.051 . . . . 0.0 110.57 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 63.5 mt -45.79 -19.28 0.05 Allowed 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.975 -1.078 . . . . 0.0 108.982 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.554 ' O ' ' N ' ' A' ' 95' ' ' GLY . 52.8 m-85 -114.71 87.57 14.82 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 178.584 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -41.62 -12.81 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.6 2.2 . . . . 0.0 112.718 -178.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -59.98 -11.89 20.0 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 59.8 p-90 -59.11 -19.72 47.1 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.579 -1.542 . . . . 0.0 109.556 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -64.6 -8.86 15.79 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.29 -0.881 . . . . 0.0 109.641 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.81 -17.5 16.86 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.455 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 31.9 m0 -71.8 7.46 1.53 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.317 -178.317 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.002 179.936 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.437 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.483 ' C ' ' H ' ' A' ' 71' ' ' SER . 4.6 m -98.61 12.75 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.141 -0.974 . . . . 0.0 109.692 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.3 mt 53.09 8.19 0.1 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.0 -1.062 . . . . 0.0 109.257 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.483 ' H ' ' C ' ' A' ' 69' ' ' VAL . 15.4 m -69.33 113.73 6.93 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.999 0.904 . . . . 0.0 108.962 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.551 HG23 ' N ' ' A' ' 73' ' ' GLY . 28.8 m -88.15 -45.98 15.81 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.785 -179.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.551 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -49.73 -12.8 0.45 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' VAL . . . -81.24 -41.9 9.83 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -82.48 -41.8 19.29 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.221 -1.164 . . . . 0.0 108.851 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.4 t -62.43 -55.82 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.623 ' ND2' ' NE2' ' A' ' 81' ' ' GLN . 0.5 OUTLIER -56.36 -53.78 53.32 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.542 ' O ' ' NE2' ' A' ' 82' ' ' GLN . 27.4 tp -47.6 -35.65 9.56 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.174 -0.954 . . . . 0.0 108.597 179.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.661 ' C ' HE22 ' A' ' 82' ' ' GLN . 0.7 OUTLIER -63.59 -38.68 92.03 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.729 -0.607 . . . . 0.0 109.769 -179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.535 HD13 ' O ' ' A' ' 80' ' ' ILE . 0.3 OUTLIER -76.88 -22.96 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.715 -1.24 . . . . 0.0 109.558 -179.577 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.623 ' NE2' ' ND2' ' A' ' 77' ' ' ASN . 8.0 mt-30 -74.51 -48.45 27.06 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 111.527 -178.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.834 ' H ' HE21 ' A' ' 82' ' ' GLN . 0.0 OUTLIER -85.01 -19.14 32.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.304 -1.497 . . . . 0.0 109.315 -179.285 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.837 ' O ' HD12 ' A' ' 84' ' ' ILE . . . -83.58 -66.28 0.91 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.161 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.837 HD12 ' O ' ' A' ' 83' ' ' ALA . 0.5 OUTLIER 29.93 77.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 CA-C-O 121.662 0.744 . . . . 0.0 110.612 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 88' ' ' ASN . 42.3 t0 51.43 65.08 6.97 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.199 -0.938 . . . . 0.0 109.331 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.439 ' O ' ' OG ' ' A' ' 90' ' ' SER . 76.9 Cg_endo -76.23 -7.29 17.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.636 2.224 . . . . 0.0 112.183 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' A' ' 87' ' ' LYS . 0.1 OUTLIER -61.31 -26.42 67.78 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.164 -0.96 . . . . 0.0 108.554 179.555 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.708 ' ND2' ' H ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -86.69 -67.7 0.8 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.436 -0.79 . . . . 0.0 109.061 179.7 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.708 ' H ' ' ND2' ' A' ' 88' ' ' ASN . 10.9 tp -45.96 -28.93 1.26 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.218 -0.926 . . . . 0.0 109.399 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.439 ' OG ' ' O ' ' A' ' 86' ' ' PRO . 95.6 p -83.07 -40.85 19.33 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.424 -0.797 . . . . 0.0 110.35 -179.481 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 2.8 ttp-105 -79.82 -20.27 46.51 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.623 -1.298 . . . . 0.0 110.678 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.522 ' O ' ' CD2' ' A' ' 93' ' ' PHE . 39.5 mt -89.62 6.96 38.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.02 -1.05 . . . . 0.0 110.875 -178.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.522 ' CD2' ' O ' ' A' ' 92' ' ' LEU . 14.4 m-85 -154.24 -74.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 120.583 -1.323 . . . . 0.0 111.275 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 93' ' ' PHE . 95.1 Cg_endo -74.49 -45.5 0.32 Allowed 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 121.567 1.512 . . . . 0.0 113.237 -179.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 99' ' ' TRP . . . -41.62 -39.89 2.7 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.347 -0.846 . . . . 0.0 111.317 -178.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.439 ' CD1' ' CE3' ' A' ' 99' ' ' TRP . 23.7 m0 -82.97 -23.38 33.41 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.698 -1.472 . . . . 0.0 110.196 -178.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 3.3 mmpp? -64.05 -9.05 13.87 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.137 -0.977 . . . . 0.0 110.337 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -114.58 -20.01 10.9 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 108.599 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.552 ' CD1' ' O ' ' A' ' 95' ' ' GLY . 22.1 m0 -80.98 -4.6 55.63 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.634 -178.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.5 m . . . . . 0 C--N 1.305 -1.349 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.537 -179.957 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.544 HG22 ' N ' ' A' ' 69' ' ' VAL . 28.1 m . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.109 -0.701 . . . . 0.0 109.109 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.544 ' N ' HG22 ' A' ' 68' ' ' THR . 6.7 p -160.75 117.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 O-C-N 121.121 -0.987 . . . . 0.0 110.159 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 50.4 mt 50.56 5.01 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -0.803 . . . . 0.0 110.537 179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.529 ' H ' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -84.94 105.49 15.75 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.846 -1.159 . . . . 0.0 108.636 179.528 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.536 HG23 ' N ' ' A' ' 73' ' ' GLY . 20.9 m -79.41 -41.99 22.87 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.019 -179.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.536 ' N ' HG23 ' A' ' 72' ' ' VAL . . . -43.5 -27.06 0.75 Allowed Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.22 -36.66 26.8 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.481 ' O ' HD13 ' A' ' 79' ' ' LEU . 11.3 mt-30 -66.07 -23.49 66.53 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 178.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.4 t -73.67 -47.16 45.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.415 ' C ' HE21 ' A' ' 81' ' ' GLN . 2.3 t-20 -56.11 -49.44 73.88 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 31.8 tp -59.85 -36.33 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.511 -0.743 . . . . 0.0 110.085 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.481 HD13 ' O ' ' A' ' 75' ' ' GLN . 2.5 mp -69.05 -24.74 64.21 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.118 -0.988 . . . . 0.0 111.495 -178.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.63 -26.32 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 120.378 -1.451 . . . . 0.0 110.708 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.415 HE21 ' C ' ' A' ' 77' ' ' ASN . 4.1 pt20 -86.51 -22.02 26.62 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.372 -1.455 . . . . 0.0 109.94 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -95.19 -42.12 8.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.95 -1.093 . . . . 0.0 108.843 179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.849 ' C ' HD12 ' A' ' 84' ' ' ILE . . . -98.01 -27.39 14.26 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.216 -0.927 . . . . 0.0 111.459 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.849 HD12 ' C ' ' A' ' 83' ' ' ALA . 0.1 OUTLIER 36.9 32.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.296 0 O-C-N 121.635 -0.666 . . . . 0.0 110.274 -177.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 84' ' ' ILE . 5.4 p-10 39.11 95.13 0.04 OUTLIER Pre-proline 0 N--CA 1.499 1.997 0 O-C-N 121.863 -0.523 . . . . 0.0 110.543 179.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.449 ' HA ' HD21 ' A' ' 88' ' ' ASN . 92.6 Cg_endo -80.23 23.26 0.7 Allowed 'Trans proline' 0 N--CA 1.491 1.344 0 C-N-CA 121.896 1.731 . . . . 0.0 111.948 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 28.5 mtmm -58.5 -32.82 69.17 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.222 -0.924 . . . . 0.0 109.219 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.775 HD22 ' H ' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -63.7 -25.29 68.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.317 -0.864 . . . . 0.0 108.96 179.814 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.775 ' H ' HD22 ' A' ' 88' ' ' ASN . 2.5 tt -80.89 -45.16 17.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.962 . . . . 0.0 108.598 179.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 93' ' ' PHE . 16.6 t -69.73 -20.62 63.51 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.354 -0.841 . . . . 0.0 109.332 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.828 ' HE ' ' HE1' ' A' ' 96' ' ' TRP . 0.0 OUTLIER -78.09 -54.52 6.18 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.283 -0.886 . . . . 0.0 109.656 -179.782 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 32.4 mt -65.4 7.75 0.2 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.199 -0.938 . . . . 0.0 109.715 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' GLY . 31.1 m-85 -146.3 157.4 49.24 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.091 -1.006 . . . . 0.0 109.463 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.548 ' O ' ' N ' ' A' ' 96' ' ' TRP . 90.6 Cg_exo -43.4 -6.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 122.651 2.234 . . . . 0.0 112.975 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.591 ' N ' ' O ' ' A' ' 93' ' ' PHE . . . -47.27 -11.19 0.07 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . 0.828 ' HE1' ' HE ' ' A' ' 91' ' ' ARG . 5.3 m0 -44.94 -16.58 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.269 -1.136 . . . . 0.0 109.374 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' A' ' 95' ' ' GLY . 0.1 OUTLIER -62.35 -8.49 6.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.85 . . . . 0.0 110.218 179.829 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -94.49 -19.23 20.73 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.845 -1.159 . . . . 0.0 108.118 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.446 ' CD1' ' N ' ' A' ' 99' ' ' TRP . 20.0 m95 -76.07 -13.0 60.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.261 0.553 . . . . 0.0 109.78 -178.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.6 m . . . . . 0 C--N 1.304 -1.373 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.489 179.917 . . . . . . . . 0 0 . 1 stop_ save_